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ABSTRACT 
For more than 100 years dithranol has been successfully used for the treatment 
of psoriasis . It is still not fully understood, however, how it exerts its anti-
psoriatic effect. From the information available to date it is clear that the actual 
process of decomposition is central to the therapeutic action of dithranol. Since 
there is an obvious parallel between the mechanism of decomposition in solution 
and that of decomposition/metabolism in skin stability studies were carried out 
in aqueous buffer (PH 5.5). The effect of various factors such as the presence of 
various metal ions and surfactants on the decomposition pattern (individual rates of 
dimer and danthron formation) of dithranol in solution were quantified. The effect of, 
in particular, surfactants on the skin permeation and decomposition/metabolism of 
dithranol were then investigated. 
Because of dithranol's poor water solubility it was necessary to develop an 
analytical technique capable of the successful quantification of low levels of 
dithranol and breakdown products in aqueous systems. A previously reported 
hplc system, which has adequate sensitivity for dithranol and danthron 
quantification, was used. Improved sensitivity for dimer (3 fold increase), thus 
allowing the accurate quantification of low levels of dimer in aqueous 
solutions, was achieved by a modification of the mobile phase. As it was also 
necessary to establish the amounts of dithranol and breakdown products on 
and in skin an appropriate extraction method was needed. A procedure 
whereby skin was first extracted using a mixture of trichloro acetic acid and 
methanol followed by hplc analysis of the extract was developed. 
Surfactant solubilisation of dithranol was used to enhance the water solubility 
of dithranol. Data from the solubilisation studies shows that in sodium lauryl 
sulphate and tween 80 (above c. m.c in aqueous buffer pH 5.5) the amount of 
dithranol in solution is directly proportional to the % of surfactant present. 
In cetrimide, solubilisatiori was observed only at low pH e.g pH 0.4. At pH 
5.5, because of the interaction that takes place between dithranol and 
cetrimide causing dithranol to ionise, dithranol ionisation is responsible for 
enhanced solubility. About 3 fold more dithranol goes into such cetrimide 
. solutions compared to equivalent concentrations of sodium lauryl sulphate and 
tween 80. 
Surfactant presence, however, had implications on dithranol's decomposition 
pattern. In the sodium lauryl sulphate and tween 80 solutions little change from 
that seen in buffer pH 5.5 was observed namely - 94 % dimer and - 4 % danthron 
were produced following complete decomposition. In the presence of cetrimide 
(PH 5.5) a marked change was seen with - 84% danthron and -14% dimer 
being formed on complete decomposition. 
The effect of the inclusion of metal ions i.e Cu2+, Zn2+ and Fe2+ on the 
kinetics of the decomposition of dithranol to dimer and danthron were quantified. 
All had a catalytic effect on the rate of dimer formation, while suppressing 
that of danthron.The catalytic coefficients were in the order of Cu2+ > Fe2+ > 
Zn2+. 
Concentration vs time data generated on placing surfactant solutions of 
dithranol in contact with animal skin (in vitro) and human skin (in vivo) allowed 
estimates of the amount of dithranol and breakdown products penetrating into 
the skin, along with the degree of skin surface decomposition taking place 
during the permeation process.A pronounced deviation was observed for 
dithranol decomposition in the formulations on the skin and when not in 
contact with skin. Skin surface decomposition was found to result in the 
formation of an ,as yet unknown, breakdown product (P4)' 
Using the 12-0-tetradecanoylphorbol-13-acetate/hairless mouse psonasls model 
it was visually established that the cetrimide-dithranol formulation negated the 
anti inflammatory effects of dithranol . The tween 80 and sodium lauryl sulphate 
dithranol formulations reduced the inflammatory response in the psoriasis 
model to the same degree as an equivalent amount of dithranol delivered in 
acetone. 
A preliminary clinical investigation on the influence of cetrimide on the 
therapeutic outcome of conventional dithranol therapy was carried out. using 
two patients with psoriasis. Cleansing the skin with a solution of cetrimide 
before and after treatment with dithranol resulted in both a reduction of side 
effects and a loss in the therapeutic effectiveness of dithranol. 
The data gathered allowed the discussion of the effect of dithranol's 
decomposition pathway on its therapeutic outcome. 
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CHAPfERl 
INTRODUCTION 
1.1 Introduction. 
Psoriasis is a disease whereby the skin exhibits a complex irregularity 
[Steigleder, (1981)] in the mechanisms which control the epidermal cell 
division. This study will therefore begin with a review of the structure of the 
human skin. 
The human skin 
The skin is a complex, dynamic organ of many cell types and specialized 
structures serving multiple functions crucial to health and survival. It is one 
of the largest and most versatile of organs. The average adult has a skin 
surface area 1.75 m2 (about 3000 in2) [McClintic, 1975, Barry ,1983] and 
comprises 7 - 12% of the body weight [ Wood & Bladon, 1985]. The skin 
provides a number of unique functions: 
(1) It protects deeper cells from environmental factors such as chemical and 
mechanical injury, desiccation, invasion by micro-organisms and the damaging 
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effects of ultraviolet light. 
(2) It regulates and helps maintain body temperature. 
(3) It serves as a neuroreceptor organ in monitoring diverse environmental 
stimuli. 
(4) It processes antigenic substances presented to it. 
(5) Hairs (specialized keratinized structures), over the scalp, body, as eyelashes 
and in the nose provide aesthetic adornment and protect eyes from small 
particles and filter air breathed into the nose. 
The human skin consists of three anatomical layers: (i) the epidermis, which 
is a thin, dry and tough outer layer, (ii) the dermis, which is essentially the 
support system containing blood vessels, nerves , hair follicles ,sebum and 
sweat glands, (iii) the subcutaneous fat layer which acts both as an insulator, 
a shock absorber and reserve depot for calories [Wilson & Washington, 1989, 
p 109]. Since in psoriasis the epidermis and dermal regions of the skin are 
involved [van Scott & Flaxman, 1973], this brief review of the structure of the 
skin, will therefore concentrate on these regions [see Fig 1.1]. 
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Fig 1.1 
Schematic drawing of the epidermis. Three major layers of living cells are distinguished: 
The columar cells comprising the basal layer, nearest the dermis; the spinous layer, 
composed of polyhedral cells with many desmosomal attachments on the cell surfaces; 
and the granular layer, interposed between the spinous layer and the stratum corneum, 
where cells take on a flattened configuration and contain dense keratohyline granules. 
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1.1.1 The epidermis 
The epidermis is a multilayer consisting of two main parts: an inner region 
of viable ,moist cells termed the Malpighian layer and an outer layer of 
anucleate, flattened, nonviable, desiccated cells known as the stratum corneum 
[Orkin ~,1991]. There are three substrata of living cells that can be 
recognized: the basal, spinous, and granular layers (Fig 1.1). These layers 
represent progressive stages of differentiation and keratinization of the living 
keratinocyte as they move toward the skin surface to become stratum 
corneum. Thus the columnar basal cells continually divide and give birth to 
daughter cells that are displaced toward the skin surface. 
In the spinous layer the cells take on a polyhedral shape and adhere to one 
another by numerous attachment devices called desmosomes. Besides this 
change in shape, other structural changes occur. Keratin filaments form a 
network within the cytoplasm, and refractile keratohyline granules and 
submicroscopic lamellar granules appear. The cytoplasmic keratin filaments 
extend across cells and loop about the perinuclear space of the cells in the 
spinous layer. 
The cells of the granular layer have a flat shape. and the keratohyalin in 
these cells accrues incrementally among the keratin filaments to form larger 
and larger masses enclosing the filaments. Histadine-rich basic protein , termed 
filagrin , has been demonstrated to facilitate the assembly of keratin filaments 
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into macrofibrils. The keratohyline granules in this layer account for the 
distinctive granules of the granular layer. 
The final stage of keratinization - the abrupt change from the granular layer 
to the stratum corneum - is attended by a variety of dramatic morphological 
and biochemical degenerative alterations including the degradation of cellular 
organelles and nuclei as well as the by the appearance of a thickened 
cellular envelope of stratum corneum cells. The cornified layer consists of up 
to 25 layers of anucleate dead cells held tightly together by means of 
desmosomes. 
1.1.2 The dennis 
The dermis lies between the epidermis and the subcutaneous adipose tissue. 
In humans the whole mass of the dermis may constitute 15 - 20% of the total 
body weight [Orkin et al ,1991]. 
Grossly, the dermis is a tough, resilient tissue with viscoelastic properties. 
A 3-dimensional matrix of loose connective tissue is composed of fibrous 
proteins (collagen and elastin) embedded in an amorphous gel of ground 
substance (glycosaminoglycans) [Orkin ~ , 1991]. The fibrous matrix serves as 
a scaffolding within which networks of blood vessels, nerves, and lymphatics 
intertwine. The dermis also contains epidermal appendages such as sweat 
glands and pilosebaceous units and provides support for these structures. 
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The dermis can be divided into an upper papillary layer, characterized by 
interlacing fine collagen fibres and ample interfibrillar spaces, and the deeper 
reticular dermis recognized by the thicker, aggregated bundles of collagen 
with lesser amounts of interfibrous space. Elastic fibres are intertwined within 
the collagenous network [Orkin ~ , 1991). 
1.2 Psoriasis 
1.2.1 Prevalence and clinical features. 
Psoriasis is a common scaly erythematous disease of unknown cause showing 
wide variation in severity and distribution of skin lesions. It usually follows 
an irregular chronic course marked by remissions and exacerbations of 
unpredictable onset and duration [Orkin ~ , 1989). Factors that may lead to 
more lesions include drug reactions, respiratory infections, cold weather, 
emotional stress, surgery ,and viral infections. 
Estimates of the prevalence of psoriasis in the general population of the world 
range from 0.1 to 2.8% [Farber & Nall , 1984].The frequency varies in different 
geographic regions: 0.5 to 1.5 % in the United States [Kraning and Odland, 
1979]; 2.8% in Scandinavia [Lomholt, 1963); 0.4% in the Henan District of the 
People's Republic of China ( Henan Dermatoses Survey Group, 1982); while in 
a study in the South American Andes no cases were found ( Convit, 1963). 
Psoriasis occurs in males and females with nearly equal frequency. The 
chap 1.6 
average age at onset is in the 20s, ranging from birth to 80 or 90 years. 
Lesions are commonly observed on the scalp, elbows, trunk, and the lower 
extremities ,but can occur on all body parts including fingernails and 
toenails. A temporary or permanent remission may occur in the course of the 
disease. The reason for this is not known. 
Psoriatic skin is characterised by the appearance of sharply defined 
erythematous patches covered with a distinctive crumbling silvery grey scale 
[Barry, 1983]. When the scales are removed, punctate bleeding points become 
visible. It's clinical appearance can vary widely and may be classified as: 
Psoriasis vulgaris 
Guttate psoriasis 
Pustular psoriasis 
Psoriatic erythroderma 
Psoriasis and arthritis 
Two categories of psoriatic skin are defined: (i) visible psoriasis , (2) non-visible 
psoriasis. The latter includes residual psoriasis (clinically non-apparent, but 
histologically recognizable) ,pre-psoriasis (epidermal thickening, increased DNA 
synthesis, histochemical parakeratosis, infiltration of macrophages, lymphocytes 
in the dermis, capillary dilatation), and latent psoriasis (absence of any 
measurable but susceptibility to visible psoriasis after injury - the so called" 
Koebner reaction") 
1.2.2 Skin changes in psoriasis 
a) Defects in the epidennis 
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Psoriatic skin exhibits a complex irregularity [Steigleder, 1981] in the 
mechanisms that control the epidermal cell division. The characteristic scales 
which are different to normal stratum corneum and overlie the epidermis are 
the result of altered keratinization. The abnormality of the keratins causes a 
decrease in the water holding capacity of the epidermis, thus total epidermal 
water loss in psoriatic skin is higher than that in normal skin [Serup & 
Blichmann, 1987 , Marks ~ , 1979]. 
Table 1.1 Histopathological changes in untreated psoriatic plaques [from Wilborn & Montes, 1974 
and Steigleder, 1981] . 
Targets normal 
parakertosis 
cell size 
non 
normal 
normal skin thickness 
tonofilaments 
intercellular space 
mitochondria 
keratohyalin 
numerous 
narrow 
few, small 
numerous 
psoriasis 
appear 
larger 
thicker 
reduced 
large 
increased, enlarged 
decreased 
Histological sections through psoriatic lesions (Table 1.1) show that the granular 
layer is reduced or absent and there is parakertosis with an increase in the 
mitotic activity in the basal layer cells [ van Scott & Ekel, 1963, van Scott & 
Flaxman, 1973, Wilborn & Montes,1974, Wood & Bladon, 1985]. The size of 
psoriatic epidermal cells are larger than normal ones. Marhle (1981) showed 
that profound alterations of cell membranes and increases in the cell surface 
area of psoriatic keratinocytes accelerate cell mitosis. The increase in the skin 
thickness or epidermal hyperplasia is shown to be the result of an increase 
in cell size [Flaxman & Chopra, 1972]. The type and number of tonofilaments 
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of psoriatic skin are different from the normal ones and the intercellular 
spaces in the psoriatic lesions are dilated [Steigleder, 1981]. Table 1.1 also 
shows that the number and size of mitochondria in psoriatic plaques are 
different from normal skin. 
Examples of other biochemical and immunological deviations from normal 
skin have been implicated. Hammar (1970) reported a significant rise in the 
activity of glucose-6-phosphate dehydrogenase in the uninvolved skin and 
within the psoriatic lesion. An alteration in arachidonic acid metabolism in 
psoriasis has been reported [Muller, 1988, Kragballe & Voorhees, 1987]. Defects 
in sterol metabolism, fatty acid metabolism and the esterification process have 
been demonstrated [Yardley, 1969]. Esterified cholesterol is a vital component 
in the ordered structure of the keratin fibrils. An incomplete catabolism of 
phospholipids during keratinisation and a deficiency in a phosphorylation 
mechanism in psoriasis were shown [Yardley & Godfrey, 1964]. The levels of 
cAMP [Prunieras ,1979 , Plummer, 1979, Zarchariae, 1979] and folic acid 
derivatives [Mier & Cotton, 1976] which deviated from normal could indicate 
the non-clinical presence of psoriasis. The immunological factors IgA and 
complement are found deposited in the lesion after hyperproliferation 
[Steigleder, 1981] whilst T-Iymphocytes are lower than normal [Zachariae,1979]. 
Polymorphonuclear leukocytes show an enhanced chemotactic response to 
various chemo-attractants. This enhancement was shown to be reduced to 
normal by dithranol [Michaelson, 1980 and Schroder ~ , 1985]. 
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b) Defects in the dermis 
Histological sections show that there is papillary oedema, dilatation and 
tortuosity of the papillary capillaries [Ross ~ , 1964]. This explains why 
removal of the scales damages not only the epidermis but also the 
underlying capillaries, resulting in a characteristic punctate bleeding point [Wood 
& Bladon, 1985, Barry , 1983]. Inherent vasodilatation and a characteristic 
psoriatic capillary network have been observed [Ryan, 1979] whilst Kemeny 
(1989) has shown that the capillary resistance of psoriatic patients is 
significantly lower than that of healthy individuals. 
1.2.3 Animal models 
The skin condition is an essential regulating parameter of percutaneous 
absorption. In most skin diseases an increase in skin permeability is observed 
which is due to a defective barrier. In dermatological therapy an important 
question that arises is that of the difference of drug penetration into diseased 
skin relative to intact skin. To be able to address such a question it is 
important to establish animal models to mimic diseased skin. 
Using normal skin, one of the simplest methods of mimicking the defective 
permeation barrier of psoriatic skin is by the removal of the stratum 
corneum by tape stripping (Shroot & Scheafer ,1987). The stratum corneum of 
normal skin can also be selectively damaged using UV irradiation [Lamaud 
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& Schalla, 1984]. The use of skin where the stratum corneum is damaged 
or removed is limited to experiments designed to give information on the 
permeation characteristics of a particular drug in diseased skin. In order to 
assess the potential of any particular agent to halt the progress of a given 
disease of the skin, it is desirable to first produce the disease state in the 
skin. For psoriasis no perfect model is available to date. An acceptable model 
is obtained by the treatment of mouse skin with tetradecanoyl phorbol 
myristate acetate (TPA) [Gupta ~ ,1989, Gschwendt ~ , 1987]. A number of 
biological effects are induced including epidermal hyperplasia, activation of 
protein kinase C, increased release of arachidonic acid and prostaglandins 
(involved in the inflammatory process) and also induction of ornithine 
decarboxylase (a participant in regulation of cell growth). The result of the 
changes induced mimics, to a certain degree, a psoriatic lesion. 
1.2.4 Treatment 
There is no cure for psoriasis. Several treatments are available , varying from 
topical to systemic modalities administered singly or in combination, and are 
all effective to varying degrees in controlling the disease. Remission may 
occur in the course of the disease. 
Topical Therapy - Dithranol, crude coal tar, and corticosteroids are the most 
frequently used agents for the topical treatment of psoriasis. A detailed 
discussion of dithranol will follow later in the chapter. 
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Tars 
Crude coal tar is a complex mixture of thousands of hydrocarbon 
compounds. It affects psoriasis by enzyme inhibition and antimitotic action. 
Few attempts have been made to assess the pharmacological activity of 
individual components of purified tar products or of different coal tars 
themselves. Preparation of 2 to 5% crude coal tar in various bases is effective 
alone and in combination with other agents such as salicylic acid [Comaish, 
1981; Tanenbaum ~ 1975, Young, 1970]. One disadvantage with these 
formulations is the variation in the activity of these products mainly because 
of the non-standard composition of crude coal tar. Other disadvantages are 
that the preparations are inconvenient, inconsistent and also usually 
unacceptable to use. Commercially, coal tar products are available as solutions 
for baths, paints, ointments , sticks and shampoos. 
Corticosteroids 
They are available as odourless, non-staining creams, gels and lotions, and 
patients are willing to use them due their cosmetic appeal. Patients with 
plaques limited to a few areas respond well to therapy aimed at removing 
scales and lubricating lesions. Occlusive pliable plastic dressings over topical 
corticosteroids increase their effectiveness [Watson and Faber, 1977]. Prolonged 
use of topical corticosteroids, especially fluorinated agents or applications 
under occlusion, may lead to atrophy of the skin, telangiectasia, straie and 
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overgrowth of bacterial and fungal infections of the skin. Rapid recurrence 
of psoriasis (rebound phenomenon) may also occur when topical corticosteroids 
are used for long periods and then discontinued. Systemic absorption of 
corticosteroids may be sufficient to cause adrenal gland suppression and 
Cushing's syndrome, especially with newer "superpotent" topical steroids (eg 
clobetasol propionate [Temovate)). 
Photochemotherapy 
Natural sunlight is effective adjunctive therapy for psonaSlS ,as most 
patients find who travel to warm, sunny climates. Artificially produced 
ultraviolet light is an effective method of treating some patients with 
psoriasis [Farber & Nall, 1984]. High intensity UVA at 360nm is capable of 
penetrating to the basal cell layer. Patients are given 8-methoxypsoralens 
.systemically and 2 hours later exposed to a controlled dose of UVA. The 
drug reacts in the skin with UVA to produce a thymidine 
antagonist.Increasing amounts of ultra-violet are administered each week. 
Treatment is only available in specialist centres; it has to be carefully 
regulated, owing to the short-term hazard of severe burning and the long-term 
hazards of cataract formation [Goldberg ~ , 1979], accelerated ageing, and 
the development of skin cancer [Stem ~, 1979]. 
Antimitotic drugs 
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Because epidermal hyperplasia may play a part in the pathogenesis of 
psoriasis, antimitotic drugs are a logical choice of treatment .Examples include 
methotrexate and hydroxyurea. These drugs are reserved for use in severe 
cases or those failing to respond to other treatment [Farber & Nall, 1984]. 
Methotrexate is more ef~ective, and thus better known, than hydroxyurea [Baker, 
1975]. It is used orally or by intramuscular injection with close monitoring 
of liver, kidney and bone marrow functions. 
Occlusive dressing therapy 
Previous studies have suggested a potential therapeutic role for occlusion on 
psoriasis. In 1970 ,Fry and colleagues reported the clinical improvements of 
a significant decrease in mitotic counts, and the reformation of the granular 
cell layer in psoriatic lesions by covering them with plastic dressings only. 
Adverse reactions to occlusion on skin such as potential increase in bacterial 
infections or discomfort after prolonged applications are likely [Sulzberger & 
Witten, 1961]. 
Systemic therapy 
Immunosuppressive drugs 
Cyclosporin A is an example. It is given orally or by intramuscular injection. 
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It is found to be effective in severe psoriasis [Griffiths ~ , 1989]. 
Retinoids 
Vitamin A has long been recognised as being vital to growth and skin 
tissue, and synthetic retinoids are demonstrated to be effective in psoriasis 
[Orfanos & Runne , 1976]. However, the major side effects including skeletal 
damage and diffuse hair loss, and high severe remission not to mention 
teratogenicity have limited the use of retinoids in psoriasis. 
1.3 Skin penneation studies 
In the development of a topical product the kinetics of liberation and 
subsequent penetration into the skin is vital information. There are two 
general approaches followed to obtain such information. One approach uses 
animal or human skin preparations in diffusion cells (in vitro methods). Another 
approach uses in vivo methods in a variety of animal species, including 
humans. 
1.3.1 In vitro methods 
There are various types of diffusion cells used, their design being dependent 
on the desired objective [Scott,R., 1986]. Franz cells are the most frequently 
used because of the following advantages: The cells are nonreactive and 
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nonadditive as they are constructed of glass. The set up is made perfectly 
water-tight by clamping the two halves together and can be used with 
whole skin, separated epidermis or even nails. The cells can be modified 
for a static study or for a dynamic one which better mimics In VIVO 
conditions [Anjo ~ , 1980], and is better adapted to non-water soluble 
substances. 
As mentioned above diffusion cells can be used to measure the permeation 
of a substance through different barriers, human or animal. Whole skin is 
easy to handle but has a major disadvantage in that most compounds tend 
to accumulate in the dermis. Animal skin e.g. rat skin has the advantage of 
being easily standardized (same weight , sex , species) which is important for 
studies comparing several vehicles for a given drug. To obviate the problem 
of accumulation in the dermis isolated human epidermis and stratum corneum 
can be used in these cells. A problem usually encountered with human skin 
is the difficulty in obtaining hairless mammalian skin, since mammalian skin 
seems most appropriate. Also the results obtained on separated epidermis are 
dependent on the thickness of the stratum corneum, and thus the origin of 
the skin [Schaefer ~ ,1982]. When skin from different origins is used a 
standard is included so that a correction coefficient can be applied. To avoid 
using separated epidermis with holes in it, tritiated water is allowed to 
penetrate through it before applying the substance. If the diffusion of the 
water into the receptor fluid is in the normal range, the epidermis is ready 
to be used for a penetration study. 
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1.3.2 In vivo methods 
In in vivo studies of permeation the main problems encountered are in 
quantifying the amount of formulation applied e.g cream, ointment, paste, 
etc and then sampling the applied formulation to quantify the release of drug 
over a time period. Such information is essential if release is to be linked 
to "activity". 
One method involves the application of a radioactively labelled e4C and 3H) 
dithranol formulation, e.g. a cream or ointment, in vivo to human or an 
animal model then biopsing the treated area. Taking several horizontal sections 
of this biopsy and analysing for radioactivity allows one to follow the 
kinetics of penetration of the substance into different cellular layers [Schaefer 
~, 1978]. In another approach, once the agent under investigation is applied 
to the skin, percutaneous absorption is determined by direct analysis of the 
urine [Wurster & Kramer, 1961]. A major drawback of the above radioactive 
methods is that information on the decomposition of the parent drug both 
on and in the skin is not readily attenable. 
1.4 Dithranol 
1.4.1 History 
The natural source of dithranol is araroba or Goa powder. Araroba IS extracted 
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from cavities m the trunk of Andira araroba. Goa powder was first analyzed 
in London in 1875 when it was found that 85 % of the powder was the 
benzene soluble chrysophanic acid which could be used as a purgative. In 
1878 Squire published a book "On the treatment of psoriasis by an ointment 
of chrysophanic acid" [quoted by Fisher & Maibach, 1975 , Faber ,1983]. The 
first synthetic antipsoriatic compound (dithranol or anthralin) was produced in 
1916 and was named Cignolin. This was after it was shown that the active 
antipsoriatic component in Goa powder was not chrysophanic acid but a 
reduced product of it known as chrysarobin (see Fig 1.2). 
(a) (b) (c) 
Figure 1.2 
The molecular structures of a) dithranol, b)chrysophanic acid and c) 
chrysarobine 
1.4.2 Stability 
An appreciation of the chemistry of dithranol is needed in order to 
understand both the risks and benefits of this drug. The keynote of this 
chemistry is instability with two focal points: phenolic hydroxyl groups at Cl 
and C8, and two reactive hydrogen atoms on CW. The hydrogen bonding 
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between the phenolic hydrogen atoms and the central carbonyl function 
account for the relative stability of dithranol in aprotic media such as 
vaseline ,but in the presence of protic solvents such as water this bonding 
is disturbed, the keto-enol tautomerism is altered and auto-oxidation centering 
on ClO can occur (see Fig 1.3). 
Dithranol 
Fig 1.3 
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dithranol [from Holder & Upadrashta (1992)J. 
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In the skin [Shroot & Brown, 1986, Cavey ~ , 1985] , cell culture [Reichert ~ 
at , 1985] , and isolated mitochondria [Fusch «-al 1990, Salet «-al , 1991] 
dithranol displays distinct chemical behaviour involving hydrogen atom 
abstraction and electron transfer to yield the corresponding anthranoyl radical 
(Fig 1.3). The release of a hydrogen atom from the methylene group at ClO 
initiates the oxidative decomposition of dithranol and the formation of free 
radicals [Krebs «-al , 1981, Colin «-al , 1981] (Fig 1.3). The free radicals 
produced are biologically active and able to produce further active radicals 
in a chain reaction [Martinmaa ~, 1981, Whitefield, 1981a, Fusch tl.al , 1990]. 
Although these radicals may be responsible for skin irritation and produce 
oxidation products that cause staining, they are presumably central to the 
clinical action of the drug [Martinmaa ~ , 1981, Misch, ~ , 1981] because 
of the difficulty of separating activity from side effects. Prevention of free 
radical formation by i) substitution of both hydrogen atoms at ClO, and ii) 
omission of the methylenic group or replacement by oxygen, produced 
inactive antipsoriatic compounds: a mono lO-acyl derivative of dithranol is 
active, but less so than dithranol itself [Schaltegger ~ , 1987]. 
The stability of dithranol will vary according to changes in the environment. 
Both rate and pattern of decomposition are affected. A number of 
environmental factors influencing stability are reviewed. 
The effect of solvent and pH - Although dithranol is fairly stable in non-polar 
solvents such as hexane , it is slowly oxidised in relatively more polar ones 
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such as acetone and methanol [Priprem ,1991] ,and also in neutral aqueous 
solutions where the oxidation rate increases with increasing pH [Upadrastha & 
Wurster (a), 1988]. The pKa of dithranol in aqueous conditions at 25°C was 
determined to be 9.06 [Upadrashta & Wurster (a),(l988)]. The autooxidation of 
the monobasic species is much more rapid than the neutral one and is rate 
determining in mixtures of both species at equilibrium [Melo ~ ,1983]. In 
basic aqueous solutions dithranol is ionised and oxidation is very fast 
resulting in the formation of danthron and smaller amounts of dimer [Melo 
et al, 1983]. In an acidic aqueous solution (pH 3.3) dithranol is non-ionised 
and was shown to be relatively stable over a 10 hour period [Wang ~ , 
1987] , the decomposition products formed under these conditions were not 
mentioned. 
Catalysis of dithranol decomposition - Using stable dithranol pastes, 
Hulsebosch & Ponec-Waelsch (1972) showed that when dithranol was brought 
into contact with rough solid surfaces such as skin, lint and glass wool, 
decomposition was catalysed especially in the presence of moisture. Though 
the catalysis of dithranol decomposition by metal ions such as Zn2+ and 
Fe2+ has been reported [Raab & Gmeiner, 1975, Hulsebosch & Ponec-Waelsch, 
1972, Priprem ,1991], none of the reports provide information on the effects 
of the catalytic agents on the individual rates of formation of danthron and 
dimer. Because of the poor water solubility of dithranol this kind of 
information for dithranol in aqueous conditions is notably absent in the 
literature. 
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The influence of light and temperature - Both of these factors will enhance the 
decomposition process of dithranol. Raab & Gmeiner (1975) showed that when 
dithranol was kept in solution (dimethylformamide) the typical absorption 
spectrum was lost over a period of time. The higher the temperature (80°C 
as opposed to 30°C) the faster the loss occurred. It was also shown that 
exposure to ultraviolet light provoked decomposition which occurred at a 
faster rate than that due to exposure to a temperature of 80°C. In contrast 
to autooxidation in the dark both the neutral and ionised species of dithranol 
are readily oxidised when exposed to UV light. The same considerations apply 
to neutral and basic aqueous solutions although in basic solution 
photooxidation leads to the formation of the monobasic form of danthron 
[Melo ~ ,1983]. In the studies mentioned above information on the kinetics 
of decomposition product formation is lacking principally due to the non 
specific nature of the spectrophotometric methods employed for solution 
analysis. 
1.4.3 Analytical methods 
The lack of sensitive and specific analytical procedures for the investigation 
of dithranol has delayed the answer to such therapeutic parameters of 
dithranol as effective dose and site of action [Mustakallio , 1981]. Dithranol 
in the presence of its decomposition products (mainly danthron and dimer) 
cannot be determined by direct UV spectrophotometry because of overlap in 
the UV spectra [Caron & Shroot ,1981]. Hplc has improved the situation 
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because this method in capable of separating and quantitating the amount 
of dithranol and its degradation products. The use of both normal and 
reversed phase Hplc has been reported [Cavey ~ , 1982 , Burton & Gadde , 
1985 , Lee, 1987 " Wurster & Upadrashta, 1986, Kneczeke ~ , 1989]. Currently 
the official method used is a normal phase system both in the B.P. (1993) 
and the U.S.P (XXI). It has been reported however [Burton & Gadde , 1985 , 
Wurster and Upadrashta , 1986] that separation between dithranol and danthron 
is better in a reverse phase system. 
1.4.4 Skin penetration studies of dithranol 
These can be divided into three groups; i) studies aimed at determining the 
flux properties of the dithranol molecule., ii) the influence of various 
vehicles on the flux properties of dithranol. , iii) events occurring on and in 
·the skin following application of dithranol to the skin. 
Dithranol flux properties - Using both radiolabelling and fluorescence as the 
detection methods, it has been shown that when dithranol is applied to normal 
skin in a vaseline base, a high concentration is found in the epidermis, this 
indicating that the molecule has a rather high flux [Shroot ~ ,1981]. When 
the barrier to permeation into the skin (horny layer) is compromised, 
dithranol penetration is facilitated. This effect was demonstrated by Schaefer 
(1980) ,who showed that the penetration of dithranol into the epidermis was 
increased when the horny layer was removed by tape stripping. It was also 
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observed that penetration of dithranol through the defective skin barrier of 
the psoriatic lesion is faster than in normal skin [Schalla ~ , 1981, 
Timmerman etal , 1990]. It is on the basis of such observations that the short 
contact therapy approach using dithranol preparations is advised. 
A study using radioactive dithranol [Selim ~ , 1981] showed that the 
penetration in vitro occurs shortly after application and the distribution rapidly 
became stabilised so that there was little difference between 1 hour and 24 
hours of application. The structure of the dithranol, particularly its 
hydrophobicity [Whitefield, 1981a] contributes greatly to its penetration 
properties. 
Vehicle type - Using vehicles varymg m hydrophobicity it was shown that 
the greater the hydrophobic nature of the vehicle, the greater was the 
penetration of dithranol into the epidermis (human skin). Penetration into the 
epidermis from the various bases was in the following order, petrolatum > 
water in oil cream > oil in water cream > single phase water miscible cream 
[Kammerau ~ ,1975]. 
Skin surface decomposition - Given the instability of the dithranol molecule, 
a full account of the skin permeation process is obtained more accurately, 
if events occurring on the surface as well as in the skin, following the 
application of dithranol are closely monitored. In the majority of dithranol 
penetration studies [Kammerau ~ , 1975, Schaefer ~ , 1981, Cavey ~ 
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1985] the emphasis is on the events occurring in the skin post application 
of dithranol dose. Some reports acknowledge the possibility of surface 
decomposition and the formation of decomposition products other than 
danthron and dimer, but no skin surface kinetic data IS reported [Schalla e1 
al, 1980, Wang ~ ,1987]. It would appear that the main reason for the lack 
of this type of information is the complex nature of the dithranol 
formulations used in such experiments, leading to sampling difficulties. In the 
present study, using Hplc and liquid formulations of dithranol the 
concentration time profiles of dithranol and decomposition products, on the 
skin surface, during the permeation process was readily monitored. 
1.4.5 Mode of action 
In a recent review of the mode of action of dithranol [Shroot, 1992] it is 
suggested that dithranol's effect is not as a result of a direct action on DNA 
but more likely to be a consequence of a potent effect on cellular respiration 
and subsequently, energy production. There is strong evidence to suggest that 
the target organelle for dithranol is the mitochondria [Morliere ~ , 1985] and 
further that the interaction occurs with the electron transport chain on the 
inner mitochondria membrane resulting finally in a reduction of ATP 
synthesis. The mechanism by which this process occurs is contested [Fusch e1 
al , 1990 , Salet euJ , 1991]. It has also been shown that many enzymes 
associated with cell proliferation; Glucose-6-Phosphate-Dehydrogenase; Ornithine 
Decarboxylase; Lipoxygenase; Protein Kinase C are inhibited by dithranol. In a 
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earlier comprehensive review [Kemany ~ , 1990] these and other targets 
such as calmodulin and cyclic nucleotides are discussed. However, as these 
reviewers point out ,dithranol at certain concentrations stimulates epidermal 
DNA synthesis and hyperplasia thus the antiproliferative effect may not be 
primordial. When all of the data available is considered, the conclusion that 
can be drawn is that dithranol's target is not restricted to one cell type, and 
it is the redox chemistry of the dithranol molecule interfering with cellular 
metabolism that accounts for the ubiquitous pharmacology of the drug. 
Cavey ~ (1985) showed that on the application of dithranol to tape 
stripped hairless mouse skin it was rapidly converted to ether extractable 
dimer and also to products insoluble in ether, which predominated over the 
ether soluble fraction. In addition to it's possible relationship to brown 
oxidation products of dithranol, this insoluble fraction could reflect covalent 
binding of the drug with e.g. proteins [MeLo ~ ,1983 , Kammerau ~ , 
1975]. The formation in vivo of free radical species from dithranol [Shroot 
& Brown ,1983] might account for such unspecific interactions, which in turn 
should have a general effect on cellular metabolism rather than specific 
effects. This lends support to the idea that active species are rapidily formed 
when dithranol is applied to diseased skin, and that the mechanism of action 
does not depend on one chemical entity but on the reactivity of the drug 
and its transformation products. Based on· the presently available information 
one question that arises is whether or not it would be possible to control 
this reactivity of the drug and improve the response to it. 
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1.4.6 Treatment of psoriasis with dithranol preparations 
Conventional Regime - Ingram (1953) introduced a combined treatment using 
tar-ultraviolet light and a dithranol paste. Patients, under the guidance of 
trained medical staff were given a coal tar bath and exposed to varying 
increments of UV light to maintain near erythema dosage. The stiff dithranol 
paste was then applied to the psoriatic plaques, which were powdered with 
talcum, and the patient was wrapped with a protective stockinette dressing. 
The Ingram method has been found to be effective and reliable. The side 
effects of the dithranol are limited as a result of the stiffness of the paste 
which prevents spreading to normal uninvolved skin. However, the regimen 
is not suitable for out-patient care and it relies on homogeneous mixing and 
the availability of dithranol from the paste [Farber & Nall, 1981]. 
At present the methods used are various modifications of the original Ingram 
regimen. 
Low Dose - Long Tenn Application - It has been suggested that a low dose 
dithranol ointment (0.01 - 0.05%) does not irritate normal skin and would be 
effective if left in contact with the psoriatic plaque for a long time 
[Brody,1981]. However, Lowe and Breeding (1981) have shown that 0.05% 
dithranol o/w cream give equal clinical response to vehicle alone. 
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High dose-short tenn application or Short contact therapy - Kammerau ~ 
(1975) used tritiated dithranol to show that the maximal epidermal 
concentrations of dithranol (from 0.1 % in petrolatum) occurred between 60 
to 300 minutes after application. Schaefer ~ (1980) found enhanced 
penetration of dithranol into epidermis from which the horny layer had been 
removed by tape stripping, and that the difference between penetration into 
normal skin and tape-stripped skin was more noticeable after a short (30 
minutes) as opposed to a longer (1000 minutes) period. They concluded that 
removal of dithranol after 30 minutes should give a relativel~ higher amount 
of dithranol penetrating into psoriatic skin, assuming that skin with horny 
layer removed was a reasonable model for psoriasis. Thus, it was suggested 
that 1 % dithranol (including 1 % salicylic acid) in petrolatum be applied for 1 
hour and then washed off [Schaefer, 1980]. Runne & Kunze (1982) used 1-3% 
dithranol ointment for 10 to 20 minutes. Short contact therapy has been shown 
·to be equally effective as conventional dithranol paste and it is suggested as 
being suitable for out-patient therapy [Marsden tl..al ,1983]. 
Adjunct Therapy - The idea of combining dithranol with other therapies has 
been explored over the years. Reshad U (1984) studied the combination of 
dithranol with Ultraviolet A (UV-A) while Morison ~ ,(1978) combined 
dithranol with PUVA. The combinations were claimed to be more effective 
than either of the treatments alone, a claim that was disputed by Grattan ~ 
al (1988). The retinoid, etretinate, was also investigated with dithranol therapy 
[Orfanos & Runne ,1976] and found to reduce clearance time when compared 
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to dithranol alone. 
1.4.7 FonnulatioD 
Though effective, the use of dithranol has a number of disadvantages such as 
its potential irritancy, its staining of skin and clothing, its chemical instability 
on long term storage in many formulations, and also its use in heavy pastes 
and ointments requiring bandaging. Ways of improving patient acceptance of, 
and compliance with, treatment regimens are therefore continually explored. 
It has been shown that of the dithranol formulations available aqueous 
creams are the most popular, mainly because they are the most convenient 
to apply [Whitefield ,1981 , van Scott & Yu , 1981 ]. Ointments are less 
preferred as the greasy base is not well absorbed into the skin and most 
of the application remains on the skin. The treated areas are therefore 
covered with protective dressings in order to avoid contamination of the 
clothing and bed linen which would become extensively stained on washing. 
An other problem is the softening of ointment bases at skin temperature with 
the result that the formulation tends to spreads beyond the confines of the 
psoriatic lesions. High strength ointments would therefore lead to excessive 
irritation of uninvolved skin. This problem of spreading ointment base is 
reduced by using a stiffer ointment by incorporation of zinc oxide and starch 
into the paraffin base [Seville ~ ,1979] .. 
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Dithranol is rapidly oxidised in the presence of water due to the availability 
of dissolved oxygen [Upadrashta & Wurster (a), 1988]. To obtain a stable 
aqueous cream of dithranol, it is dissolved in the oily phase while a water 
soluble antioxidant is added to the aqueous phase as stabiliser (all dissolved 
oxygen is removed). In the cream because of dithranol's poor water solubility 
it partitions in favour of the oily phase and the water soluble antioxidant 
in favour of the aqueous phase. The stabilised cream therefore consists of 
dithranol dissolved in oily globules surrounded by an aqueous phase free 
from dissolved oxygen. The aqueous phase aids hydration of the skin, and 
also allows the cream to be completely rubbed into the skin. 
Recently a new cream formulation in which dithranol is encapsulated in a 
matrix of semicrystalline monogl ycerides [Lindahl, 1992] has been developed 
and marketed under the trade name Micanol. It is a stable formulation which 
contains no greasy components and is therefore easy to wash off. Clinical 
studies reported [Gunnar Volden ~ ,1992] have found Micanol to be 
effective and well suited for both short-and long-contact regimens for in- as 
well as out-patients. Nils Jorgen Mork ~ (1992) report that by carefully 
instructing the patients to thoroughly rub the cream into the lesions the rate 
of clinical improvement may be increased further. Christensen & Brolund (1992) 
conducted studies using a combination of Micanol and UV-B at day centres. 
They showed that there was no clinical difference between Micanol and other 
dithranol formulations, however side effects, cosmetic properties, and patient 
preference were mostly in favour of Micanol. 
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1.5 Surfactants and dithranol 
1.5.1 Surfactants - These are molecules characterized by the possession of 
both polar and non-polar . regions on the same molecule. The polar or 
hydrophillic region of the molecule may carry a positive or negative charge, 
giving rise to cationic or anionic surfactants, respectively ,or may be 
composed of a polyoxyethylene chain, as in most of the non-ionic surfactants. 
The non-polar or hydrophobic portion of the molecule is most commonly a 
flexible chain hydrocarbon. Because of this dual nature, when surfactant 
molecule are placed in an excess of water they tend to associate in solution 
forming particles of colloidal dimensions called micelles. Micelle formation 
confers unique properties on the solution. The micelles exhibit an interfacial 
region separating the polar bulk aqueous phase from the hydrocarbon like 
interior [Tan ford , 1988, Israelachvili, 1985]. The interfacial region (also called 
the Stem layer) has a width equivalent to the surfactant head-group and in 
the case of ionic surfactants, contains the ionic head- groups ,a fraction of 
the counter ions and water [Tanford , 1980 , Fendler, 1982 , Israelachvili , 1985 
,Bunton & Savelli 1986]. The Stem layer is very anisotropic causing 
properties of this region to change abruptly over a distance of a few 
angstroms. The anisotropy of the micelle renders micellar solutions a special 
medium in which hydrophobic, amphiphilic or ionic compounds may be 
solubilized and reagents may be concentrated or separated in aqueous solution 
[Fendler, 1982 , Bunton & Savelli, 1986]. 
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Typical examples of the main classes of surfactants are: 
(1) Anionic - The anion is the surface active species eg sodium lauryl sulphate 
( molecular weight 288.4). 
CH3.CH2.CH2.CH2.CH2.CH2.CH2.CH2.CH2.CH2.CH2.CH2.S04"Na+ 
Hydrophobic Hydrophillic 
(2) Cationic - The cation of the compound is the surface active species eg 
Hexadecyl(cetyl)trimethylammonium bromide (cetrimide , molecular weight 365.4). 
CHJ(CH2),sN+(CH3)3Br 
(3) Non-ionic - The water soluble moeity of this type can contain hydroxyl 
groups or a polyoxyethylene chain, eg polyoxyethylene (20) sorbitan mono-oleate 
(Tween 80 , molecular weight 1309), which is an example of a polysorbate. 
Commercial polysorbates are a mixture of sorbitol and its mono- and di-
anhydrides condensed with an appropriate number of moles of ethylene oxide. 
They have a complex molecular formula. 
I.S.2 Solubilization - To enable the formulation of dithranol in aqueous 
solution, the problem of it's poor solubility and stability in water needs to 
be addressed. In this study the solubilization of dithranol in aqueous solutions 
of surfactants is the approach to be undertaken to improve solubility. 
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Solubilization by surfactants has been shown to be an effective method for 
the enhancement of the aqueous solubility of a variety of poorly water 
soluble drugs [D.E. Guttman~, 1961, H.B Klevens,1949, Goodhart & Martin, 
1962]. The advantage of this approach is that the drug entity can be used 
without chemical modification and hence toxicological data do not have to be 
repeated as would be the case when alternative approaches are used to 
produce more soluble compounds. 
1.5.3 Percutaneous absorption 
Surfactants can either reduce percutaneous absorption of a compound by 
reducing its thermodynamic activity in the vehicle or enhance absorption by 
acting directly on the skin. In a micellar solution of surfactant and penetrant 
both of these effects will usually operate although which predominates depends 
on the physicochemical characteristics of the drug, the concentration of the 
surfactant, and the ability of the surfactant to interact with the skin. Mechanisms 
by which different surfactants enhance the permeability of the skin are yet to 
be satisfactorily elucidated. 
With the cationic surfactants (eg cetrimide) it seems likely that the main action 
is on the keratin fibrils of cornified cells and the resulting disruption of the 
cell/lipid matrix leading to enhanced permeability [Ashton d...il , 1986]. 
Nonionic surfactants (eg Tween 80) cause fluidization of lipid components of 
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the stratum corneum [Rubin & Ann , 1967] ,and their ability to enhance 
absorption is related to the ease with which they penetrate cholesterol 
monolayers, thus it would appear they act primarily on lipids. 
Most anionic surfactants (eg sodium lauryl sulphate) seem capable of both 
interacting strongly with keratin and lipids. Sodium alkyl sulphates cause 
swelling of the human stratum corneum. The swelling is the result of 
interaction with the keratin filaments in the cornified cells causing an 
conversion of the filaments. This results in their uncoiling and thus causes 
swelling. Uncoiling of the keratin filaments means that the stratum corneum 
presents less of a barrier to percutaneous adsorption [Scheuplein & Ross ,1970]. 
Anionic surfactants generally accelerate absorption more than cationic or 
non ionic ones. Whatever the anionic groups, maximum enhancement IS 
obtained by surfactants having a hydrophillic tail consisting of a linear alkyl 
chain of 12 carbons. 
On the whole, there can be little doubt that not only will the surfactants 
affect the stability of dithranol In solution, and possibly on the skin, but 
they will also affect dithranol's penetration to a lesser or greater degree and 
hence its activity. 
1.6 Purpose of study 
At present dithranol is the main drug used for the treatment of psoriasis. As 
chap 1.34 
indicated in the above introduction problems arise in its use because of its 
instability, its staining effects and its irritancy particularly on normal skin. 
Though the molecular mechanism by which it is effective in psoriasis IS as 
yet not fully understood (Fusch ~ , 1990) there is evidence to suggest that 
there is a significant parallel between the mechanism of its decomposition in 
solution and that of its decomposition/metabolism in skin (Cavey ~, 1985). 
Both involve free radical reactions the main decomposition products being 
danthron and dimer. Danthron is considered to be inactive and it may be 
responsible for the staining and irritancy effect, the dimer mayor may not 
be active [Cavey ~ ,1985]. The most likely possibility is that it is the 
process involving the production of the free radical intermediates (See Fig 
1.3) that is responsible for the observed effects. Hence study of the effect 
of factors governing stability in solution must be pertinent to anti-psoriatic 
effects. Also it is generally observed that hydration of psoriatic skin aids 
anti-psoriatic effects e.g. use of occlusive dressings, aqueous creams, and the 
hydrogel formulation developed by Priprem, (1991). It seems reasonable to 
suggest that to aid skin hydration and formulation sampling and Perhaps the 
psoriatic activity of dithranol, there is a necessity for a stable, aqueous 
solution of dithranol. 
Very little information is to be found on the stability profile for dithranol 
in solution particularly with regard to the rate of formation of danthron and 
dimer. This is particularly true for dithranol in aqueous solution at pH 5.5 -
the pH of the outer layer of skin. There is also a lack of information on 
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how the presence of possible accelerants and inhibitors of dimer and danthron 
formation ,e.g metal ions, antioxidants and surfactants, quantitatively and 
selectively affect dithranol's stability profile. As the above are of considerable 
relevance to the proper formulation of dithranol preparations and to its skin 
"activity", studies involving the production and evaluation of stability profiles 
for dithranol in solution, particularly aqueous solution at pH 5.5 ,and the 
quantitative effect of the presence of possible accelerants or inhibitors will 
form a major part of the present project. 
An essential part of the above, because of the poor water solubility of 
dithranol ,will be solubilisation studies with various surfactants with the 
objectives of maximising dithranol's aqueous solubility and stability. 
Following on from the above, in vitro metabolism and permeation studies 
using the developed aqueous formulations will be carried out using in the 
main hairless mouse skin. The objectives here are two fold, namely, to allow 
evaluation of the effect of the presence of a) skin on the stability profile 
of dithranol and b) the presence of the surfactants on the permeation rate 
and the metabolism of dithranol in the skin. A preliminary comparison will 
be made with the in vitro results obtained using human psoriatic skin 
obtained from the Dermatology Department of Aberdeen Royal Infirmary. 
Because of the ease of sampling, a preliminary study will be carried out 
with the objective of establishing the stability/metabolism/permeation profile 
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seen in vivo following the application of the aqueous surfactant solutions of 
dithranol to the surface of normal human skin. Particular attention will be 
paid to any observed relationships between changes in the profiles and 
corresponding changes in the observed staining and/or irritancy effects of 
dithranol. The ultimate objective is one of being able to control dithranol 
stability in skin with a view to controlling and understanding the relationship 
between stability and therapeutic effect. So , finally an attempt will be made 
using TPA to produce an animal model to assess the antipsoriatic activity 
of the dithranol-surfactant aqueous formulations. A brief clinical evaluation of 
one of these formulations will be made 10 collaboration with the 
Dermatology Department of Aberdeen Royal Infirmary. 
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CHAYfER2 
THE DEVELOPMENT OF ANAL YfICAL PROCEDURES 
2.1 Introduction 
To fulfill the purpose of this study, it was essential to develop procedures 
to quantify and monitor dithranol and decomposition products In a variety 
of media. Dithranol, danthron and/or dimer will be required to be quantified 
in aqueous solutions of surfactants, in whole skin (hairless mouse) and in 
receptor media (permeation studies). 
For analytical work involving dithranol the current method of choice [B.P 
1993] is hplc. Priprem (1991) developed a reversed phase hplc technique 
which has both high sensitivity and good separation between dithranol and 
danthron. Throughout the study this will be the hplc technique used for 
dithranol and danthron. Though the dimer peak is well resolved from those 
of dithranol and danthron, the sensitivity is much poorer compared to that 
for dithranol and danthron in this system. Modification of the system will 
be undertaken to maximise the sensitivity for dimer, and also shorten analysis 
time by reducing retention time. Fluorescence spectrophotometry will be used 
to study the ionisation behaviour of dithranol in aqueous solutions in the 
presence and absence of surfactants. To facilitate dithranol permeation studies 
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using whole skin, the quantification of dithranol ,danthron and dimer in skin 
was required. It was therefore necessary to develop a procedure for the 
quantification of these compounds in skin. 
2.2 Methods 
2.2.1 MATERIALS AND EQUIPMENT 
Chemicals and reagents 
Dithranol and danthron were obtained from Sigma (St.Louis, U.S.A.): and 
dithranol dimer (dimer), B.P. chemical reference substance was from the B.P.C. 
Laboratory (Stanmore, U.K.). Dithranol and dimer were stored in a desiccator 
at room temperature in the dark. Fluorene, used as the internal standard in 
hplc work, was from Fisons Scientific Equipment (Loughborough, England). 
Surfactants - Sodium dodecyl sulphate (NaLS) , approx. 99% pure , 
Hexadecyltrimethylammonium bromide (CET) 99% pure, polyoxyethylene sorbitan 
mono-oleate (Tw) ,were all obtained from Sigma (St.Louis U.S.A). 
Buffer components - Sodium acetate was from Fisons Scientific Equipment 
(Loughborough, England) ,1M Hydrochloric acid was from May & Baker 
Laboratory Products (Manchester, England). 
Solvents - Methanol ,hplc grade, was from Rathburn Chemicals (Walkerburn, 
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U.K.). Glacial acetic acid (GAA) was from BDH Limited (Poole, England). Hplc 
water was purified by a millipore Milli-Q system (Harrow, U.K.) 
The containers used to store solutions of dithranol and dimer were amber 
glass unless otherwise specified. Standard and stock solutions of danthron were 
kept in transparent glassware. All chemicals and reagents were used as 
received. 
Chromatographic system 
EQUIPMENT - A Waters Associates (Milford, MA, U.S.A.) Model 6000A solvent 
delivery pump system was used. Detection was by a Model LC 871 UV-VIS 
detector operating at 254 nm fitted with a nominal 18 ILl flow cell. Injection 
was by a Rheodyne model 7125 valve (Cotati, C.A., U.S.A.) fitted with a 200 
. JLl fixed volume loop. Recording of chromatograms was accomplished with a 
BBC recorder SE 120 (BBC Goerz, Austria). Columns were 100 x 2mm ID slurry 
packed in the laboratory with C-18, 5ILm ODS Hypersil, HETP (Macclesfield, 
U.K.). These were used for all quantitative work. Analysis was performed at 
room temperature (nominally 20 ±2°C). Equilibration with the mobile phase was 
complete in about 30 minutes. For all studies, the absorbance range used was 
0.005 AUFS. 
SOLVENT SYSTEM - The isocratic mobile phase consisted of methanol, hplc water, 
and glacial acetic acid 60:38:2 % v/v (PH 2.3 ± 0.02 , at 20°C). The flow rate 
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was O.Smllminute. The combination of mobile phase, temperature and flow rate 
yielded a back pressure of about lSOO psi. The mobile phase in the reservoir 
was degassed using a filter prior to use. 
Spectrofluorimetry 
A Perkin-Elmer Model LS-SB Luminescence Spectrometer was used. The 
excitation and emission slit widths were set at 2.S and 10 nm. The 
calibration scale of the instrument was fixed at 1.00. The scanning speed was 
30nm/minute and recorder speed 20 nm/cm. The integration time for reading 
the fluorescence intensity (FI) at a particular wavelength was 4.2 seconds and 
for the recording of spectra 16.8 seconds. A I-cm cuvette was used. 
Miscellaneous 
The following apparatus was used where and when required: 
A Model FSlOO ultrasonic bath (Decon, Sussex, England): A Coming pH meter 
model 10, Coming Limited (Essex, England), standardised with pH 4.00 and 
7.00 buffer solutions: A Sartorius Balance (Sartorius Werke AG, Gottingen, 
Geremany.) for weighing more than SOmg weight of materials and a Mettler 
Model AE 240 (Mettler Instruments, Buckinghamshire, U.K.) for S mg or more. 
Centrifugation was performed using a model MSE Micro Centaur, Fisons , 
(England). 
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2.2.2 STOCK SOLUTIONS 
Dithranol 
10 ml of a solution of dithranol in GAA of about 400jLg/mL, was accurately 
prepared (monthly) and stored at -21°C. Using such a solution, less concentrated 
stock solutions in acidified methanol (methanol 98% , GAA 2%) were prepared 
fresh on a day to day basis. Once prepared solutions in acidified methanol 
were protected from light and the container kept in ice. Such solutions· were 
not kept longer than 6 hours. 
Danthron 
An accurately prepared solution of danthron in methanol (-I00jLg/mL) was 
used throughout the study. 
Dimer 
Accurate concentrations of dimer in acetone (about 100 JLg/mL) were freshly 
prepared. 
2.2.3 STANDARD SOLUTIONS AND CALmRA TION 
Hplc 
20 JLg/mL fluorene in methanol, stored at room temperature was used 
as an INTERNAL STANDARD (IS) solution. 
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DITHRANOL - The GAA stock solution of dithranol was diluted to lOOJLg/mL 
using GAA. O.OSml of the 100JLg/mL stock solution of dithranol was transferred 
to a lOmL volumetric flask. GAA was added to this such that the final 
volume of GAA was O.2ml. Methanol was then added to make the volume 
up to the lOml mark resulting in a dithranol solution of O.S JLg/mL in 
acidified methanol (see above). This procedure was then followed to produce 
1, 1.S and 2 JLg/ml solutions of dithranol in acidified methanol. The acidified 
methanol solutions were diluted 1: lOusing mobile phase before injection onto 
column. O.OSmL of the internal standard stock solution (resulting in O.lJLg/mL 
of fluorene in the solution to be injected) was added at the stage of dilution 
with mobile phase. ALL solutions were prepared in triplicate. 
DANTIIRON - The stock solution was first diluted to 3JLg/mL usmg methanol. 
0.1, 0.2, 0.3 and O.4ml of the 3JLg/mL stock solution was transferred to 4 
separate lOml volumetric flasks.O.OSml of the 20JLg/mL fluorene solution was 
also added to each volumetric flask. The volume was then made up to the 
lOmL mark using mobile phase. The final concentration of danthron was thus 
in the range of 0 - 0.12JLg/mL. The diluted solutions were injected unto the 
column. All solutions were prepared in triplicate. 
2.2.4 DlMER ANALYSIS - Starting with the mobile phase shown below (Priprem, 
1991), modification was made to the amounts of methanol and water (see 
Table 2.1). 
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Methanol.. ... .. ... .. .... . ..... 60 % 
Water ........................ 38 % 
Glacial acetic acid ..... ..... 2 % 
Table 2.1 
% Methanol % Water % Glacial acetic acid 
(A) 60 38 2 
(B) 75 23 2 
(C) 80 18 2 
The detection wavelength was fixed at 254nm and using the above mobile 
phases in tum, dimer 0.20J-Lg/mL' was injected onto the column and peak 
characteristics at various flow rates investigated. 
2.2.4.1 Calibration grapb for dimer using mobile pbase-A and mobile pbase-8 
at a flow rate 0.3 mUmin. 
The acetone stock solution was diluted to 50"g/mL. 0.03, 0.06, 0.09, 0.12 and 
O.24mL of this solution was transferred to each of 5 different lOml 
volumetric flasks. The volume was then made up to the lOmL mark using 
mobile phase-A. The procedure was then repeated using mobile phase-B diluent. 
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The concentration range of the diluted dimer solutions was thus 0 - 1.2",g/mL. 
The diluted samples were injected on to the column and the average peak 
height (dilutions done in triplicate) plotted against concentration of the 
standard. 
Calibration 
The calibration lines for the three analytes were checked on a monthly basis 
with calibration procedure being done in triplicate for each analyte. Linear 
regression was used for analysis of the ratio of peak height to concentration 
for dithranol and danthron but not for dimer. The average correlation 
coefficient, slopes and intercepts are shown in Table 2.2 (dithranol & danthron) 
and Table 2.4 (dimer) . 
. 2.2.4.2 The effect of water on analyte peak height. 
Using methanol, the stock solutions described in 2.2.2 were diluted to 20 and 
12",g/mL for dithranol and danthron respectively. For dimer acetone was used 
to dilute the stock solution to 27",g/mL. 6 , 10mL volumetric flasks containing 
9.8 , 6 , 4 , 2 ,1 and 0 ml of water were then set up. 0.1 and O.OSmL each 
of the 20",g/mL dithranol and 20",g/mL fluorene solutions was added to each 
of the 6 volumetric flasks. Volume was made up to the lOmL mark using 
mobile phase-A.The solutions were then injected onto the column and the 
heights of the peaks measured and recorded. The whole procedure was 
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repeated first using the 12",g/mL solution of danthron (with mobile phase-A 
as diluent) and then with the 27",g/mL solution of dimer along with mobile 
phase-B as diluent. With the dimer solutions fluorene was not added and 
9.9ml (instead of 9.8) of water was used in one of the volumetric flasks. 
2.2.4.3 The effect of surfactant presence on analyte chromatography 
(retention time and peak height) 
Surfactant solutions (NaLS, CET ,Tw) of concentrations 0.0, 0.5 , 1 , 2 , 3 
, 4 , 5 % w/v were prepared in 0.2M aqueous acetate buffer pH 5.5. 2mL of 
each concentration was transferred to a volumetric flask (lOmL). O.lml of the 
20",g/mL dithranol solution (see 2.2.4.2) was added to each volumetric flasks 
and volume made up to the 10ml mark using mobile phase-A. The solutions 
were then injected onto the column and peak characteristics recorded. The 
procedure was repeated using O.lmL of the 12",g/mL danthron and 20",g/mL 
fluorene solutions (see 2.2.4.2) with mobile phase-A as diluent. 
2.2.5 SAMPLE PRETREA TMENT AND ANALYSIS 
Hplc 
AQUEOUS SOLUI10NS (WI1H AND WI1HOur SURFACfANTS) - Samples to be injected 
onto the column were first diluted with mobile phase. For the quantification 
of dithranol and its breakdown products dilutions were such that the aqueous 
phase did not constitute more than 20% by volume of the solutions to be 
onto the column (see Results/Discussion). 
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2.2.5.1 HAIRLESS MOUSE SKIN - A mixture of trichloro acetic acid (TCA) and 
methanol, 20:80 respectively, was used as the extraction solvent. TCA is 
added because it facilitates the homogenisation process and also enhances 
stability ,especially for dithranol , due to a lowering of the pH. The ability 
of TCA to precipitate proteins is another reason for it's inclusion. The TeA 
: Methanol mixture is used cold ( 4°C) as this aids the settling down of any 
precipitates in solution. The temperature is kept low during the extraction 
procedure by surrounding the sample holder in the homogeniser with ice. 
Methanol is a reasonably good solvent for dithranol, danthron and dimer and 
therefore aids extraction. Also should the sample require concentration, solvent 
removal can be achieved at reduced temperatures by blowing off the 
predominantly methanol solvent. 
2.2.5.2 Hairless mouse skin extraction procedure.- Frozen whole skin was 
used. This was first allowed to thaw by leaving it in a sealed glass 
container at room temperature. Skin to be extracted (2cm2) is first weighed 
and then cut into smaller pieces and placed in the glass sample holder of 
the blender, which is cooled by surrounding it with ice. 3mL of the TeA 
: Methanol mixture (4 °C) is added to the skin which is then homogenised 
at 13 000 rpm for about 3 minutes. 0.4 mL of the supernatant is diluted to 
4 mL with cold mobile phase ( 4°C). A sample of this solution is then 
centrifuged (13 000 rpm for 2 minutes) and the clear supernatant injected onto 
the column (Any further dilution is done using cold mobile phase). A 
standard mixture of dithranol ,danthron and dimer was added to a piece of 
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chopped up skin in the glass sample holder of the homogeniser and the 
extraction procedure followed. The percentage recovery of each of the 
compounds was ascertained. 
2.2.6 Calibration graphs for dithranol, danthron and dimer in the 
presence of skin homogenate. 
Using methanol for dithranol and danthron the stock solutions in 2.2.2 were 
first diluted to 40 and 20J-Lg/mL respectively. The dimer stock solution was 
diluted to 50J-Lg/mL using acetone. A 2cm2 piece of hairless mouse skin was 
then weighed and chopped up into smaller pieces and placed into the glass 
sample holder of the blender. 0.05mL each of the diluted standards of 
dithranol and danthron and 0.06mL of the dimer standard were added to 
the chopped skin. 0.2mL of the 20J-Lg/mL fluorene standard solution was then 
added. The volume was made up to 4mL using the TeA: Methanol mixture 
and the extraction procedure as per 2.2.5.2 followed. O.4mL of the supernatant 
is diluted to 4mL with cold mobile phase-A (for dithranol and danthron) and 
cold mobile phase-B for dimer. The diluted solutions are injected on to two 
separate columns and all peak heights recorded. Using a fresh piece of skin 
each time more solutions were prepared such that the solutions to be 
injected on to the columns all contained O.lJ.'g/mL fluorene and were in the 
range 0.05 - 0.20J.'g/mL for dithranol, 0.02 - O.lOJ.'g/mL for danthron and 0.06 
_ 0.24 for dimer. All solutions were prepared in triplicate. Linear regression 
was used for analysis of the ratio of the peak height (dithranol and danthron) 
to internal standard on concentration. For the dimer, the relationship between 
dimer peak height and concentration of the standard was the one analyzed 
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by linear regression. The results are shown in Table 2.5. Calibration graphs 
produced as described above were used for all skin determinations. 
2.2.7 Spectrofluorimetry 
Using the GAA stock solution of dithranol a standard solution of dithranol 
(ll'g/mL) was prepared in acidified methanol (methanol 98%, GAA 2%). The 
prepared standard is protected from light (amber coloured container) and kept 
cold by placing the container in ice. O.03mL of the standard is added to 
2.97mL of the solution under investigation, resulting in a mixture containing 
dithranol in the region of IOng/mL which is a concentration within the 
linear range of response [Priprem, 1991]. The cell is inverted once to ensure 
mixing of the contents and the fluorescence reading taken quickly to avoid 
loss of ionised dithranol due to decomposition. 
2.3 Results/Discussion 
Hplc 
The chromatographic system used for dithranol and danthron analysis was the 
one developed by Priprem (1991). A representative chromatogram of dithranol 
danthron and fluorene is shown in Fig 2.1 
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Calibration graphs 
The characteristics of the calibration graphs for dithranol and danthron are 
shown in Table 2.2. The table shows that correlation coefficients ranging from 
0.997 to 0.999 were obtained. Linearity of response was obtained throughout 
the period of the study. It is also seen in the table that the slope for the 
danthron line is approximately twice that for dithranol, thus indicating that 
the system has a higher sensitivity for danthron. 
For the analysis of dithranol and danthron the hplc system reported by 
Priprem (1991) is adequate in terms of sensitivity and analysis time. In this 
system the reported detection limits are 15-20, and 1.5-2 ng/mL for dithranol 
and danthron respectively. The analysis for both compounds is done in less 
than 10 minutes. This system, however, is only of limited use when used for 
dimer analysis. The major drawbacks are a lengthy retention time of 24 
. minutes and a broad peak which results in reduced sensitivity. Starting with 
the mobile phase reported by Priprem (1991) and increasing the methanol 
content from 60 to 75 % ,and reducing that of water from 38 to 23 % , the 
retention time was reduced from 24 to 3.5 minutes when the flow rate was 
set at 0.5mUminute. With a retention time of 3.5 minutes the dimer peak 
was not well resolved from the solvent front, reduction in flow rate to 
0.3mL/minutes achieved this resolution as the dimer peak has a retention 
time of 5.8 minutes. These results are shown in Table 2.3. The superior 
sensitivity of the modified mobile phase is shown when the two mobile 
phases are used to obtain calibration graphs for dimer (see Fig 2.2). The 
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characteristics of the calibration lines are tabulated in Table 2.4. Linearity of 
response was obtained using both mobile phases ,comparing the slopes of the 
two lines shows that there was more than a three fold increase in the slope 
on modification of the mobile phase. At a signal to noise ratio of 3 the 
detection limit in the mobile phase with 60% methanol is 55 ng/mL compared 
to 10 ng/mL with 75 % methanol. 
There are a number of reports in the literature dealing with the Hplc 
analysis for dimer. Irene C.L U (1989) report a reverse phase system 
where the detection limit for dimer was lOng/mL and the analysis time was 
just under 15 minutes. The disadvantage of this system compared to mobile 
phase-B is the use of a 25 cm column and a flow rate of 2mLlminute 
leading to increased consumption of mobile phase. In the mobile phase-B system 
the column length is 10 cm and flow rate O.3mLlminute. The analysis time 
of around 6 minutes in mobile phase (B) is much shorter than the 15 
minutes in the report by Irene C.L ~. Caron and Shroot (1981) report a 
system where dimer retention was 8.42 minutes, the disadvantages are the 
use of a 25 cm column, flow rate 2mUminute and operation at 60°C which 
would introduce stability problems. Lee (1987) reports the use of the Caron 
and Shroot system run at 20°C where dimer retention time was 12 minutes. 
The same disadvantages of longer column, faster flow rate and longer analysis 
time are still present when compared to mobile phase-B. The present 
disadvantages of using mobile phase-B are that a suitable internal standard has 
not been identified and also that two chromatographic systems need to be 
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run at the same time to enable the simultaneous determination of dithranol • 
danthron and dimer. However a fixed volume loop (20ILL) was used on the 
dimer system and repeated injection of dimer O.lOlLg/mL gave a peak height 
of 10.3 + 0.2 (n =5). The small standard deviation showing that peak height 
reproducibility was good. Mobile phase-B will thus be used for all work 
requiring the hplc analysis for dimer. 
Assay validation 
For assay validation purposes the effect on the chromatographic analysis of 
(i) variation in the water content; (ii) the presence of surfactants of di!ferent 
type and concentration; (iii) the possible presence of interfering substances 
from the hairless mouse skin extractions, in the injected samples required to 
be established. Also the % recoveries from the skin for dithranol, danthron 
, dimer and fluorene and the characteristics of the calibration lines 
subsequently obtained required to be established. 
Effect of water content variation in the injected samples 
All samples injected onto the column were first diluted with mobile phase. 
Because of dithranol's poor aqueous solubility the solutions to be analyzed 
usually contained low concentrations of dithranol. With such solutions dilutions 
such as 1: 10 (and greater) are possible at the beginning of experiments when 
dithranol concentrations are still relatively high. As decomposition proceeds 
chap 2.52 
and dithranol levels decrease less dilute samples need to be injected onto the 
column. When less dilute samples are used it means that there is an increase 
in the amount of aqueous phase present in the sample injected. Fig 2.3 shows 
the influence on analyte peak height of varying amounts of H20 in samples 
injected onto the column. For all the analytes the presence of aqueous phase 
up to 20% v/v did not alter analyte peak height. Above this concentration a 
general increase in peak height is observed. For dithranol and danthron 
injection of samples containing > 60% aqueous phase resulted in - 100% 
increase in initial peak height while for dimer and fluorene around 30% 
increase was observed. Retention time was observed not to be influenced by 
water content variation. Because of this effect of water, sample dilution 
(before injection) of less than 1:5 were not made. 
The effect of the presence of surfactants of different type and concentration in 
the injected samples on the chromatographic analysis 
The results in Fig 2.4 show that the presence of all three surfactants up 
to 1 % vlv did not alter the chromatography of the analytes. Both retention 
time and peak height remained constant as surfactant concentration was 
increased from 0 to 1 % v/v. During the course of the study dithranol and 
its breakdown products was required to be determined in aqueous solutions 
containing up to 4 % surfactants. Since no sample dilutions (using mobile 
phase) of less than 1:5 were made before injection onto the column, the 
highest concentration of surfactant present in the sample to be injected 
was 0.8% v/v (1:5 dilution of a 4% surfactant solution). Determinations in the 
chap 2.53 
surfactant solutions can, therefore, be done without any chromatographic 
interference from the surfactants. 
Hairless mouse skin: the effect of interfering substances on the 
chromatographic analysis and assay validation. 
By following the TeA-Methanol skin extraction procedure developed 
chromatograms for dithranol, danthron and dimer are obtained that indicate 
that interference from any substances present in. the skin is successfully 
removed. These chromatograms are shown in Fig 2.5 & 2.6. In Fig 2.7 the 
results for the recovery of dithranol , danthron ,dimer and fluorene when a 
standard mixture of the four compounds is added to skin which is then 
put through the extraction procedure, are shown. For all four compounds 
around 90% recovery was observed. Effects such as binding to protein and 
the efficiency of the homogenisation of the skin, make 100% recovery 
almost impossible to achieve. When calibration was done in the presence 
of skin homogenate Table 2.5 shows that linearity of response was 
obtained in all cases. The slopes of the three lines were however 
smaller than those obtained in the absence of skin homogenate, this is 
most likely linked to the % recoveries possible. 
Spectrofluorimetry 
The monoanionic species of dithranol is the fluorescent form. It is also 
very unstable particularly at pH values above it's pKa value of 9.4 [Melo 
~ (1983)]. In solutions of pH 5.5 dithranol is non ionised and no 
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fluorescence is observed. Introduction of CET , however ,leads to dithranol 
ionisation ,even at this low pH ,and the appearance of fluorescence (see 
chapter 5). When fluorescence characteristics were investigated in solutions 
of pH > 9.5 isoascorbic acid (0.1 % w/v) was added to stabilise the 
fluorescence signal, which would otherwise decay rapidly ( > 90% decay 
within 5 minutes) in these alkaline conditions. When the fluorescence signal 
from a 10ng/mL solution of dithranol (0.02M glycine buffer pH 10 + 0.1 % 
isoascorbic acid) was set to read 100%, a standard deviation of ± 11 % 
(n =5) for repeated determination of the same concentration was obtained. 
This indicates that the fluorescence signal was reasonably reproducible. 
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Fig 2.1 
Representative chromatogram of dHhranol, danthron , dimer and fluorene (internal 
standard) analysed using mobile phas.A at a flow rata of O.5mL/minute. 
1 = danthron , 2 = dHhranol , 3 = dimer , IS -= intemal standard. 
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Table 2.t 
Calibration line characteristics for dithranol and danthron. 
Slope C.C Intercept 
Dithranol 6.116 (0.300) 0.997 (0.001) 0.02 (0.01) 
Danthron 11.823 (0.441) .. 0.999 (0.000) 0.01 (0.01) 
Results are shown as mean ± SEM (in brackets, na ,). C.C - correlation coefficient. 
Table 2.3 
The effect of the alteration of the methanol:water ratio and flow rate of the mobile 
phase on dimer retention. 
Retention time 
% MeOH % H:P % GAA Flow rate mL/min (minutes) 
60 3S 2 0.5 24.0 
75 23 2 0.5 3.5 
SO lS 2 0.5 2.2 
75 23 2 0.3 5.S 
MaOR • methanol, GAA • glaeial acetic acid 
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Fig 2.2 Dimer calibration graphs • mobile phase-B flow rate O.3mUminute. II. 
mobile phase-A flow rate O.5mUminute. 
Table 2.4 
Dimer calibration line characteristics 
I Slope C.C Intercept 
Mobile phase-A 1 7.4 (0.1) 0.996 (0.001) -0.15 
Mobile phase-B 124.4 (0.2) 0.999 (0.000) -0.02 
Results are shOWD as mean ± SEM (ill brackets.D-". c.c· correlation coemcieut. 
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Fig 2.3 The effect on peak height of % of water present in samples 
injected onto the Hplc column. • dithranol, ~ danthron, y dimer, + 
fluorene. 
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The effect on a) peak height and b) retention time I of the amount of surfactant present 
in samples injected onto the Hplc column. - dithranol I '" danthron I 'Y dimer I • fluorene. 
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Fig 2..5 chromatagrama of the TCA-Methanol extract of (1) hairiesa mouse sldn , (Ii) 
hairless mouse skin with climer added. The chromatograms were obtained using mobile 
phase-a at a ftaw rata of O.3mL/minute. D - dlmer. 
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Fig 2.8 Chromatograms of a TCA-Methanoi extract of hairleu mOUN skin with (1) 
Fioure
ne 
added, (D) with danthron (1) , dithranol (2), and ftuorene (3) added. The 
chrOmatograms w .... obtained using mobile phase-A, at • ftow rate of O.5mLlmin. 
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Fig 2..7 The recovery of a standard mixture of dithranol, danthrcn, dimer 
and fluorene from hairiess mouse skin following the TCA-methanol 
extraction procedure (n=3). . 
Table l.5 
Calibration liDe characteristics for dithranol, danthron and dimer in the presence of skin 
homogeD2te 
Slope C.C Intercept 
Dithranol S.78 (0.09) 0.996 (0.002) 0.03 (0.02) 
Da.ntllIon 10.84 (0.67) 0.997 (0.001) -0.08 (0.01) 
Dimer 20.4 (1.1) 0.996 (0.001) I.3S (0.10) 
RdaJts ar. sbOWll as meu ± SEM (lD brackets, a-l). c.e • cornlatloD coeftld ... The mobile pbue 1I.Md 
lor dJdIruoi ud duttaroa was (A), ud (B) was used lor dlmer (see Tabl. %.l lor mobile pilue 
composidoa). 
chap 2.63 
CHAYfER3 
THE ENHANCEMENf OF THE AQUEOUS SOLUBILITY OF 
DITHRANOL USING VARIOUS SURFACTANTS. 
3.1 Introduction 
Dithranol is practically insoluble in water (BP 1988). Determination of the end 
point for dithranol saturation solubility in aqueous systems is difficult to 
achieve with great accuracy because of the formation of a colloidal dispersion 
especially when dithranol is present in excess. This is reflected in the literature 
where a range of solubilities are quoted - 2/-Lg/mL M.Whitefield (1981) , 
5/-Lg/mL Upadrashta and Wurster (1988), 3/-Lg/mL Caron ~ (1982),0.1 -
O.4/-Lg/mL M.Kneczke ~ (1989). Variations in pH and temperature conditions 
for the solubility determinations are contributory factors. There are various 
approaches that can be taken to enhance the solubility of poorly water 
soluble drugs. The approach that will be concentrated on here is 
solubilization in surfactant solutions (see 1.5.2). Surfactants have also been 
shown to influence the percutaneous absorption of drugs [Chowan and Pritchard 
(1978) , Shahi and Zatz (1978), Hwang and Danti (1983) , also see 1.5.3]. This 
property of surfactants could be exploited to improve the effectiveness of 
delivery of solubilized drug to active sites in the skin. 
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3.2 Methods 
3.2.1 Materials and Equipment 
Details of the spectrophotometer used are given In 5.2.l. All other materials 
and equipment used were as described in 2.2.1 
3.2.2 Solubilization 
Equilibrium solubility of dithranol in NaLS and Tw 80 was determined by adding 
an excess of the drug to the test solution containing the assigned quantity 
of the solubilising agent in acetate buffer (0.2 M sodium acetate adjusted to 
pH 5.5 using 0.4 M HCI). For CET , solubilization studies were carried out in 
·1 M HCl (PH 0.4) solutions. To enhance the stability of dithranol iso-ascorbic 
acid (0.5 %) was added to the Tw, NaLS and CET pH 5.5 solutions. Because 
of dithranol's good stability properties at low pH (see chapter 4) iso-ascorbic 
acid was not added to the CET solutions in 1M HCI. The solutions, in 10mL 
volumetric flasks protected from light with aluminium foil, were left in a 
water bath at 25°C with periodic shaking. Priprem (1991) showed that the 
time taken for dithranol to reach equilibrium solubility in aqueous solutions 
(250C) was approximately 1 hour. The NaLS, Tw and CET in 1M HCI 
solutions were therefore analysed for dithranol in solution after I hour. 
Because of CET ionisation effect in the case of the pH 5.5 CET solutions 
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analysis for dithranol in solution was carried out after 5 - 10 minutes. For 
all solutions a ImL sample was removed using a pipette and this was 
centrifuged at 13000 rpm for 2 minutes. After this an aliquot of the clear 
supernatant was suitably diluted using the mobile phase, the internal standard 
added and the diluted sample analysed by hplc. 
3.2.3 Ultraviolet absorption spectrophotometry 
The effect of surfactant concentration on the UV -absorption spectrum of 
dithranol in the three surfactants was investigated. The spectra for a fixed 
concentration of dithranol (4-5J4g/mL) under the following conditions were 
obtained. 
(1) Sodium acetate-HCI buffer pH 5.5 at 25°C. 
(2) 1M HCI at 25°C. 
(3) Chloroform (Analar) 
(4) Increasing concentrations (0 - 0.32 % w/v) of NaLS and Tw (0 - 0.1 % w/v) in 
buffer pH 5.5, and CET (0 - 0.06% w/v) in 1M HCI , all at 25°C. 
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3.4 Results/Discussion 
Though literature in the field of micellar solubilization is extensive and many 
monographs and review articles are available [M.E.L MCbain & E.Hutchinson 
(1955), P.H Elworthy ~ (1968), T. Nakagawa (1967) , I.H. Fendler & E. Fendler 
(1975) , K. Shinoda (1967) ] ,there is no information that deals specifically 
with the solubilization of dithranol. Reference to dithranol solubilization 
without any quantitative or qualitative data presented has, however , been 
made. C.M Lawrence ~ (1987) suggested that the solubilization of dithranol 
by Teepol (anionic surfactant) facilitated it's physical removal from th~ skin 
during short contact therapy. Indeed the general practice in short contact 
therapy is to remove excess dithranol by washing the treated area with soap. 
It is somewhat surprising ,therefore, that the effectiveness of surfactant 
solubilization of dithranol has not been investigated. 
Surfactants are able to increase the solubility of poorly water soluble drugs 
by solubilisation because of their unique ability to form micelles in solution 
(see 1.5.1 & 1.5.2). The nature of solubilisation in micellar solutions and the 
effects of the solubilized species on the monomer-micelle equilibria depend on 
the nature of the interactions of the solubilized species with the monomers 
and the micelles [M.E.L. MCbain and Hutchinson (1955) , P.H. Elworthy ~ 
(1968) , T. Nakagawa (1967)]. Relatively non-polar solubilized species do not 
interact with the monomers to an appreciable extent. Their solubilization can 
chap 3.67 
be ascribed to the micelles. In solutions of flexible chain surfactants a 
characteristic feature of such micellar solubilization is the existence of a 
small range of concentrations below which there is no solubilization and 
above which the solubility increases approximately linearly with the 
concentration. Some suitably defined concentration within this narrow range 
is the critical micellization concentration (c.m.c) of the system containing the 
solubilized species. This feature reflects the highly cooperative character of 
the self association of the monomers that leads to the existence of the c.m.c 
and to the formation of micelles. 
On saturating increasing concentrations of NaLS, Tw and CET with 
dithranol the solubility profiles obtained in the three surfactants was typical 
of micellar solubilization (see Fig 3.1 , 3.2 & 3.3). Plotting the data in Fig. 
3.1, 3.2, & 3.3 as tlS/ tlC v C with tlS/ tlC defined as (S2-SI)/(Cr C1) where C2 
and C1 are adjacent surfactant concentrations in mol/Litre and S2 and SI are 
-the corresponding solubilities of dithranol in mol/Litre, C is the average of 
C
1 
and C2 ,shows that the rate of change of dithranol solubility with 
concentration of the surfactant increased from a value of nearly zero to a 
high, nearly constant value, over a narrow range of concentrations around the 
c.m.c (Fig 3.4, 3.5 & 3.6). Again this is typical of micellar solubilization. If 
the aqueous surfactant solutions were behaving as cosolvents a plot of AS/AC-
v C would produce monotonically increasing curves [Shinoda ~ 1963]. Fig 
3.4 , 3.5 & 3.6 show that no such curves were obtained for dithranol in the 
surfactant solutions. The possibility of the surfactant solutions behaving as 
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good cosolvents can thus be ruled out and the enhanced solubility observed 
ascribed to micellar solubilization. 
To gain an understanding of the location and distribution of the solubilised 
dithranol inside the micelles UV spectroscopic properties were used. The UV 
spectra of many compounds are sensitive to changes in the environment of 
the absorbing molecules [Cardinal & Mukerjee, 1978]. Since micelles are 
characterised by possession of regions of different polarity, an estimate of 
the location of solubilized material within micelles can be made from UV 
spectra. On comparison of the UV spectra for dithranol in a polar environment 
(buffer pH 5.5) and in a non-polar one (chloroform) it is evident (see Fig 3.7) 
that the spectrum in the polar solvent lacks the spectra detail that it 
obtained in the non-polar solvent. In the buffer no distinct peaks are 
identified, whereas in chloroform three peaks, at 258nm , 288nm and 355nm, 
are evident. 
When a fixed concentration of dithranol ,was placed In increasing 
concentrations of NaLS solutions at pH 5.5 it was observed that the spectrum 
obtained for dithranol became more and more like that obtained In 
chloroform (see Fig 3.8). The indications are that dithranol molecules are 
located in an increasingly non-polar environment as NaLS concentration 
increases. The conclusion from the spectrophotometric evidence gathered is that 
solubilization is such that the molecules of dithranol are embedded in the 
hydrocarbon core of the NaLS micelles. 
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In Tw ,the spectrum for solubilized dithranol was very similar in feature to 
that obtained in buffer alone except for the shoulder at around 388nm and 
the peak at 258nm both of which are indicative of the presence of the 
ionised form of dithranol (see Fig 3.9). The similarity in the spectra of 
dithranol in buffer alone and when solubilised in Tw micelles is an 
indication that the molecules are in an environment where the polarity is 
close to that of aqueous buffer - i.e polar. The ionisation peak at 258nm 
shows that upon solubilisation dithranol molecules enter an environment where 
the hydrogen bonding which stabilises the keto form of dithranol molecules 
is disrupted leading to the appearance of the enol form, and thus more of 
ionised dithranol following the deprotonation of the enol form by water 
molecules (see scheme 5.1). The micelles that non-ionic surfactants containing 
polyoxyethylene head groups form in aqueous solutions have a hydrocarbon 
core surrounded by a mantle, which can be described as a dense solution 
of polyoxyethylenes. Solubilization in such micelles may involve two broadly 
defined loci: (a) the hydrocarbon core (non-polar region) along with its interface 
and, (b) the polyoxyethylene mantle (polar region). From the spectrophotometric 
evidence obtained in Tw solutions the indications are that the solubilized 
molecules of dithranol are located in the polar polyoxyethylene mantle of the 
micelles. 
With CET it was observed that the introduction of dithranol into pH 5.5 
solutions led to an interaction between the two resulting in the ionization of 
dithranol (see chapter 5). To obtain solubilization data free from the effect of 
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this interaction the determinations were done at low pH (1 M HCI) , where 
the interaction is effectively suppressed. When a fixed concentration of 
dithranol was placed in increasing concentrations of CET in 1 M HCL the 
spectra obtained showed a gradual change from the poorly defined spectrum 
obtained in buffer alone to the well defined type similar to that obtained 
in chloroform (see Fig 3.10). From this spectrophotometric evidence the 
indications are that the environment for dithranol molecules became 
increasingly non-polar as CET concentration rose. It can thus be concluded 
that the seat of solubilization is the hydrocarbon core of the micelles. Further 
evidence supporting this conclusion was the lack of any signs of ionisation 
of dithranol at 258nm. This is an indication that upon solubilisation the 
molecules of dithranol enter an environment where the hydrogen bonding that 
stabilises the keto form of the dithranol molecules is not disrupted thus the 
possibility of the ionisation of dithranol is eliminated. 
Following the establishment of the fact that dithranol was successfully 
solubilised by the three surfactants investigated, the amounts of dithranol 
going into solution was required to be established. The results of carrying 
out the solubilization procedure using NaLS (PH 5.5) , Tw (PH 5.5) and CET 
(PH 0.4) all covering the concentration range 1 - 8% w/v are shown in Fig 
3.11. The solubility profiles show that over the concentration range studied 
the solubility of dithranol was linearly dependent on the per cent of 
surfactant present. CET solubilised dithranol with greatest efficiency followed 
by NaLS and then Tw. 
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With regard to the formulation of solubilised systems of dithranol the 
solubilisation results indicate that the higher the surfactant concentration the 
greater the amount of dithranol that goes into solution. As the solutions are 
intended for direct application to the skin, the limiting factor regarding 
surfactant concentration is the ability of the skin (diseased and normal) to 
tolerate the concentration of surfactant used. In the case of CET the ability 
of the skin to withstand treatment with a formulation with a pH as low as 
0.4 also needs to be considered. Another problem is the tendency for NaLS 
and CET to come out of solution as concentration is increased (> 1 %) 
especially at temperatures below 25°C. This precipitation problem was not 
observed with Tw. 
In CET solutions at pH 5.5 around three fold more dithranol went into 
solution at any given surfactant concentration, compared to solutions of pH 
0.4 (see Fig 3.11). This is because of the dithranol-CET interaction that 
occurs at pH 5.5 (see chapter 5). While this is ideal for the enhanced solubility 
of dithranol ,the formulation is unstable because of the presence of ionised 
dithranol. It is therefore necessary to take precautions such as antioxidant 
addition in order to improve stability and thus the shelf life of the 
formulation (see chapter 4). 
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The rate of change of dithranol solubility with increasing concentrations of NaLS 
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The solubility profile of dithranol in aqueous surfactants (1 • 8% w/v) at 25°e • 
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CHAYfER 4 
THE STABILITY OF DITHRANOL IN METHANOL 
AND IN AQUEOUS SURFACTANT SOLUfIONS. 
4.1 Introduction. 
In the previous chapter it was established that the poor aqueous solubility of 
dithranol can be improved by solubilization in aqueous solutions of 
surfactants. Here, using the hplc methods discussed in chapter 2, the stability 
of dithranol will be monitored in such solutions with and without the 
addition of antioxidant. The antioxidant will be chosen after investigating 
the stabilising capacity of a number of antioxidants usmg methanolic 
solutions of dithranol. In an effort to simulate conditions on the outer layer 
of the skin, stability studies will be conducted at pH 5.5. The influence of 
temperature will also investigated. 
Metal ions are known to cause dithranol instability. Also, trace amounts of 
metal ions are expected to be present in the skin, here, their influence on 
dithranol decomposition both in the aqueous surfactant solutions and 
methanolic solutions will be investigated. Methanolic solutions will be used 
initially to study the stability of dithranol because of its poor water 
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solubility. Further work will show that the stability patterns 10 an aqueous 
environment are similar to those observed in methanolic solutions. 
The reasons for studying the above will be, firstly, to identify the conditions 
of maximum stability for the dithranol - surfactant solutions , so that studies 
designed to assess the potential of delivering dithranol to the skin using 
these solutions can be done. Secondly, to try and achieve selective control 
over dithranol's decomposition pattern to dimer or danthron. Danthron is an 
inactive antipsoriatic compound, but is implicated in dithranol's staining and 
irritancy effects.It remains, as yet, unclear whether or not dimer IS an active 
antipsoriatic compound [Cavey ~ ,1985 , Krebs ~ , 1981]. A more 
established observation is the fact that the formation of the oxidation 
products of dithranol (danthron and dimer), via the free radical route, is 
central to both the therapeutic and side effects of dithranol [Martinmaa ~ 
., 1981 ,Misch ~, 1981]. An appreciation of the relative importance of the 
formation of danthron or dimer will aid a better understanding of the 
relationship between dithranol's decomposition pathway and its mechanism of 
action. 
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4.2 Methods 
4.2.1 Materials 
Chemicals 
Ferrous sulphate heptahydrate (99% pure) , Zinc sulphate heptahydrate , Cupric 
sulphate pentahydrate (99% pure), L-ascorbic acid 6-palmitate, O-isoascorbic acid, 
Citric acid monohydrate, Salicylic acid and L-ascorbic acid were from BOH 
Chemicals (Poole. U .K). 
All other chemicals were as In 2.2.1 
4.2.2 Stability of ditbranol in metbanone and aqueous solutions 
4.2.2.1 In metbanolie solutions. 
Effect of metal ions - Using concentrated solutions (10 mg/mL) in methanol 
of Fe2+ ,Zn2+ and Cu2+ along with a concentrated solution of dithranol 
(-400JLg/mL) in acidified methanol (methanol 98% glacial acetic acid 2%), a 
solution was prepared, in triplicate, containing 40 JLg/mL of dithranol and 
20JLg/mL of Fe2+ in a 25mL volumetric flask using acidified methanol to 
make up the volume. This was repeated, in triplicate, using Zn2+ and Cu2+ 
respectively in place of the Fe2+ . A blank was also prepared omitting the 
chap 4.86 
metal ion. Once prepared ,samples at selected time intervals were 
withdrawn, appropriately diluted with mobile phase, the internal standard added 
and analysis done by hplc. 
Effect of antioxidants - Stock solutions (1 % w/v) of a number of antioxidants, 
and a stock solution of Fe2+ (lOmg/mL) were prepared in acidified methanol. 
U sing these, along with a concentrated solution of dithranol prepared as in 
4.2.2.1 the following mixtures of dithranol (40J.(g/mL), Fe2+ (20J.(g/mL) and an 
antioxidant (0.5 % w/v) were prepared in 25mL volumetric flasks using 
methanol as solvent. 
(i) Dithranol alone 
(ii) Dithranol + Fe2+ 
(iii) Dithranol + Fe2+ + Ascorbyl-6-palmitate 
(iv) Dithranol + Fe2+ + Salicylic acid 
(v) Dithranol + Fe2+ + Citric acid 
(vi) Dithranol + Fe2+ + Ascorbic acid 
(vii) Dithranol + Fe2+ + Isoascorbic acid 
Once prepared the solutions were transferred to amber coloured bottles and 
placed in a water bath at 25°C. At selected time intervals samples were 
withdrawn, appropriately diluted with mobile phase, the internal standard added 
and analysis done by hplc. 
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4.2.2.2 In Aqueous systems 
Dithranol stability at pH 5.5 and pH 0.4. - The methanol stock in 4.2.2.1 
was diluted to 100JLg/mL using methanol. The diluted solution was used to 
prepare aqueous solutions (lOml) of dithranol ( - 2#lg/mL) in 0.2M sodium 
acetate - HCI buffer, pH 5.5 and in 1M HCI (pH 0.4). The volumetric flasks 
,protected from light using aluminium foil , were placed in a water bath 
at 25°C. Solutions were prepared in triplicate. At selected time intervals 
samples were withdrawn, appropriately diluted with mobile phase and analysed 
by hplc. To monitor the effect of Cu2+ ions on the stability of dithranol in 
aqueous solution at pH 5.5, about lOJLg/mL (Cu2+) was incorporated into the 
pH 5.5 solutions prepared as described above, and analysed at selected time 
intervals as per 4.2.2.1 
4.2.3 Stability of dithranol in surfactant solutions 
Tbe effect of NaLS , CET and Tw - Aqueous solutions of dithranol were 
prepared as per 4.2.2.2 but incorporating NaLS, Tw and CET respectively 
to cover the concentration range 0 - 4 % w/v. Samples were withdrawn at 
selected time intervals, appropriately diluted with mobile phase, internal 
standard added and analysis done by hplc. 
Tbe effect of CuH - The following solutions were prepared as per 4.2.2.2 
but incorporating Cu2+ (lOJLg/mL). 
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NaLS (i) 0.02% w/v (below c.m.c) 
(ii) 2% w/v (above c.m.c) 
Tw (i) 0.003% w/v (below c.m.c) 
(i) 2% w/v (above c.m.c) 
CET (i) 0.04% w/v (below c.m.c) 
(ii) 2% w/v (above c.m.c) 
Once prepared samples were withdrawn from the the solutions at selected 
time intervals appropriately diluted with mobile phase and analysed by hplc. 
The effect of antioxidant - 4 % w/v solutions of the surfactants containing 
40ILg/mL of dithranol were prepared with and without the inclusion of 0.5 % 
w/v isoascorbic acid. The solutions were protected from light (amber coloured 
bottles) and placed in a water bath at 25°C. Once prepared samples from 
the solutions were withdrawn and then analysed at selected time intervals as 
per 4.2.2.1 
The effed of storage temperature - The isoascorbic acid, stabilised surfactant 
solutions of dithranol (prepared as outlined above) were left at room 
temperature (21 ±2°C) and in the fridge (4-5°C). Once prepared samples 
from the solutions were withdrawn and then analysed at selected time 
intervals per 4.2.2.1 
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4.3 Results/Discussion 
Decomposition in methanol solutions 
Metal ions such as Zn2+ and Fe2+ have been shown to cause dithranol 
instability [Raab and Gmeiner (1975), Priprem (1991)]. Their presence in trace 
amounts is expected in skin, it was decided therefore to investigate their 
effect on dithranol decomposition both in the presence and absence of 
surfactants. The influence of the presence and absence of metal ions on the 
rates and amounts of danthron and dimer formed were of particular interest, 
because the intention was to see whether the decomposition process could be 
selectively directed towards the formation of either dimer or danthron only. 
Since dithranol is poorly water soluble preliminary investigations were carried 
out using methanolic solutions of dithranol (- 40J.'g/mL). 
The influence on dithranol decomposition of Zn2+, Fe2+ and Cu2+ (all 20J.'g/mL) 
is shown in Fig 4.1. The decomposition of dithranol followed first order 
kinetics. In methanol the decomposition rate was 0.043 hr-'. In the presence 
of 20J.'g/mL of Cu2+,Zn2+, and Fe2+ the rate was increased to 0.257,0.047, 
and 0.074 hrl respectively. Decomposition in the absence of any metal ions 
led to the appearance of danthron and dimer in solution. When introduced 
,the presence of all three types of metal ion caused an enhancement in the 
rate of dimer formation while danthron formation was markedly decreased. 
In the concentration time profile for dimer formation in methanol (see Fig 4.2) 
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it is seen that, in any given time period, e.g. in the first 5 hours, more 
dimer was formed in the solution containing Fe2+ compared to that without. 
In the case of danthron (see Fig 4.3) Fe2+ greatly reduced its rate of 
formation (similar profiles were obtained when either Zn2+ or Cu2+ were 
present). 
Using the data in Fig 4.1 for dithranol decomposition in methanol in the 
absence of any metal ions, Table 4. 1 shows that on comparing the amount 
of dithranol decomposed to the amount of dimer formed it is clear that the 
dimer concentration is half that of the dithranol reacted this indicating that 
dimer is being immediately formed. The table also shows that danthron is 
formed but the amount formed is very small relative to the dimer. Fig 4.4 
shows the direct relationship between amount of dithranol decomposed and 
dimer formed. The gradient of 2.22 shows that for every two moles of 
.dithranol decomposed one mole of dimer is formed. 
Dithranol decomposition resulting in the formation of dimer and danthron 
is proposed to proceed via a free radical intermediate (see chapter 1 , Fig 1.3). 
Here, based on present results it is proposed that the mechanism for dimer 
formation is a consecutive one as shown below. The first step is the slow 
, 
rate determining first order step whereby the free radical intermediate is 
formed from dithranol. The second step is the rapid conversion of the 
intermediate to dimer. 
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slow fast 
Dithranol-----------> intermediate------> Dimer 
Rate detennining step 
The relationship between the amount of dithranol decomposed and amount of 
dimer and danthron appearing in solution both in the presence and absence 
of metal ions (see Table 4.2 & 4.3) is evidence which supports dimer formation 
in solution is as shown above. 
Fig 4.1 shows that in the presence of the metal ions first order kinetics still 
apply, but the rates are increased. The rate is dependent on the type and 
concentration of metal ion used. Reducing the concentration of Fe2+ resulted 
in a slower rate of dimer formation (see Fig 4.2), showing that with varying 
Fe2+ the reaction followed pseudo first order kinetics. The results show that 
metal ion presence had a catalytic effect on the decomposition reaction. This 
is supported by the fact that the final ratio of dimer: danthron (when the 
reaction is complete) was the same with and without the metal cations. 
For first order kinetics the general catalysis equation gIven below, can be 
applied to find the individual catalytic coefficient values for any catalytic 
agent(s) present. 
Eq.4.1 
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where kexp = the overall first order rate constant, leo = the specific reaction 
rate in methanol alone, kM2+ = specific reaction rate associated with catalytic 
species (catalytic coefficient) , [MH] = concentration of catalytic species (metal 
cations). 
At a concentration of 20J,Lg/mL for all three metal ions the mean catalytic 
coefficients (n=3) were 1.22 ± 0.14 x 1()l M hr-! for Cu2+ which was 7.5 times 
greater than that found for Zn2+ (1.63 ± 0.21 x 102 M hr-!) ,while the catalytic 
coefficient for FeH 2.61 ± 0.27 x 102 M hr-! was 1.6 times greater than that 
for Zn2+. 
The overall conclusions that can be drawn from the results using methanolic 
solutions are that metal ion presence was selectively enhancing the rate of 
dimer formation while markedly reducing that of danthron. The increase in 
rate of dimer formation is also dependent on metal ion type. Metal Ion 
presence can therefore be used to control the rate of formation of these two 
degradation products. 
For the purpose of stabilisation of the final preparation an antioxidant was 
required. A variety of compounds have been suggested as an antioxidant for 
dithranol, e.g salicylic and ascorbic acid (Lee, 1987) various alpha hydroxy 
acids [Van Scott and Yu, (1985)], ascorboyl-6-palmitate Weller ~ (1990).The 
stabilising capacity of these compounds was assessed using methanolic solutions 
of dithranol. Antioxidant assessment was done in the presence of Fe2+ so as 
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to eliminate those antioxidants that gave only a small degree of protection 
to dithranol. The results are shown in Fig 4.5 where it can be seen that 
isosascorbic acid gave the greatest protection, prolonging the half-life of the 
dithranol - Fe2+ mixture by approximately 5.7 fold from 5.9 to 32.3 hours. 
In the presence of ascorbic acid and ascorboyl-6-palmitate the half-life was 
prolonged to 26.6 and 25.2 hours respectively. Protection was much less 
however with salicylic and citric acids where half-life was prolonged to 12.5 
and 11.5 hours respectively. 
Decomposition in aqueous solutions 
There is only a limited amount of reported work on the decomposition 
characteristics of dithranol 10 aqueous solutions. There is, however , 
considerable variation in the results, in the few reports available. Cavey ~ 
(1982) investigated the stability of dithranol in an aqueous buffer (1 % acetone 
_ Ringer buffer, pH 7.5) at 37°C, reporting that dithranol underwent complete 
decomposition within 4 hours, with the resultant formation of dimer (40%) and 
no detectable danthron. The results reported by Priprem (1991) differ from 
these. Priprem found that using phosphate buffer pH 7 at 20°C, dithranol 
showed reasonably good stability (t l12 =:= 7 days) , and following complete 
decomposition, danthron (4%) was detected in solution while no dimer was 
found. For the above, variation in experimental conditions most likely 
accounts for the discrepancies observed. Two different buffer systems were 
used and there is also a 17°C difference in temperature. There were also 
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differences in the co-solvent used in the preparation of the aqueous solutions 
of dithranol. Cavey ~ (1982) dissolved dithranol in acetone which was then 
added to the Ringer buffer whereas Priprem (1991) dissolved dithranol in 
glacial acetic acid and then this was added to the aqueous medium. Apart 
from the difference in temperature and buffers used the co-solvents used 
also would affect the intramolecular hydrogen bonding, responsible for 
dithranol stabilisation, leading to variation in observed results. In the presence 
of glacial acetic acid decomposition is delayed possibly due to less 
interference with dithranol's intramolecular hydrogen bonding whereas in the 
presence of acetone the interference is greater leading to less stable 
preparations. 
The results reported by Upadrashta and Wurster (1988) are in closer 
agreement with those of Cavey ~ (1982). They showed that at pH 7.4 (Tris-
HCl buffer) at 25°C dithranol decomposed following first order kinetics with 
a half-life of 43.9 minutes. Cavey M..Al reported complete decomposition 
within 4 hours (1 % acetone - Ringer buffer) at 35°C. Using the time taken for 
complete decomposition (240 minutes) to occur an estimate of a half-life of 
24 minutes is obtained if decomposition is said to be complete after 10 half-
lives. When the lOoC difference in temperature is considered the half-life 
estimate is seen to be in good agreement with the results reported by 
Upadrashta and Wurster (1988). As mentioned above Upadrashta and 
Wurster (1988) showed that dithranol decomposition in aqueous solutions 
followed first order kinetics. This is in agreement with the findings of Melo 
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~ (1983) who used aqueous buffer pH 10.4 . Using acetate buffer pH 5.5 
and 1M HC1 (PH 0.4) present results also show that dithranol decomposition 
followed first order kinetics in these aqueous conditions (see Fig 4.6). At pH 
5.5 the decomposition rate constant was 0.636 hr- I (correlation coefficient 0.998) 
giving a half-life of 1.09 hours; in 1M HCI (pH 0.4) the decomposition rate 
constant was 0.037 hr- I (correlation coefficient 0.995) and half-life 18.8 hours. 
The difference in stability of dithranol at the two pH values is in general 
agreement with the trend observed by of Upadrashta and Wurster, (1988) who 
showed that in aqueous solutions dithranol stability was enhanced with a 
reduction in pH. 
Following decomposition in aqueous solutions present results show that 
dimer and danthron were the main breakdown products detected , - 94 % 
dimer and - 4 % danthron being formed on complete decomposition (see Table 
.4.4). Both in the presence and absence of Cu2+ ions the ratio of dithranol 
decomposed to dimer formed approachs the expected value of 2 only towards 
the end of the period over which the experiment was run (see Table 4.5 & 
4.6). When the amount of danthron formed in solution is taken into account 
(very small relative to dimer amounts) ,it is seen that for any given time 
period, especially in the initial stages, more dithranol has decomposed than 
the amount of dimer appearing in the solution. These results indicate that 
dimer was not being formed as soon as dithranol started decomposing. This 
suggests the formation of an intermediate which builds up then goes on to 
form the dimer. This is different from the observations in methanol where 
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the results suggest dimer was formed as soon as dithranol started 
decomposing. 
Qualitatively the patterns observed in methanol were also observed in the 
aqueous solutions (similar mechanism of degradation). The main difference was 
the indication of intermediate build up observed in the aqueous conditions 
which was absent in methanol. It could well be that the situation is closer 
to that observed in methanol, but because of the practical problems linked 
to working in aqueous conditions using much reduced concentrations (16 times 
less concentrated), a deviation was observed. Also, in the presence of Cu2+ 
the reaction rate was extremely rapid, this factor making it difficult to 
obtain many data points. In retrospect a reduction in the concentration of 
Cu2+ (perhaps 10 fold) would have slowed the reaction down allowing more 
data points to be obtained. In methanol solutions higher concentrations 
( _ 40JLg/mL) of dithranol were used, and also methanol provides a less 
problematic analytical environment. 
Kinetically the presence of Cu2+ ions in the aqueous dithranol solutions ,at 
pH 5.5, resulted in an increase in dimer formation (danthron formation 
remaining very small in comparison to dimer) due to the catalytic effect of 
the ions (see Fig 4.7). Using equation 4.1 and data such as that shown in Fig 
4.8 the mean catalytic coefficient (n=3) of Cu2+ (lOJLg/mL) was calculated as 
6.58 + 0.31 x 10" M hr-I. The catalytic coefficent (bearing in mind the 
difference in dithranol and metal ion concentration) is around 54 times greater 
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in aqueous conditions compared to the situation in methanol. The fact that 
there was no statistically significant difference (p < 0.05) between the 
amounts of danthron and dimer formed following complete decomposition (see 
Fig 4.9) in the presence and absence of Cu2+ ,provides supportive evidence 
that metal ion presence had a catalytic effect. 
Present results for the amount of danthron formed, about 4 % , following 
dithranol decomposition at pH 5.5 are in agreement the findings of Priprem 
(1991) who found a similar amount of danthron at pH 5. Present findings, 
however, differ from those of Cavey ~ (1982) who reported no detectable 
danthron at pH 7.5. The results for dimer formation also show discrepancies. 
Present results show that at pH 5.5 94% dimer was formed. In complete 
contrast to these findings Priprem found no detectable dimer at pH 5, while 
Cavey ~ found 40% dimer at pH 7.5 . 
The hplc method used by Priprem (1991) is capable of very adequately 
seperating dithranol, danthron and dimer, but suffers a lack of sensitivity for 
dimer (see chapter 2). Dithranol concentrations of about 4",g/mL were used in 
the investigations carried out by Priprem therefore only low dimer levels are 
expected in solution ,thus the finding of no dimer in solution was most 
probably due to the poor sensitivity of the system. The method used by 
priprem has been modified and sensitivity for dimer increased (see chapter 2) 
. Using this improved method for dimer analysis shows that at pH 5.5 there 
was 94% dimer formation. The finding of 40% dimer formation by Cavey 
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~ is consistent with dithranol decomposition at the higher pH value of 
7.5 compared to pH 5.5. As pH is increased the fraction of ionised dithranol 
in solution also increases (see chapter 5) resulting in less dimer and more 
danthron production. It is not clear, however, why Cavey ~ did not detect 
any danthron in solution. 
Decomposition in surfactant solutions 
Below c.m.c - Table 4.4 shows that in NaLS (0.02%) and Tw (0.003%) both 
in the presence and absence of Cu2+ the percentages of dimer and danthron 
formed was not altered relative to the situation in buffer alone. In CET 
(0.04%) dithranol decomposition resulted in a large increase (from -4% to 
_ 84 %) in the amount of danthron formed, while dimer formation decreased 
from -94% to -14% . On the addition of Cu2+ the effect observed was 
similar to that seen in aqueous solutions in the absence of surfactant (see Fig 
4.7 - 4.9). Using surface tension measurements [Moody & Lubwika ,(1992) , also 
see chapter 5] evidence was obtained for the possibility of a surface interaction 
between dithranol and cetrimide, particularly at pH 5.5. Formation of a 
dithranol-CET complex with dithranol present in the ionised form along with 
decomposition at the surface, where O2 is abundant would account for the 
large amount of danthron formed in the CET solution. 
With regard to the kinetics, dithranol. decomposition still followed first order 
kinetics both in the presence and absence of Cu2+ (see Figs 4.10 - 4.12). In 
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the absence of Cu2+, decomposition rate constant for dithranol in 0.02 % 
NaLS was 0.986 hr-I (correlation coefficient 0.994) giving a half-life of 0.702 
hours. In 0.003% Tw the rate was 1.08 hr-I (correlation coefficient 0.996) 
giving a half-life of 0.642 hours, and in 0.04% CET the rate was 0.299 
min-I (correlation coefficient 0.989) glvmg a half-life of 2.31 minutes. On 
addition of Cu2+ the decomposition rate constant in NaLS was increased to 
6.726 hr-I (correlation coefficient 0.995) giving a half-life of 0.103 hours. In Tw 
the rate constant was increased to 8.668 hr-I (correlation coefficient 0.998) 
giving a half-life of 0.080 hours. In CET it was not possible to follow the 
rate of dithranol decomposition with time, as dithranol decomposition was 
almost instantaneous on the addition of the Cu2+ ions. 
Above c.m.c - Surfactant presence above the c.m.c was observed not to alter 
the percentages of dimer and danthron formed following complete 
decomposition of dithranol ,this being similar to the observations below the 
c.m.c. Using unbuffered aqueous solutions of NaLS ,Tw and CET at 25°C 
the following patterns regarding decomposition products were observed . In 
CET the ratio of dimer : danthron formed following complete decomposition 
of dithranol was 3:2, while in both NaLS and Tw the ratio was 4: 1 [Moody 
& Lubwika , (1992)] . The ratios of decomposition products formed in the 
unbuffered solutions cannot be directly compared to those obtained at pH 5.5 
(present results) because of the pH influences on the molecular species of 
dithranol present (see chapter 5), which in tum influences decomposition 
products formed. 
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The effect of Cu2+ on dithranol decomposition rate in surfactant solutions 
above their c.m.c is shown in Table 4.7. The results show that in 2% NaLS 
solutions Cu2+ addition resulted in dithranol decomposition rate being 
increased from 0.383 to 0.468 hr- I . This increase in decomposition rate is 
smaller than that seen below the c.m.c where decomposition rate was 
increased by a factor of 6.82 compared to l.22 above the c.m.c. The 
indications are that Cu2+ is less efficient as a catalyst of dithranol 
decomposition when dithranol is located in the non-polar interior of the 
NaLS micelles (see chapter 3). This situation bears some s.imilarity to the 
observations made in methanol and aqueous buffer where it was seen that the 
catalytic coefficient of Cu2+ was greater for dithranol decomposition in the 
more polar aqueous buffer, compared to the relatively less polar methanol 
solutions . 
. In Tw solutions the addition of Cu2+ resulted in an increase in dithranol's 
decomposition rate by a factor of 3.86 which was about half the effect seen 
below the c.m.c where decomposition rate was increased by a factor of 8.02. 
Because of the similarity of the catalytic efficiency of Cu2+ above and below 
the c.m.c, the indications are that dithranol is in a relatively polar 
environment when solubilised in the micelles of Tw. This is in agreement (see 
Fig 4.15) with the observation that in the micellar environment of Tw the 
rate of dithranol decomposition was close to that observed in buffer alone. 
It also agrees with the assessment that solubilised molecules of dithranol in 
Tw micelles were located in the polyoxyethylene mantle (see chapter 3). 
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In CET solutions at concentrations below c.m.c (PH 5.5) it was observed that 
introduction of Cu2+ resulted in an extremely rapid decomposition of dithranol 
(reaction more than 90% complete inside a minute). Above the c.m.c the effect 
of Cu2 + was less dramatic. The decomposition rate of dithranol being 
increased by a factor of 4.73. Again the results indicate that the solubilization 
of dithranol ,here in the micelles of CET ,results in dithranol entering an 
environment where Cu2+ IS less efficient a catalyst of dithranol 
decomposition. 
Investigating the effect of surfactant concentration on dithranol decomposition 
rates yielded the following results. For dithranol ( - 2.5ILg ImL) in NaLS 
solutions when surfactant concentration was greater than 0.18% w/v the rate 
of decomposition of dithranol was observed to reduce with increasing 
surfactant concentration ,while below this concentration increase in surfactant 
concentration resulted in an enhanced rate of decomposition (see Table 4.8 & 
Fig 4.13). A similar pattern was observed in CET solutions (PH 0.4) below 
and above 0.079% w/v (see Table 4.9 & Fig 4.14). In both surfactant solutions 
the concentration at which the change in the stability pattern of dithranol 
was observed is in close agreement with the literature c.m.c values quoted 
for these surfactants - NaLS (0.24% w/v) , CET (0.09% w/v). The results for 
Tw are shown in Table 4.10 and Fig 4.15. The plot of koo..t vs Tw 
concentration is bell shaped, similar to what was obtained in NaLS (PH 5.5) 
and CET (PH 0.4). Unlike the case in NaLS and CET, there is no point on 
the graph where dithranol decomposed at a slower rate than that observed 
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in buffer alone The results show that in the presence of the micelles of Tw 
(Literature c.m.c value 0.014% w/v) dithranol decomposition was actually 
enhanced compared to buffer alone. It was also observed that above 0.5 % 
w/v there was little further change in the observed rate of decomposition, 
with increasing surfactant concentration. 
The ability of surfactants present in aqueous solutions to influence reaction 
rates was established many years ago. Fendler and Fendler (1975) give a 
comprehensive compilation of various aspects of micellar catalysis and 
inhibition covering a number of decades. A more recent review of this 
subject is given by De Oliveira and Chaimovich (1993). In accounting for the 
influences of surfactants on micellar reaction kinetics ,micellization and 
micellar structure have been discussed in terms of various models [Fisher and 
Oakenfull (1977)]. For kinetic work it is convenient to use the pseudophase 
model i.e to assume that a micelle can be regarded as a submicroscopic 
aggregate which behaves as a seperate reaction medium with its own 
properties [Shinoda ~ (1963) , Schick (1967)]. Reaction can then be regarded 
as ocurring either in the aqueous or micellar pseudophases, with reactants 
being rapidly equilibrated beween the two pseudophases [Bunton ~ (1968), 
Bunton and Robinson (1968), Menger and Portney (1967), Fendler and 
Fendler 1970]. In the present studies decomposition of dithranol in the aqueous 
solutions investigated was observed to follow first order kinetics. Such kinetics 
are a characteristic of unimolecular reactions i.e those reactions where the 
rate determining step (RDS) involves only one molecule [Morrison and Boyd 
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(1983)]. In the case of dithranol the RDS is the formation. of the anthranoyl 
free radical (see chapter 1, Fig 1.3). There are examples in the literature of 
a number of unimolecular reactions whose rates are changed by incorporation 
into a micelle [Fendler and Fendler (1975), Bunton (1977)]. Since 
concentration of substrate in a .micelle does not affect the first order rate 
constant for the reaction, the micellar rate effect upon unimolecular reactions 
must arise from the properties of the micelle as a submicroscopic reaction 
medium [Bunton (1977)]. For unimolecular reactions incorporation of substrate 
into micelles results in the substrate entering an environment which may 
favour or inhibit the reaction. In the case of dithranol , incorporation in the 
micelles of NaLS and CET resulted in prolonged half-lives showing that the 
micellar environment favoured dithranol stability, while in Tw the micellar 
environment caused an enhancement in rate of dithranol decomposition relative 
to that in water. 
Use of the pseudophase model is convenient for the consideration of the 
influence of surfactants on micellar reaction kinetics. The relationship 
between the reaction rate constant and surfactant concentration can be treated 
very simply by considering the distribution of substrate between the aqueous 
and micellar pseudophases (scheme 4.1). 
K 
, 
DT., \ S.DT 
L PRODUCTS J k, 
Scheme 4.1 
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I In scheme 4.1 Sa = micellar surfactant, DT., = dithranol in· the aqueous phase 
, SaDT = dithranol associated with the micelles. 
The rate equation for scheme 4.1 is given by; 
-d(DT,,+SrJ)T) = d[DT] = d[P] 
de de de Eq. 4.2 
where [DTJ is the stoichiometric concentration of dithranol at time t. 
, 
Starting with Eq.4.2 an equation, which allows the calculation of the rate of 
decomposition in the micelles and also the association constant for the 
binding of solubilised agent with the surfactant micelles relation can be 
derived [Fendler & Fendler, 1975]. 
1 = 1 + 1 N 
k 1-kob• a k 1 -k2 k 1 -k2 ' K(CD-c.m.c) Eq. 4.:3 
In Eq.4.3 kl = first order decomposition rate in absence of surfactant, kl = 
first order decomposition rate for solubilised dithranol, K = micelle association 
constant, CD = total concentration of surfactant (molL'l) , c.m.c = critical 
micelle concentration, N = aggregation number. 
A plot of the left hand side of Eq. 4.3 vs 1 I (CD - c.m.c) allows the 
calculation of kl and K. Eq. 4.3 has been used in the literature to obtain 
binding constants between micelles and a variety of drugs, mono-p-nitrophenyl 
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dodecanedioate [Menger and Portnoy (1967)] ,p-substituted phenyl acetates 
[Broice ~ (1968)] , p-nitrophenyl diphenyl phosphate [Bunton and Robinson 
(1969a)] also 2,4-dinitrophenyl sulphate [Fendler ~ (1970)]. Because of the fit 
of experimental data to equations such as Eq. 4.3 , its use is justified. One 
must be aware, however, of the approximations used in its derivations [Colter 
klAl (1964)]. In deriving Eq. 4.3 it has been assumed that the substrate does 
not complex with monomeric surfactant, that the association has 1: 1 
stoichiometry , that the substrate does not significantly alter the micellization 
and the c.m.c. In NaLS (see Fig 4.16) the micellar decomposition rate 
constant was 0.157 he-I and K was 29.8 x N. In CET (PH 0.4 , see Fig 4.17) the 
micellar decomposition rate was 0.002 hr- l and K was 60.80 x N. The values 
obtained for the association constants suggest that dithranol's association with 
NaLS micelles is less than with CET micelles. 
The kinetic data for dithranol decomposition in Tw solutions (see Fig 4.15) 
shows that there was little change in dithranol's decomposition rate at 
concentrations above 0.5% .Eq. 4.3 , therefore, can not be applied in this case. 
The good fit , however, of the data for NaLS and CET to Eq. 4.3 means 
such equations can be used to predict the rate of decomposition of 
micellized dithranol in these surfactants at a given surfactant concentration, 
this being of some importance for formulation purposes. This ability to 
predict stability was tested by placing a known amount of dithranol in a 
solution of known micellar concentration and allowing decomposition to 
proceed for a selected time period . The amount of dithranol remaining is 
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assayed after this time period and compared to the calculated amount 
expected using Eq.4.3. Using NaLS of micellar concentration 0.38% (dithranol 
5JLg/mL) Eq.4.3 predicts a decomposition rate constant of 0.50 hr" giving a 
half-life of 1.39 hours. Allowing decomposition to proceed for 3.84 hours 
should have resulted in about 15 % of initial dithranol remaining in solution. 
When done experimentally 13 ± 2 % was found. In CET, 0.2 % micellar 
concentration , 50 % of initial dithranol was predicted would be present after 
21.34 hours. Experimentally 46 ± 1. 7% was found. In both surfactants stability 
predictions were reasonably accurate, experimental findings being within 5 % 
of predicted amounts. In CET solutions when the pH is raised to 5.5 Eq 4.2 
can not be used for stability predictions because of the interaction between 
the two at this pH. In using Eq.4.3 it is assumed that no interaction between 
surfactant monomers and the solubilizate occurs. 
The dithranol stability modifications observed can be explained by considering 
the site of solubilization of dithranol (see chapter 3). Incorporation of dithranol 
into the hydrocarbon core of micelles is expected to result in a reduced rate 
of decomposition compared to that in water as dithranol is more stable in 
a non-polar environment. This is the observed effect with both NaLS and 
CET (at pH 0.4) and is in agreement with the evidence in chapter 3 for the 
site of solubilisation of dithranol in these two surfactants. In Tw it was 
shown that dithranol is located in a polar environment upon solubilisation 
(see chapter 3). Since dithranol is unstable in polar environments the 
enhanced rate of decomposition observed following solubilisation is expected 
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,and is in agreement with the assessment of dithranol's environment m Tw 
micelles (see chapter 3). 
After identifying isoascorbic acid as the most suitable antioxidant of the ones 
investigated, its effect on the stability of dithranol in the surfactant solutions 
was assessed. The results are shown in Table 4.11. The table shows that IAA 
had an effective stabilising influence in all three surfactant solutions. The half-
life for dithranol decomposition was prolonged by factors of 30, 19 and 4 
in NaLS, Tw and CET respectively. Antioxidants such as isoascorbic acid act 
by providing electrons and easily avialable hydrogen atoms that are then 
accepted by free radicals (see proposed decomposition pathway) ,this process 
stops the chain reaction [Martin ~ , p385]. Inclusion of isoascorbic acid in 
the dithranol - surfactant solutions will therefore serve to maximise stability. 
Using the stability data presented in Table 4.11 the shelf-life (taken as the 
time taken for 10% decomposition of initial dithranol to occur) for the 
dithranol - surfactant solutions was calculated as shown in the table. In a 
clinical setting the NaLS solutions would be preferred because of the longer 
shelf-life, the prepared solutions being useful for up to 12 hours after which 
they should be disCarded. For the Tw and CET solutions the shorter shelf-
lives would require that freshly prepared solutions were made each time the 
dithranol - surfactant solutions were needed. 
For Tw solutions stored in the fridge (4 - 5°C) the shelf-life was prolonged 
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from 1.4 to 15 hours. At such temperatures NaLS and CET were observed 
to precipitate from solution, thus fridge storage would be disadvantageous. 
Taken together the information gathered indicates that for the purpose of 
delivery of dithranol to the skin in aqueous solutions of surfactants , there can 
be no doubt that choice of surfactant and concentration will markedly affect 
the stability of dithranol. Based on the observed results the recommendations 
are: 
(1) As high a surfactant concentration as possible be used both for stability 
and solubility reasons (see chapter3), the final concentrations used being kept 
below those where skin irritation is observed. 
(2) Isoascorbic acid be added in order to maximise stability. 
(3) For CET and Tw solutions stored at room temperature, freshly prepared 
solutions should be used. NaLS solutions should be used within 12 hours 
once prepared. Tw solutions stored in the fridge should be used within 15 
hours. NaLS and CET solutions should not be stored in the fridge. 
(4) With regard to pH of the solution, it should be as low as can be 
tolerated by the skin ,in particular with CET solutions ,as this will prolong 
the shelf-life of the formulation. In CET solutions, though more dithranol will 
go into solution if the pH is increased, there is a problem with the stability 
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of such solutions and precautions such as antioxidant addition are necessary 
. Here ,the reason for using solutions of pH 5.5 was because the intention 
was to simulate stability on the surface of the skin. 
(5) The presence of metal ions and choice of surfactant ,by changing the 
kinetics of the decomposition of dithranol ,may well alter the anti psoriatic 
effect observed. 
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Fig 4.1 First order plots showing the effect of metal ions (20pg/mL) 
on the decomposition of dithranol (-40pg/mL) in methanol at 25°C . 
• Metal ions absent,. Zn2+ ,. Fe2+ , T Cu2+ • 
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F.ig 4.3 Danthron formation following 
dithranol decomposition (-40pg/ml) in 
methanol at 25°C . 
• Fez" absent, • Fe2" 1 0 & 20pg/mL 
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Table 4.1 
Table showing the amount of dime:- and danthron formed at 
different times following dithranol (1.76 ~0·4 M) decomoosition 
in methanol at 25°C. • 
Time (hr) 
6.9 
13.8 
23.6 
[OT]l.~: [DT] n&fteC rO~]l=-i (OAN1 t=-i 
1.20xlO·4 5.60XlO·s 2. 51~O·5 a .15xlO·s 
6.22xlO·s 9.36~0-5 4.14xl.0· s a .55Xl.0·s 
4.73xlO·s 12.78xlO·5 5.77xlO·s 0.57xlO·s 
15 
- 12 ::E 
111 
I 
0 
-)( 9 
"t:J 
CD 
-u 6 
ca 
CD 
... 
.... 3 C 
0 
0.0 1.2 2.' 3.5 '.11 1.0 
Dimer formed (x 1 0-5 M) 
Fig 4.4 The amount of dimer formed following 
decomposition of dithranol(1.76x10-4 M)in methanol at 
25°C. 
DT = dithranol. y = 2.2256(x} + 0.0296 (cc = O.999) 
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Table 4.2 
Table showing t.he amount. of dimer formed at diffe=ent. t.imes 
following dit.hranol (1.76 xlo~ M) decomposition in met.hanol at. 
2S DC in the absence of any met.al ions. 
Time (h::') [DT na=ecI] - [DAN] [OM] f--' Rat.io 
6.9 S.45xlO·' 2.5lxl.0·1 2.2 
13.8 8. SSxlO·' 4.14x:!.0·1 2.1 
23.8 12.30xlO·' 5.77Xl.0·1 2.1 
Table 4.3 
Table showing the amount. of dimer formed at diffe=ent. times 
following dith--anol (1.76 xlO~ M) decomposition in methanol at. 
25 DC in the prese:l.ce of Fe2- (3. 58xl0-4 M) • 
Time' Chr) [DT] na=ecl [DM]t .... Ra:io 
4.1 6.70xlO·' 2.07xlO·
s 3.2 
8.2 10. S6xlO·
1 4.14xlO·' 2.6 
14.4 14.33xlO·s 6.07xlO·
s 2.4 
16.3 14.99xlO·
s 6.66xlO·s 2.3 
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Fig 4.5 
The effect of various antioxidants (0.5% w/v) on the half-life for the decomposition 
of dithranol (-40pg/mL) in the presence of Fe2+ (20pg/mL) in methanol at 25°C. 
Results are shown as mean ± SEM (n=3). 
A • OT alon •• B • OT + F." • C • citric acid • 0 • salicylic acid • E • .scorboyl-6.palmltate I 
F • ascorbic acid I G • Isoascorblc acid. 
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Fig 4.6 The first order decomposition plots of dithranol (-2pg/mL) in 
aqueous solutions at 25°C . 
.. 1 M HCL (pH 0.4) t • buffer pH 5.5. 
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" 
Table 4.4 
The amoun~s of dallthron and dimer formed. from di thrano:' 
(2.SP9/mL) following complete decomposi~ion in aqueous surfac~ant 
CU2+ abse.n~ CU2 + prese.n~ 
Dimer Dan Dimer Dan 
Buffer pH 5.5 -94% -4% -94% -4% 
0.02% NaLS -94% -4% -94 -4% 
0.04% CET -14% -84% -14% -84% 
0.003% 'l'w -93% -2.6% -94% -3% 
Table 4.5 . 
Table showing the amount of dimer formed following the 
decomposition of di~h:anol (-2.Spg/mL) in aqueous buffer pH 5.5 
a~ 25°C. 
Time (mins) [DT nac::ad] [Dimer foned] Ra~io 
10 1.11 xlO·' 0.67 xlO·' 1.6 
20 2.12 xlO·' 1.02 xlO·' 2.1 
30 3.02 xlO·'· 1.09 x.lO·' 2.8 
40 3.83 xlO·' 1.42 xlO·' 2.7 
60 5.2:1- xlO·' 1.82 x.lO·' 2.9 
90 6.80 xlO·' 2.51 xlO·' 2.7 
Table 4.6 
Table showing the amount of dimer formed following the 
decomoosition of dith=anol (-2.Spg/mL) in aqueous bu::er pH 5.5 
at 25-oC in the presence of CU2• (10pg/mL). . 
Time (mins) [DT nac::adJ [Dimer foned] I Ratio 
3.6 5.7 xJ.0·' 1.35 xlO·' 4.2 
7.2 B .11 xlO·' 1.89 xlO·' 4.3 
,. 13.5 10.13 XlO·' 4.95 xlO·' 2.0 
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Fig 4.7 First order plots for dithranol (,.., 2.5pg/mL) 
decomposition in aqueous buffer pH 5.5, at 25 0 C .• Cu2+ 
absent • Cu2+ resent. 
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Fig 4.8 Dimer formation following dithranol (,.., 2.5pg/mL) 
decomposition in aqueous buffer pH 5.5, at 25°C. Results 
are shown as mean ± SEM (n=3) .• Cu2+ absent, A Cu2+ 
present. 
chap 4.118 
c 
0 
.-
ut 
~ 
cD 
> 
c 
0 
(J 
~ 
100 -
80 -
60 -
40 -
20 -
o~~~~----~~-----~~----~~------
Oiln OU 
Cu 10ug/mL ildded. 
OU 
No Cu added 
Fig' ".9 Dimer and danthron formation following 
complete decomposition of dithranol(-2.5~g/mL) in 
aqueous buffer pH 5.5 at 25°C. Results are shown as 
mean ± SEM (n=3). Dan =danthron, DM =dimer 
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Fig 4.10 Dithranol decomposition in 0.02% NaLS of pH 5.5 
at 25°C, • Cu2+ absent,.Cu2+ present. 
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Fig 4.11 Dithranol decomposition in 0.003% Tw of pH 5.5 
at 25°C, • Cu2+ absent,ACu2+ present. 
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Table 4.7 
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Fig 4.12 Dithranol decomposition in 0.04% CET of pH 5.5 
at 25 0 C, with Cu2+ absent. 
The effect of Cu2+ on the rate of decomposition of dithranol ( - 25JLg/ml) in 2 % solutions (PH 
5 5) at 25°C . . 
Surfactant Half life (hr) Half life (hr) 
No Cu2+ With Cu2+ 
2% NaLS 2.01 1.48 
2% CET 0.90 0.19 
2% Tw 0.50 0.13 
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Table 4.8 
The first order rate constants for dithranol decomposition in NaLS solutions pH 5.5 at 25°C 
NaLS (%w/v) Ko.,IId hours·1 
0.00 0.635 
0.02 0.986 
0.04 1.202 
0.10 1.262 
0.18 0.624 
0.50 0.533 
1.00 0.430 
1.50 
1.28 
-I 1.06 oS:. 
-
'V 
~ 0.84 
a 
:II:: 
0.62 
0.40 
0.0 0.2 0.4 0.6 0.8 1.0 
NaLS (Sw/v) 
Fig 4.13 The effect of NaLS on the rate of dithranol 
decomposition in aqueous solutions of pH 5.5 at 25 0 C 
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Table ".9 
The tirst order rate constants tor dithranol decomposition in 
CET solutions pH 0." at 2S·C. 
CET (% w/v) k nllsti hours·' 
0.00 0.018 
0.01 0.021 
0.02 0.026 
0.04 0.032 
0.08 0.040 
0.12 0.018 
0.24 0.015 
0.50 0.012 
0.0.0 
0.032 
-::s 0.02. 
-: 
... 
• 
~ 0.01. 
0..00& 
0.000 
0.00 0.10 G.20 0 .. 0 ... 0.50 
cer {s w/v} 
Fig 4.14 The effect of CEr concentration on the rate of 
dithranol decompostion in aqueous solutions of pH 0.4 at 
~o~ . 
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Table ".10 
The first order rate constants tor the decomposition of 
dithranol in TV solutions pH 5.5 at 2S·C. 
Tw (% 
0.00 
0.003 
0.015 
0.05 
0.15 
0.50 
1.00 
.,... 
I 
.s::. 
-
w/v) kOb!ld hours·' 
0.635 
1.08 
3.24 
3.35 
2.57 
1.36 
1.37 
u~-----r----~~----~----~----~ 0.4 Got 
Tw (% w/vJ 
Fig 4.15 The effect of Tw on the rate of dithranol 
decomposition in aqueous solutions of pH 5.5 at 25°C 
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Fig 4.16 The relationship between the observed rate of 
dithranol decomposition and NaLS concentration (above 
c.m.c.) in aqueous solutions of pH 5.5 at 25°C. 
Correlation coefficient (r) = 0.998. See Eq4.J and accompanying text. 
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Fiq 4.17 The relationship between the 
observed rate of dithranol decomposition 
and CET concentration (above c.m.c) in 
aqueous solutions of pHO.4 at 25°C. 
Correlation coefficient (r2) = 0.992. See Eq4.3 and 
accompanyinq text. 
Table 4.11 The decomposition rate characteristics of dithranol 
in surfactant solutions of pH 5.5 at 25°C. 
TO.5(hours) TO.5 (hours) k (hr-l) SL(hours) 
IAA 0.5% IAA 0.5% IAA 
absent present 0.5% IAA 
4% NaLS 2.9 ± 0.5 86 ± 0.7 0.008 12.5 
2% CET 0.9 ± 0.2 4.1 ± 0.3 0.171 0.6 
4% TW 0.5 ± 0.1 9.6 ± 0.3 0.072 1.4 
The results are presented as .ean t SBN (n-3). lAA • isoascorbic acid. SL 
• Shelf life , which is taken as the tiae for lOt deco.position of initial 
dithranol to occur. 
chap 4.126 
CHAPTERS 
THE EFFECT OF SURFACTANTS ON TIlE IONISATION 
BEHAVIOUR OF DITHRANOL IN AQUEOUS SOLUflONS. 
S.l Introduction 
Dithranol is a weak acid. It's ionic equilibrium in solution is influenced by 
factors such as pH changes and the presence of other ionic species. The UV 
absorption spectra for the ionised and non-ionised form of dithranol are 
markedly different [Upadrashta and Wurster (1988)]. This property of the 
molecule can be used to monitor the relative amounts of ionised and non-
ionised dithranol in solution. This can also be achieved by fluorescence 
measurements, by exploitation of the fact that of the two forms only the 
ionised species is fluorescent [Melo ~ (1983)]. 
Upadrashta and Wurster (1988) studied the ionisation behaviour of dithranol 
in aqueous buffers varying in pH from 5.10 to 11.74. Using absorbance 
measurements at 258nm they determined the pKa to be 9.06 at 25°C. Despite 
the presence of three ionisable phenol groups no spectroscopic evidence for 
the second and third ionisation reactions were observed. 
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In this study surfactants will be used as a means of enhancing the water 
solubility of dithranol (see chapter 3). It is therefore desirable to investigate 
any effect that the surfactants to be used will have on the ionic equilibrium 
of dithranol in aqueous solutions. This will be done using both absorbance 
and fluorescence measurements. Surface tension measurements will be made 
to ascertain any changes in surface activity caused by possible intermolecular 
reactions between the surfactants and dithranol. 
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5.2 Methods 
5.2.1 MATERIALS and EQUIPMENT 
Chemicals and reagents 
Glycine, (Fisons Scientific Equipment) Sodium hydroxide 1M (May & Baker 
Laboratory Products). All other chemicals as in 2.2.1 
Equipment 
UV absorbance measurements were made using a Perkin Elmer Lambda 15 
UV/Visible Spectrophotometer. All other equipment is as described in 2.2.1 
5.2.2 Ionic equilibrium of dithranol in aqueous solutions 
5.2.2.1 pKa determination using absorbance measurements 
Dithranol solutions (2.73#-,g/mL) were prepared in 0.02 M glycine -NaOH 
buffer of varying pH ( 8.1 - 9.4 ), and the absorption spectra, with appropriate 
blanks placed in the reference beam, obtained. lcm cells thermostatted at 
25°C ,were used. Maximum absorbance for the concentration of dithranol used 
was obtained using buffer pH 11. Minimum absorbance (i.e absorbance of 
dithranol when fully non-ionised) was obtained using pH 1. 
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5.2.2.2 pKa detennination using fluorescence measurements 
The method of Moody & Lubwika, 1993 was followed.3mL of O.02M glycine 
_ NaOH buffer (pH 6.9 - 9.5) were pipetted into lcm fluorescence cells 
thermostatted at 25°C. Using a 100 J.'L adjustable pipette, 30J.'L of buffer 
was removed and replaced with 30J.'L of a IJ.'g/mL solution of dithranol in 
acidified methanol. The final concentration of dithranol was therefore in the 
region of lOng/mL. Solution preparation was done in the fluorescence cell, 
to enable a fluorescence reading to be taken as soon as a solution was 
prepared. The excitation and emission wavelengths were set at 390nm and 
5I8nm respectively. The maximum fluorescence for the concentration of 
dithranol used was obtained using glycine - NaOH buffer pH 10.5. 0.1 % 
isoascorbic was added to stabilise the signal. 
5.2.3 The effect of surfactants on the dissociation of dithranol in aqueous 
solutions. 
5.2.3.1 Cetrlmide. 
The effect of pH and CET concentration on the absorbance at 258nm. 
3mL of 0.2M sodium acetate - HCl buffer pH 5.5 were transferred to lcm 
UV absorbance cells. Gradually increasing concentrations of CET ( 0 - 0.5 % 
w/v) were prepared directly in the cells. Dithranol was added to these 
solutions by removing 30J.'L of buffer from the absorbance cell and replacing 
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it with 30JLL of a 430JLg/mL solution of dithranol in acidified methanol. Thus 
the final concentration of dithranol in each CET solution was 4.3JLg/mL. 
Using appropriate blanks absorption spectra were then obtained. This procedure 
was then repeated in the range 0 - 0.5% w/v CET at pH 4.6 and in 1M HCI 
(PH 0.4). 
The effect of change in the dithranol concentration on the absorption 
spectrum and the absorbance at 258nm in the presence of a rlXed excess of CET 
(0.2% w/v). 
2mL of 0.2 % CET in 0.2M acetate buffer pH 5.5 were transferred to a 0.5 cm 
UV absorbance cell. Gradually increasing amounts of dithranol were then 
added directly to the cell. The dithranol was added by removing a volume of 
the 0.2 % CET solution, using a graduated pipette, and replacing this with the 
same volume of a 500JLg/mL solution of dithranol in methanol. The solutions 
were such that the final concentration of dithranol was 5.0 , 7.5 , 10.0 ,12.5, 
and 15.0JLg/mL. The absorption spectra were then recorded. 
The effect of pH and CET concentration on the measured fluorescence Intensity 
using an excitation wavelength of 390nm and emission wavelength of 518nm 
For fluorescence measurements the CET concentration range used was 0-
0.16 % w/v. Using a IJLg/mL dithranol in methanol solution, dithranol was 
added to each CET solution as per the procedure described above for 
absorbance investigations to give a final concentration of lOng/mL dithranol 
in each solution. Fluorescence measurements were done at pH 5.5 and pH 4.6. 
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5.2.3.2 Tw and NaLS 
The effect of pH and CET concentration on the absorption spectra of 
dithranol in Tw and NaLS. 
Tw solutions covering the concentration range 0 - 0.3% were prepared in 
0.2M acetate buffer pH 5.5 and in 0.02M glycine buffer pH 8 and 10. Dithranol 
was added to each of the Tw solutions as described for the absorption 
measurements for CET the final concentration of dithranol in each solution 
being 4.3J.'g/mL. The absorbance spectra of these solutions was then recorded. 
The procedure was repeated using NaLS (0 - 0.5 %) in glycine buffer pH 10. 
5.2.3.3 The dissociation constant detennination for dithranolln the presence 
of an excess of CET 
Using UV absorbance measurements. 
0.2M acetate buffer solutions pH 4.55 - 5.50 were prepared. Each buffer 
solution contained 0.2% w/v CET. 3mL of each buffer prepared was 
transferred to a lcrn UV absorbance cell and dithranol added to the 
absorbance cell. Dithranol (4.3J.'g/mL) was added as per 5.2.3.1 (the effect of 
pH and CET concentration on the absorbance at 258nm). The absorbance 
spectra of the solutions were then recorded. Maximum absorbance was 
determined using pH 11. 
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Using fluorescence measurements 
0.2M acetate buffer solutions (PH 4.55 -5.50) at 25°C were prepared as 
described above. After transfer of 3ml of each of the buffer solutions into 
a lcm fluorescence cell, 6Op.L was removed and replaced with 30p.L of a 
4% CET solution in water, the solution was mixed by inversion of the 
contents in the cell after which 30p.L of a lp.g/mL solution of dithranol in 
acidified methanol was added and the fluorescence reading obtained. The final 
concentration of CET ,therefore, was 0.04%. Maximum fluorescence was 
determined using buffer pH 5.7 containing 0.3% CET with 0.1 % isoascorbic 
acid added to stabilise the fluorescence signal. 
5.2.4 Surface tension measurements at pH 5.5 and pH 0.4 
These were performed using a White torsion balance. The value recorded was 
the mean of three replicate samples. Measurements were done at room 
temperature (21 ±1°C) 
CET solutions (lOmL) covering the concentration range 0 - 0.02 % were 
prepared in O.2M acetate buffer pH 5.5 . The surface tension of these solutions 
was recorded. Using an accurately prepared concentrated solution of dithranol 
( _ 860JLg/mL) in acetone 50p.L was added to each of the CET solutions to 
give a final concentration of dithranol in each of about 4.3JLg/mL. 
For the measurements at pH 0.4 the procedure described above was repeated 
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using 1M He! (PH 0.4). 
5.3 ResultslDiscussion 
Dithranol is a weak organic acid. It's pKa in aqueous conditions at 25°C was 
determined as 9.06 by Upadrashta and Wurster (1988), who used UV 
absorbance measurements at 258nm of dithranol in aqueous buffers. Using the 
data presented in Table 5.1 and the equations outl.i.sled by Upadrashta and 
Wurster (1988), graphical determination of pKa (see Fig 5.1) gave a value of 
9.12 ± 0.10 (n=3) ,which is in good agreement with the value obtained by 
Upadrashta and Wurster. 
As with absorbance measurements the relative amounts of ionised and non-
ionised dithranol at a particular pH can be determined by measuring the 
fluorescence at the given pH. The pKa can be determined usmg the 
appropriate fonn of the Henderson - Hasselbach equation 
F pH=pKa+Log obsd (constanttemperature) Eq. 5.1 
Fmax-Fob• d 
where F oIHd = % fluorescence intensity at a given pH 
Fmas = % fluoresence intensity of fully ionised dithranol. 
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Eq. 5.1 shows that a plot of pH v Log Fobad I Fmax - Fobad is a straight line. 
This indicates a direct relationship between the pH of the solution and the 
ratio of ionised to non-ionised dithranol. The equation also shows that when 
the Log of the ratio is zero, pH = pKa, this, therefore ,allows the graphical 
determination of pKa. Using a fixed concentration of dithranol (lOng/mL) 
the data presented in Table 5.2 was obtained. Using this data and equation 
5.1 graphical determination of the pKa (see Fig 5.2) gave a value of 8.64 
± 0.26 (n=3). Though measurement of fluoresence has the advantage of 
being specific for the ionised form only and is about 100 times more 
sensitive than UV absorbance measurement, there is the problem of signal 
instability , especially at high pH. Since this method depends on the acurracy 
of the F max value, any error in it will lead to inaccuracies in the pKa 
determination. This would contribute to the statistically significant difference 
(p < 0.05) in the pKa values obtained using the two methods. The pKa 
determined using absorbance is more reliable because the absorbance of 
ionised dithranol is relatively more stable than the fluoresence arising from 
it. 
Tbe ~ffect of surfactants on the ionic equilibrium of aqueous dithranol 
In Fig 5.3 the effect of CET concentration (0 - 0.02% w/v) on the absorbance 
spectrum of dithranol (-4.3}Lg/mL) at pH 5.5 is shown. On the addition of 
CET up till 0.02 % w/v a linear relationship is observed between the 
absorbance at 258nm and 388nm and CET concentration. When CET is 
increased beyond 0.02 % loss of linearity is seen with a gradual increase to 
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a plateau region. The effect observed was pH dependent, the lower the pH 
the less the absorbance seen (see Fig 5.4). By comparing the gradients of 
the linear portions of the absorbance vs CET concentration plots (see Fig 5.5) 
it can be seen that the absorption capacity of the ionised dithranol at 388nm 
is about half that seen at 258nm. Hence for quantitative determination of the 
ionised form measurement at 258nm would be preferred. The UV spectra 
obtained when the above procedure was carried out in 1 M HCI are shown 
in chapter 3 (see Fig 3.10). Unlike the results seen at pH 5.5 ,there was no 
increase in the peak at 258nm with increasing CET concentration. This is 
a clear indication that the ionisation reaction was effectively suppressed. What 
was observed instead was a gradual change in the spectrum from one lacking 
in spectral detail to the type obtained in chloroform. The change being 
associated with the solubilisation of dithranol (see chapter 3) . 
. On monitoring the effect of CET using fluorescence a similar pattern to that 
obtained using absorbance measurements was observed. Gradually increasing 
the concentration of CET while keeping pH and dithranol concentration 
constant resulted in fluorescence gradually increasing to a plateau region (see 
Fig 5.6). 
Fixing the pH at pH 5.5 ,and the CET concentration at 0.2% w/v (a 
concentration in the plateau region of the absorbance v CET concentration 
plot) and adding increasing amounts of dithranol to such solutions resulted in 
the absorbance values shown in Table 5.3. A plot of the absorbance (258nm) 
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v dithranol concentration shows that the relationship between the two was 
linear (correlation coefficient 0.998). The gradient of this plot gives the Beer 
Lambert Law constant which was calculated to be 4.68 x lQ4 mol-I dm3 em-I. 
Using the data in Table 5.1 (i.e A = 0.642, for dithranol 2.73J.Lg/mL at pH 11) 
the Beer Lambert Law constant for fully ionised dithranol was calculated as 
5.3 x lQ4 mol-I dm3 em-I. Comparing the two values of the Beer lambert law 
constant shows that in 0.2 % CET at pH 5.5 dithranol is - 88 % ionised. 
According to Eq.5.7 if pH is fixed, then pK' and the log ratio will also be 
fixed. Since dithranol is - 88% ionised a value of 4.63 is obtained for pK'. 
This value agrees well with 4.68 found when a fixed concentration of 
dithranol was placed in 0.2 % CET solutions of varying pH (see later). 
Both absorbance and fluorescence measurements showed that dithranol was 
being made to ionise at pH values much lower than pH 9 when CET was 
introduced into solution. The indications are that there is an interaction 
between the two molecules which results in an increase in the acid strength 
of dithranol. The shape of both the absorbance (see Fig 5.4) and fluorescence 
(see Fig 5.6) profiles shows that the interaction between the two molecules 
rises to a maximum before reaching a pH dependent plateau region, where 
the reaction becomes independent of the amount of CET present. This IS an 
indication that the reaction is at equilibrium for that pH. Since the acid 
strength of the complex is greater than that for dithranol, as the pH nses 
so the complex ionisation will increase. This is the reason why the plateau 
regions with both the absorbance and fluorescence measurements increase as 
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pH is increased (see Fig 5.4 and Fig 5.6). 
The dissociation of dithranol as shown above is influenced by CET 
presence. By carrying out pKa determination of dithranol in the presence of 
an excess of CET i.e a CET concentration where the dithranol-CET 
interaction is independent of CET concentration, the pK' value can be 
obtained. Using 0.2 % w/v CET and a fixed concentration of dithranol 
(4.4pg/mL) the data presented in Table 5.4 was obtained. Using such data a 
pK' value of 4.68 + 0.09 (n =3) was determined. Fluorescence measurements 
were also used for pK' determination. Using 0.04% w/v CET and dithranol 
10ng/mL the data in Table 5.5 was obtained. Using such data pK' was 
determined as 5.01 + 0.13 (n=3). The two methods give rise to two 
significantly different (p > 0.05) pK' values. As previously outlined the 
reliability of the fluorescence method depends on the accuracy of the F max 
determination, which itself is prone to error because of fluorescence signal 
instability. Using absorbance measurements an almost identical pK' value was 
obtained despite two different approaches being undertaken. Keeping pH and 
CET concentration constant and varying that of dithranol lead to a pK' 
estimate of 4.63 and keeping CET and dithranol concentration constant and 
varying pH lead to a pK' estimate of 4.68. 
Based on these results it is postulated that the relationship between dithranol 
and CET may be represented as; 
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[DT] + [CET] ~< ====;J [CET-DT] + [H+] Eq.5.2 
(constant temperature) 
K= [CET-DT] [H4'] [CET] [DT] (constanttemperature) Eq. 5.3 
The equilibrium equations 5.2 and 5.3 show that increasing either dithranol 
or CET concentration will drive the equilibrium to the right i.e promote 
complexation and ionisation of dithranol. The equations also show that 
increasing H+ will drive the equilibrium to the left i.e suppress complexation 
and ionisation. Reducing H+, it is predicted will promote complexation 
formation and of ionisation of dithranol. In the presence of a fixed 
concentration of CET the equilibrium equation 5.3 can modified to that shown 
in Eq.5.4 which can be further modified, through the steps indicated, to the 
equation shown in Eq 5.7. 
at constant [CET], 
K=K[CET] .. [CET-DT] [H·] 
[DT] 
[H1" K'[D7] 
[CET-D7] 
Log[H1=LogK'+ Log[D1] 
[CET-D7] 
Eq. 5.4 
Eq.5.S 
Eq.5.6 
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pH=pK' + Log[CET-D1] 
[D7] 
[CET-DT] = ionised dithranol (complexed) 
[DT] - non-ionised dithranol 
pK' - apparent dissociation constant 
Eq.5.7 
Eq. 5.7 shows that a plot of pH v Log [CET-DT] /[DT] should be a 
straight line, which allows the graphical determination of pK' (cf pKa 
determination using Eq.5. 1). The pK' value obtained in an excess of CET 
was 4.68 and 5.01 using absorbance and fluorescence respectively. The pK' 
value obtained using absorbance measurements is the more reliable result 
because, as already explained, the chance of error in the pk' determination 
using fluorescence is greater. What both results indicate clearly, though, is 
that in the presence of CET the acid strength of dithranol is considerably 
increased, and ionisation is occuring 4-5 pH units lower than the values seen 
in aqueous solutions without CET present. The implications therefore are that 
for the pH 5.5 surfactant solutions to be applied to the skin; dithranol in the 
CET fonnulation will be - 88 % ionised (calculated using Eq.5. 7 and pK' = 
4.68). 
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From the above it can be postulated as to how the presence of CET in 
solution leads to the appearance of ionised dithranol. While it is known that 
the keto form is the predominant form in chloroform, acetone , 
dimethylsulphoxide, and pyridine the exact nature of the tautomer in aqueous 
solution remains ambiguous [Holder & Upadrashta , 1992]. Because of the overall 
stability of the keto form compared to the enol form it is likely that this 
is the predominant form in aqueous solutions. It is possible that CET and 
dithranol molecules come together by a hydrophobic interaction and because 
of the positive charge carried by CET molecules, the hydrogen bonding 
responsible for the stability of the keto form would be interfered with. The 
consequence of this would be a hydrophobically bonded dithranol-CET 
complex in which dithranol was a stronger acid because of being present in 
the enol form. Water molecules (or a stronger base e.g OR) can then 
deprotonate the unstable enol form leading to the formation of ionised 
. dithranol [Meto ~ , (1983)]. This sequence of events (see scheme 5.1) would 
be a plausible explanation as to how CET causes the ionisation of dithranol 
in aqueous solution. 
It has previously been shown that surface activity was most marked for CET-
dithranol solutions, compared to NaLS-dithranol and Tw-dithranol [Moody & 
Lubwika, 1992]. A possible explanation for these observations can now be 
advanced. In scheme 5.1 it is proposed that a dithranol-CET complex is 
formed. Such a complex would be relatively large thus being able to reduce 
the surface tension of water to a greater extent than CET molecules alone. 
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Since it has been shown that the dithranol-CET interaction is pH sensitive, 
being suppressed at low pH and promoted as pH increases, it was anticipated 
that the surface activity of such mixtures should be pH sensitive. The results 
in Fig 5.7 shows that this was indeed the case. At pH 5.5 surface tension 
measurements of CET solutions done with and without a fixed amount of 
/ Keto fonn 
Enol fonn lonill8d dithranol 
DT-CET 
DT~ET complex where dithranol I. ionill8d 
Scheme 5.1 
The possible interaction between CET and dithranol in aqueous conditions 
leading to the formation of ionised dithranol. 
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dithranol (- 4.3J.'g/mL) present show that the extent to which the surface 
tension of water was reduced was greater in the presence of dithranol. At 
pH 0.4 (see Fig 5.8) there was little difference between the solutions with and 
without dithranol. It was also observed that at pH 5.5 there was a reduction 
in the c.m.c of dithranol-CET solutions (see Fig 5.7). In the absence of CET 
c.m.c was 0.016% (21 ± 1°C) whereas in the presence of CET the c.m.c was 
reduced to 0.011%(21 ±1°C).This shift in c.m.c is consistent with the idea 
of a large complex being formed. The observed c. m.c is smaller because less 
of the large complex would be required to cover the surface of the water 
compared to the situation at pH 0.4 ,where because the dithranol-CET 
complex is not formed more CET monomers are required to cover the water 
surface. 
In NaLS solutions at pH 5.5 ,containing a fixed concentration of dithranol 
(4.3J.'g/mL), there was no evidence for an interaction between NaLS and 
dithranol similar to that seen with eET, though evidence for solubilisation 
is obtained (see chapter 3). NaLS molecules being negatively charged, it is 
not all together surprising that no ionising interaction was observed. To 
investigate the interaction of ionised dithranol with NaLS, the pH was 
increased to pH 10 ,which means that there is > 90% ionisation of all 
dithranol molecules present. At pH 10 it was observed that there was a 
reduction in the absorbance at 258nm as NaLS concentration increased. Plotting 
the absorbance at 258nm against the NaLS concentration gIves a curve 
typical of solubilisation (see Fig 5.9). The indications are that solubilisation is 
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altering the extent of ionisation ,the explanation for this being that ionised 
dithranol enters the less polar hydocarbon core of the micelles, where some 
of the ionised molecules convert to the non-ionised form thus the drop in 
the ionisation peale 
In Tw solutions of pH 5.5 there was no UV spectrophotometric evidence to 
suggest an interaction with dithranol similar to that observed with CET. In 
order to investigate the effect of the presence of Tw on ionised dithranol the 
pH was increased to pH 10. It was observed that introduction of Tw lead to 
very unstable preparations. It was therefore decided to use solutions of pH 8. 
Increasing concentrations of Tw were observed to cause a gradual shift to 
the longer wavelengths of the lamda max (see Table 5.6) of the peak in the 
350nm region. This shift in the lamda max is indicative of change in the 
environment of the dithranol molecules. The environment is becoming less 
polar, thus the UV spectra tend towards that observed in non-polar solvents 
such as chloroform (see chapter 3). As Tw concentration increased a shoulder 
appearS at 388nm, this indicates the presence of ionised dithranol. This is 
confirmed at 258nm where above 0.12 % Tw absorbance increased with Tw 
concentration. A plot of absorbance v Tw concentration (see Fig 5.10) is 
indicative of the occurrence of solubilisation. The spectrophotometric evidence 
suggests that on solubilisation the aqueous ionic equilibrium is altered because 
dithranol molecules enter an environment where there is a small increase in 
the extent of ionisation. 
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On the whole it has been shown that surfactants have a pH and type 
dependent influence on the ionic equilibria of aqueous dithranol. At pH 5.5 
CET presence has a marked effect while Tw and NaLS have little or no 
effect. Currently literature suggests two possible routes for dithranol 
decomposition (see chapter 4). The consequence of CET's disruption of 
dithranol's aqueous ionic equilibrium is that the decomposition pattern is 
observed to change from mainly dimer to mainly danthron (see chapter 4). 
Current thinking with regard to dithranol's mode of action is that the 
decomposition process is vital to the effectiveness of the drug. What is not 
known, however, is which, if any, of the two possible routes is the 
therapeutically beneficial one. Since the molecular species of dithranol present 
will influence the decomposition pathway, it follows that surfactants have the 
potential to influence the effectiveness of dithranol. In the presence of 
surfactants like CET the danthron pathway is promoted, while in the 
presence of surfactants like NaLS. and Tw the dimer pathway is promoted. 
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Table 5.1 
The UV absorbance of dithranol solutions (2.73SLg/mL) in glycine buffer at 25°C. 
pH Absorbance (258nm) 
8.1 0.171 
8.6 0.29S 
9.0 0.329 
9.4 0.459 
9.7 0.501 
The absorbance of fully IODised dithranol was 0.641 (determined at pH ll).For Doa-ioDised ditbranol it was 
0.12 (determined at pH 1). 
0.50 
0.20 
'-
" 
-0.10 
-0) 
0 
..J 
-O.~O 
-0.70 
~~.~--~------~------~----~----~ -t.OO I 
8.0 a.~ a.a 8.2 9.5 10.0 
pH 
Fig 5.1 The graphical determination of pKa for dithranol using absorbance 
measurements (see Table 5.1). 
y. Q.S660(X) -7.9245 (correlation = 0.992) 
For tlW equation piouad see Wul'S1Itr Upadtashta (1988). 
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Table 5.2 
The observed fluoresence of dithranol (lOng/mL) in glycine buffer at 25°C. [Excitation 
wavelength 390nm, Emission wavelength 518nm]. 
pH % fluorescence intensity 
6.9 3.0 
8.1 21.9 
8.5 36.9 
9.1 61.5 
9.5 69.6 
The maximum % fluorescence (or the concentration of dithranol used was 84.7 (determined at pH 10.5) 
== c. 
Fig 5.2 
u 
U~,------~,------~,~----~.------~.------~i 
·1,",0 ·I.a, - -0.1' 1U0 L7I 
Log ~ I F... F 
-
The graphical detennination of pKa for dithranol using ftuorescence measurements 
(see TableS.2). . 
y -1.2191(x) + 8.6435 (correlation. 0.999) 
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Fig 5.3 
::.o.oa 
"'00 
The effect of CET concentration on the UV absorbance of dithranol (4.3 P9/ml) in 
acetate buffer at pH 5.5 at 25°C. 
At 258 and 388nm 1 = buffer, 2 = 0.005% GET, 3 = 0.01 % GET, 4 = 0.015% GET, 
5 = 0.02% GET. 
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Fiq 5." 
The effect of CET concentration at pH 5.5 C.) and 
pH 4.6 C.) on the absorbance of dithranol measured 
at 258nm. 
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0.75 
0.60 
GJ 
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~ 
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0 
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<: 
0.15 
0.00 -t----.,....---.,....---~----:------., 
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CET (% W/V) 
Fig 5.5 
The absorbance of dithranol(-4.3J19/mL) in CET solutions of increasing 
concentration at 25°C. pH of solutions = 5.5. A = 258nm I ... = 388nm. 
At 258nm y. 27.1800(x) + 0.1~ : At 388nm • 'I • 10.0800(x) + 0.0605 
(Correlation coefficient • 0.991). (Correlation coefficient • 0.992) 
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The effect of pH and CET concentration on the fluorescence of dithranol ( N 1 Ong/mL) 
In acetate buffer at 25°C. & = pH 4.6 I • = pH 5.5 
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Table 5.3 
'!'he effect of dithranol concentration on the absorbance at 2SSmn 
in a fixed concentration of CET (0.2% w/v) at pH 5 5 . . 
CET (\' w/v) pH Di~hranol(~g/mL) Absorbance (25Snm) 
0.2 5.5 5.0 0.5l7 
0.2 5.5 7.5 0.75l 
• 
0.2 5.5 10.0 1.022 
0.2 5.5 l2.5 1.269 
0.2 I 5.5 I l5.0 1.577 
Table 5.4 
The effect of pEl: on absorbance at 258nm. of 
concent-ation of dithranol (4.4~g/mL) in 0.2% CET. 
a 
-
~T (0.2%'w/v) I pH I Di~hranol (lLg/mL) I Absorbance (:258nm) 
0.2 I 4.00 I 4.4 1 0.350 
0.2 I 4.50 4.4 I 0.486 
0.2 4.75 4.4 I 0.600 
0.2 5.00 I 4.4 1 0.714 
0.2 I 5.30 I 4.4 'I 0.802 
0.2 I 5.50 I 4.4 I . 0.917 
Ab.or~&:ee of tully ioni •• d diehr&:ol (4.4~g/=L) dee.r.:ined at pH 11 • 0.'94. 
'I'h. ab.or~a.ne. for non ioni.ed cU. thranol (pH 0.4) va. 0.lEi1. Both were c!.Ql:le:!.Xl 
ue abaane. of err. 
Table 5.5 
The observed % fluorescence of dithranol (lOng/mL) in acetate buffer at 25°C, in the 
presence of 0.04% w/v CET. 
Cetrimide (%w/v) pH % Fluorescence 
0.04 4.6 42 
0.04 4.8 67 
0.04 S.O 98 
0.04 5.3 131 
0.04 5.5 145 
MaxilDum nuoraeeDce (190) was determined usiae acetate buffer pH 5.7 with 0.30/. CET aad 0.1./. 
isoaseorbie aeid. 
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Fig 5.7 
Surface tension measurements of CET solutions of pH 5.5 at 2S DC. Measurements 
were made with and without tbe addition of dithranol (-4.3119/mL) •• = no dithranol 
• = dithranol present. 
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Fig 5.8 
Surface tension measurements of CET solutIons of pH 0.4 at 25°C. Measurements 
were made with and without the addition of dithranol (-4.3pgJmL). 4 = no dithranol 
• = dithranol present. 
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Fig 5.9 
1.
5 1 
1.2 ~ 
~ 
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Tne effec: of increasing concentrations of NaLS on the acsorcance of ditr:rcoJI 
(";.1.3,ug/mL) in glyc:ne buffer pH 10 at 4:~C. The absor:ance at 2:enm is shown 
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Table 5.6 
The effect of Tw on the wavelength of maximum absorbance for dithranol in glycine 
buffer pH 8 at 25 ° c. 
Tw (%w/v) 
0.00 
0.01 
0.03 
0.05 
0.08 
0.12 
0.20 
0.30 
0.50 
G 
u 
c 
... 
.D 
0 
... 
.D 
< 
wavelength of maximum absorbance (run) 
350.8 
352.4 
353.4 
354.4 
357.4 
356.8 
366.0 
366.0 
367.2 
0.35 
0.32· 
.... 
0.29· / 
0.25 / 0.23· 
-. 
-• 0.20 I i 
0.00 0.10 0.20 0.30 0.40 0.50 
Tw IS w/v) 
Fig 5.10 
The effect of Tw on the absorbance of dithranol(-4.3pgJmL) in 
glycine buffer pH 8 at 25°C. Absorbance at 258nm is shown. 
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CHAPrER6 
THE IN VIVO AND IN VITRO INTERACTION OF AQUEOUS 
SURFACTANT SOLUTIONS OF DITHRANOL WITH SKIN 
6.1 Introduction 
Solubility investigations (undertaken in the present study) have shown that the 
aqueous solubility of dithranol can be enhanced by surfactant solubilization, 
and following stability studies on such solutions conditions for maximum 
stability have been identified (see chapter 4). In this chapter skin permeation 
studies will be carried out using these aqueous solutions of dithranol along 
with hairless mouse, normal human and psoriatic skin. Also to be investigated 
is the antipsoriatic potential of the dithranol-surfactant preparations using the 
TPA psoriasis model (see 1.2.3). 
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6.2 Experimental Methods 
6.2.1 Materials 
Dithranol , (Sigma Chemical Company) 
Sodium dodecyl sulphate (NaLS) approx. 99% pure ,(Sigma Chemical Company). 
Hexadecyltrimethylammonium bromide USP (Cetrimide) 99% pure, (Sigma 
Chemical Company). 
Polyoxyethylenesorbitan mono-oleate (Tween 80), (Sigma Chemical Company). 
Sodium acetate trihydrate , (Fisons Scientific Equipment) 
Sulphuric acid, Rathburn chemicals (Walkerburn , U.K.) 
Hydrochloric acid 1M, (May & Baker Laboratory Products) Sodium hydroxi~e 1M 
, (May & Baker Laboratory Products) 
Acetaldehyde, (May & Baker Laboratory Products) 
Diphenylamine, (Sigma Chemical Company). 
Calf thymus DNA, (Sigma Chemical Company). 
Perchloric acid, (May & Baker Laboratory Products) 
12_0-tetradecanoylphorbol-13-acetate (TPA), (Sigma Chemical Company). 
All chemicals were used as obtained. 
6.2.2 Preparation of the surfactant solutions. 
The constituents of the buffer were dissolved in distilled water and then the 
pH adjusted to 5.5 using O.4M HCI. The volume was then made up to the 
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mark using distilled water, such that the final concentrations were 0.2M sodium 
acetate, 0.5% IAA, 4% NaLS or Tw and 2.5% CET. 
The CET and NaLS formulations should be stored above 25°C to prevent 
precipitation of surfactant especially at concentrations above 3 % w/v. Should any 
precipitation occur the solutions should be warmed and gently shaken. 
6.2.3 Skin penneation procedures. 
6.2.3.1 In vitro penneation procedure 
Skin source. 
Skin was obtained from male and female hairless mice (Crl:nu/nu 28 - 42 days 
old -Charles River UK, LTD). The animals were sacrificed by cervical 
dislocation and the entire skin removed and stored at -70°C. When required 
the skin was thawed at room temperature, appropriate sized pieces cut and 
all subcutaneous fatty tissue removed before mounting the skin in the 
diffusion cells. Human psoriatic skin was obtained from the lower forearm of 
a patient with visible psoriasis from Ward 29 of the Dermatology Department 
of Aberdeen Royal Infirmary. The skin was kept frozen (-70°C) and used within 
24 hours. 
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Permeation procedure 
Skin permeation experiments were done using flow through diffusion cells. The 
type used were those updated in design by Gummer ~ (1987). Some 
advantages of this design include instantaneous stirring of receptor phase and 
a water jacket extending up to the level of the skin. (The cells were 
manufactured to the required specifications by Norlab LTD ,Aberdeen (see 
diagram at end of chapter). Skin was mounted in the diffusion cell with the 
dermis side in contact with the receptor medium, and the stratum corneum 
side (effective area lcm2) with the donor solution (2mL). Silicone grease was 
used to ensure there was no leakage when the two cell compartments were 
pressed together. Water from a water bath, set at 3rC ,was circulated through 
the water jacket. The flow rate of the receptor medium (methanol 60 , H20 38, 
GAA 2 + 0.5 % IAA - 37°C) was set at O.5mUmin. 
6.2.3.2 In vivo normal human skin permeation procedure 
Formulation application 
Two healthy adult volunteers of African origin (one male and one female 
both aged 33) were used. The formulations were applied to the forearm skin. 
To apply the dithranol-surfactant solutions the method recommended by 
Schaefer and Lamaud (1987) was followed, but instead of using a glass ring 
a specially designed glass cap (made to required specifications by Norlab 
LTD, Aberdeen- see diagram at end of chapter.) was used to both delimit the 
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area (2cm2) to be treated and allow sample withdrawal for analysis. After 
gluing the cap to the skin (using super glue 4) 0.7ml of the dithranol-surfactant 
formulation was introduced through a hole in the top of the cap which was 
then temporarily sealed to prevent escape of material by leakage and 
evaporation. Samples for analysis (lO",L) are withdrawn, using a micropipette 
through the hole in the top of the cap, at selected time intervals for hplc 
analysis. 
6.2.4 Assessment of the anti psoriatic potential of the surfactant fonnulations of 
dithranol 
Fonnulation application to hairless mouse skin in vivo. 
The method outlined in 6.2.3.2 was followed with the glass caps being 
glued to the backs of the mice. 10 ",mol of TPA dissolved in 50",1 of acetone 
was then applied to the backs of the animals using a pipette. The top of the 
glass cap was not sealed for about 10 minutes to allow acetone to 
evaporate. When both TPA and a dithranol-surfactant preparation were to be 
applied to the animal's backs ,the surfactant formulation (lOO",L) was applied 
after allowing the acetone to evaporate. The caps were then sealed to prevent 
leakage of the aqueous preparations. The animals were killed (cervical 
dislocation) 48 hours post treatment. Before killing the animals an inflammation 
score, based on an arbitrary scale of 0 - 4 ,was given (see Table 6.3).The 
treated area was excised, placed in a sample bottle and frozen at -70°C to 
prevent enzyme degradation. 
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6.2.5 DNA quantification using diphenylamine (Burton method). 
Aqueous acetaldehyde (1.6%) was prepared by transferring ImL of commercial 
acetaldehyde to 50mL of distilled water. Diphenylamine reagent (DPAR) was 
prepared by transferring 1.5g diphenylamine to a volumetric flask (l00mL), 
1.5mL concentrated H2S04 is then added to the flask and volume made up to 
the mark using glacial acetic acid. Before using the DPAR 0.1 mL of 1.6 % 
aqueous acetaldehyde is added per 20mL of reagent. 
6.2.5.1 Preparation of DNA standards 
Calf thymus DNA was weighed (0.0162g) and dissolved in 0.005 M NaOH 
(25mL). The amount of DNA in solution was quantified spectrophotometrically 
using the unit definition whereby one unit yields an absorbance at 260nm 
(A
260
) of 1 in ImL of buffer (lcm light path). One unit equals approximately 
50p.g of DNA (Sigma Chemical Company, 1992). 
3mL of 0.OO5M NaOH were pipetted into a lcm path absorbance cell, 
0.5mL of this was removed and replaced with the DNA solution. The cell 
contents were mixed by inversion of the cell. The absorbance at 260nm of 
the resultant solution was 1.03 equivalent to 51.40lLg/mL DNA. The 
concentration of the standard prepared was therefore 51.40 x 6 (dilution factor) 
= 308.40p.g/mL. 
The DNA standard was diluted 1:2 using N perchloric acid and then heated 
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at 70°C for 15 minutes. After heating, aliquotes of the mixture were diluted , 
using 0.5N perchloric, to give DNA solutions of concentration 10 - 50JLg/mL. 
Each dilution (lmL) was then mixed with DPAR (2mL) and the mixtures 
incubated at 25 - 30°C for 15 -17 hours after which absorbance was read at 
600nm. The calibration graph results are shown in Fig 6.11 
6.2.5.2 Determination of DNA content of hairless mouse skin 
Frozen hairless mouse skin was left in a closed container was left to thaw 
at room temperature. Circular discs approximately 2cm2 were cut and weighed 
before being placed in O.5N perchloric acid (3mL). The mixture was then 
homogenised at high speed for 2 minutes after which it was heated at 70°C 
for 20 minutes. After the heating stage, 1 mL of the skin extract is added to 
2mL of DPAR and the mixture incubated at 25 - 30°C for 15 - 17 hours. On 
running the UV spectrum of the incubated mixture a high background 
reading was obtained, the problem was resolved by taking 0.5mL of the 
extract and adding it to 1 mL diethylether and then obtaining the UV 
spectrum. The absorbance at 600nm was recorded (the standards used for 
calibration graph preparation were also treated in a similar fashion). 
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6.3 Results/Discussion 
Skin permeation characteristics of dithranol have been studied by a number 
of workers [Kammerau ~ 1975 , Schalla rul 1981 , Schaefer rul 1980 , Cavey 
tl.al1985, Wang ~ 1987 ,Priprem 1991]. Dithranol has been delivered to the 
skin mainly in ointments, creams and gels and other semisolid or solid 
(polymeric disk and hydrogel) formulations while, in the main, permeation 
characteristics have been established by using radioactive-labelled dithranol 
(CI4) and the skin punch biopsy method (see Schaefer and Lamaud , 1987). The 
skin biopsy method is invasive and radiochemical methods have the 
disadvantage of being relatively non-specific. This is particularly true of an 
unstable compound like dithranol. Thus separation is essential to achieve 
positive identification of dithranol and its decomposition and/or its metabolic 
products. This is particularly of necessity for kinetic studies. Another 
disadvantage is the use of radioactive material for in vivo studies. The natural 
substance would be preferred. Some workers [Wang ~ (1987)] have 
recognised the shortcomings of the radioactivity approach and have used hplc 
to generate such data using formulations, such as those previously 
mentioned. 
In this study liquid preparations of dithranol were placed in contact with 
skin and analysis done by hplc. The main advantages of the present approach 
compared to others is the simplicity of the technique (no formulation release 
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problems) along with the ability to account for breakdown product formation 
during the skin permeation process. The use of a liquid formulation of 
dithranol allows measurements to be made at various time points post 
application of the dose and hence generation of concentration time profiles 
for dithranol and its breakdown products during the permeation process. To 
generate such data using other formulations would require more complex 
experimental set ups. 
In aqueous solution, it has previously been shown that dithranol in the 
surfactants is expected to produce danthron and dimer in varying amounts. 
However in contact with the skin it was observed that an unknown peak was 
repeatedly obtained with a retention time of around 4 minutes (this peak will 
now be referred to as P4). This effect was seen with all the dithranol-
surfactant formulations and with both hairless mouse and human skin. 
The chromatograms shown in Fig 6.1 were obtained on analysing the DT-
surfactant solutions after a period of time in contact with hairless mouse 
skin. The chromatograms show that the p. peak is fully resolved from those 
of danthron, dithranol and the internal standard. It was therefore possible, by 
using the hplc column, to isolate the individual fractions as they came of the 
column. By repeated collection of the P4 and dithranol fractions enough 
( _ 2mL of each fraction) was collected to enable absorption spectra to be 
obtained. The spectra for the two fractions are very similar (see Fig 6.2) 
except that the p. spectrum is shifted towards the longer wavelengths. The 
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retention time of P4 is shorter than that of dithranol showing that it is a 
comparatively more polar structure. To elucidate the structure of P4 larger 
quantities than those obtained using the hplc column would be necessary to 
carry out procedures such as molecular weight assignment using mass 
spectrometry. Time constraints did not allow this to be explored. 
Scheme 6.1 shows the proposed reaction pathway for the formation of the 
oxidation products of dithranol [modified from Holder & Upadrashta (1992)] .It 
is possible that, once formed, free radical (iii) follows two different 
pathways, these being homolytic H - abstraction to form danthron and H· 
abstraction from another dithranol molecule to form an oxanthrone derivative, 
which can possibly undergo further oxidation to form danthron. Compounds 
of this structure (oxanthrone derivatives) are known to occur naturally as 0-
glycosides in cascara bark (Trease and Evans, 1983). An oxanthrone derivative 
. formed in this way would be very similar in structure to dithranol. Further 
, 
because of the lack of resonance enhancement due to the saturated nature 
of the bond at C 10 in such a derivative ,it can be expected that there is 
little change in the absorption spectrum relative to dithranol. The spectra 
shown in Fig 6.2 show that this indeed was the case. 
There are no reports in the literature of chromatographic data ,obtained during 
dithranol skin permeation process, of a dithranol metabolite similar to that 
observed in the present study. This could perhaps be because no skin 
permeation studies using aqueous solutions of dithranol have been reported. 
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To check if P 4 production ~as observed because of having the combination 
of dithranol, water and skin, dithranol was delivered to the skin in 
methanol. 
o H-O O-H 0 H-O 
F::.::a, ~O 0 +02 
. ~ 
HomoI)Oc claavage \ (I) 
Dithranol 
Oxanthrone 
Scheme 6.1 
"H 
Anthranoyl free radical 
Homolyltc dea .. go 0' ... 
• 
o_ldolion 
possible allemathe 
(II) 
Danthron 
The possible' reaction pathways for the formation of the oxidation products 
of dithranol in and on skin [modified from Holder & Upadrashta (1992)] 
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P4 formation was still observed. The production of P4 is therefore not due 
to the aqueous conditions but more because of dithranol being in contact with 
the skin. This was further supported by the fact that application of the 
vehicle blanks did not result in P4 formation, and also shows that P4 did 
not derive from the glass cap or the glue used. Since P4 was formed on 
both hairless mouse skin and human skin, it follows that it's formation is 
not influenced by the presence or absence of sweat glands. 
The results presented in Fig 6.4 - 6.7 show the concentration vs time profiles , 
for periods up to 10 hours , for dithranol and decomposition products when the 
DT -surfactant formulations were placed in contact with hairless mouse skin 
. Figures for the conversion of dithranol to P 4 are estimates as the exact 
nature of P4 is unknown. The UV spectra shown in Fig 6.2 show that the 
absorbances at the analytical wavelength (254 nm) for dithranol and P4 are 
very similar along with the whole spectrum. Based on these observations 
it was assumed that the molar absorptivity of the two compounds is also 
very similar thus estimates for the amounts of P4 were obtained using the 
calibration graphs for dithranol. The concentration vs time graphs show that 
skin surface metabolite formation reached a maximum by 3 and 6 hours in 
the CET and NaLS and Tw formulations respectively. Table 6.1 shows the 
distribution and total recovery of dithranol 6 hours after the start for NaLS 
and Tw, and 3 hours after the start for CET. With all three surfactant 
formulations recoveries of 87% or greater were obtained. In view of these 
results the assumptions made in estimating the amounts of P4 formed during 
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the permation process, seem reasonable ones to make. 
In all three surfactants the amount of dithranol remaining with time was 
observed to follow first order kinetics and in all cases concentration decline 
was faster in the presence of skin (see Fig 6.3). In CET the rate of 
decomposition was increased to 0.322 from 0.161 hr-', in NaLS to 0.040 from 
0.018 hr-' ,while in Tw the rate was increased to 0.125 from 0.078 hr-l. 
This effect of an enhanced rate of decomposition for dithranol when in contact 
with hairless mouse skin is in general agreement with observations of 
Hulsebosch & Ponec-Waelsch (1972), who showed that dithranol decomposed at 
a faster rate when in contact with surfaces such as lint, skin and glass 
wool. 
In the CET formulation dithranol decomposition 10 solution results in a 
particularly marked increase in danthron formation and a significant increase 
in that of dimer. Dimer reaches a maximum in about 3 hours whilst danthron 
increases linearly with time. Danthron formation both in solution and when 
in contact with skin was observed to follow zero order kinetics ( see Fig 
6.4(b) ). There was no difference (p < 0.05) found between the rate of 
formation in the solution, and when the solution was in contact with the 
skin, the two rates being 4.51 and 3.94",g hr-' respectively. On skin the dimer 
levels are much reduced while those of danthron are of a similar order to 
those seen in the solution not in contact with skin. The most significant 
change is the production of P4 ,at the expense of dimer, over the initial 
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3 hour period. P4 reaches a steady state after 3 hours. 
In the NaLS formulation dithranol decomposition results in the appearance 
of both dimer and danthron in solution (see Fig 6.5 ). The dimer levels are 
about 5 - 6 times greater than those of danthron. Formation of both reaches 
a plateau in about 6 hours. In contact with skin a similar pattern for dimer 
and danthron formation is observed (see Fig 6.5). An increase in the amount 
of both decomposition products was observed, though in this case dimer 
levels are about 4 times those of danthron. P4 formation is also observed, the 
levels being twice as much as those of danthron. On skin, decomposition 
product formation reaches a plateau in about 4 hours. 
Dithranol decomposition in the Tw formulation results in the formation of 
more dimer than danthron, the levels being 8 - 9 times those of danthron (see 
Fig 6.6). Dimer formation reaches a steady state in about 6 hours. A large 
decrease in the dimer formed was observed due to skin contact, while there 
was, approximately, a two fold increase in danthron formation ( see Fig 6.6(b) 
). P4 formation is observed and results show that it is at the expense of 
dimer. 
P
4 
showed a pattern of increased formation on the skin surface followed, in 
the Tw formulation, by a gradual penetration into the skin shown by a 
steady decline in the concentration on the surface (see Fig 6.7). With the 
CET and NaLS formulations a plateau region is observed. From the data 
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presented in Table 6.1 it is seen that in NaLS, dithranol was held on the 
skin surface where it was protected from decomposition and also only released 
slowly to the skin. Because of this slow release of dithranol to the skin P4 
formation with NaLS was very slow and any formed tended to stay on the 
skin surface. This perhaps reflecting the inability of NaLS to enhance the 
rate of permeation of molecules, when the contact time with skin is short 
(see later). With the CET formulation more P4 was formed (about twice that 
in NaLS) though skin permeation was still relatively slow. Again perhaps 
because of the fact that it is an ionic surfactant, like NaLS , there was little 
permeation enhancement over the short contact period. In the non ionic Tw 
formulation the observed P4 penetration into the skin is more likely due to 
the more rapid ability of Tw , as will be discussed, to enhance percutaneous 
absorption compared to the ionic surfactants . 
. In the diffusion cells decline in dithranol concentration is either due to 
penetration into the skin, metabolite formation or both. At the end of a 
selected time period, establishing the % of the initial amount of dithranol 
applied , along with the % converted to metabolites , which are still present 
on the skin surface and subtracting these two figures from the initial amount 
of dithranol gives an indication of the amount that penetrates into the skin. 
carrying this out with the data presented in Fig 6.3 - 6.7 it was found that 
as regards skin permeation between 3.2 - 10.8% of the initial amount of 
applied dithranol penetrated the skin using the NaLS formulation. In 
comparison 10.3 - 27.3% was observed with the CET formulation and 57.6-
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65 % in the Tw formulation. Dithranol skin permeation was therefore 
greatest in the presence of Tw and poorest in the NaLS formulation. It must 
be pointed out here that these permeation results are mainly indicators of 
trend. This is because of the limited efficiency of the skin extraction procedure 
(see chapter 2). Present findings on the skin permeation effect of NaLS , CET 
and Tw are in general agreement with the findings of Ashton elJ\l (1992) 
who investigated the effects of surfactants on the transdermal flux of 
methylnicotinate. They found that B36T (non ionic surfactant) acted rapidly on 
the skin to produce small increases in the transdermal flux. In contrast the 
increased transdermal flux produced by the ionic surfactants (sodium lauryl 
sulphate and cetyltrimethylammonium bromide) occurred over a much longer 
time scale. The hypothesis put forward by Ashton ~ (1988) is that as non 
ionic surfactants are more lipophillic than ionic ones it is possible that entry 
into the stratum corneum is faster, and since the effect of surfactant entry 
into the stratum corneum is a disruption of the barrier function, increases 
in skin permeability are relatively rapid. This hypothesis is consistent with 
present findings. 
In skin permeation studies, skin permeability coefficient data are usually 
reported. This was not done in the present study due to the fact that whole 
skin was used. One factor that governs the permeation of a molecule through 
the skin is the thickness of the skin preparation. This was demonstrated by 
Wang ~ (1987) using a 1 % dithranol microemulsion gel, and normal human 
skin sectioned to varying thickness. After 8 hours contact no penetration· of 
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dithranol occurred when the skin was 255 I'm thick, whereas progressively 
more dithranol penetrated through skin preparations of 183 , 114 and 80#Lm 
respectively. The thickness of the hairless mouse skin used in the present 
studies was around 400 I'm. It was therefore understandable that no dithranol 
was observed to penetrate through the skin during the course of the 
experiments. 
Compared to hairless mouse skin events ocurring on the surface of normal 
human skin in vivo took place much faster. This can in part be linked to 
the fact that the area exposed to the formulations in the human skin 
experiments was twice that in the hairless mouse skin experiments. I.n the 
CET formulation dithranol decomposed at a rate of 8.01 hr-I , while in NaLS 
the rate was 1.04 compared to 3.59 hr- I in Tw (see fig 6.8). In all three 
surfactant formulations the major metabolite formed was P4 (see fig 6.9). No 
dimer and only very small amounts of danthron were detected in both the 
Tw and NaLS formulations. With the CET formulation around 3 % danthron 
was formed during the permeation period (1.5 hours). Permeation observation 
period was short (1.5 hours) for CET due to rapidity of events occurring on 
the skin surface. For Tw and NaLS observation period was 2.5 hours. 
The appearance of P4 on the surface of normal human skin can also be 
accounted for by the sequence of events proposed in scheme 6.1. The 
concentration time profile of P4 in CET and Tw shows that there was a 
rapid increase in skin surface P4 followed by penetration into the skin (see 
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Fig 6.9). Using the "tail end" of the profiles (all first order kinetics) the rate 
of penetration of P, was calculated. In CET the penetration rate constant was 
3.59 hr-1 (correlation coefficient 0.995) compared to 0.48 hr-1 (correlation 
coefficient 0.996) in Tw. In NaLS the profile shows that P, remained on the 
skin and did not penetrate into the skin. The difference in the penetration 
of P, into normal human skin compared to hairless mouse skin could, in 
part , be due to the fact that human skin has sweat glands and hair follicles 
,providing other possible routes of entry into the skin. In hairless mouse 
skin these features are absent therefore all penetration is through the strateum 
corneum ,this slower penetration leading to steady states in the P, 
concentration time profiles generated on hairless mouse skin. The fact that 
twice the area of the hairless mouse skin exposed was used in the human 
skin experiments can also contribute to the enhanced rates observed. 
The results from the human skin experiments show that there was a 
significant deviation from the decomposition pattern in the formulations when 
not in contact with skin. Whereas both dimer and danthron were formed in 
the formulations not in contact with the skin - indicating dithranol decomposition 
via both danthron and dimer routes, on normal human skin the only 
decomposition products detected were danthron and P" this indicating that 
dithranol decomposition was ocurring through the danthron route only. 
An indication of dithranol permeation into the skin using the DT -surfactant 
formulations was obtained as was done for hairless mouse skin. The data 
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used are presented in Fig 6.8 & 6.9. In the CET formulation skin surface 
decomposition was pronounced, 70 ± 7% of the initial dithranol was converted 
to P4 inside 7 minutes of skin contact. 11 ± 3% was present as unchanged 
dithranol while 3 ± 2 % was converted to danthron. The results indicate that 
between 72 - 82 % of the dithranol applied decomposed on the skin surface 
(within 7 minutes) while between 4 - 28% penetrated into the skin. Factors 
contributing to the wide variations observed include differences in skin from 
person to person and also site differences on the same person . 
With the Tw formulation 40 ± 6% of initial dithranol was converted to P4 
in around 47 minutes, at the end of this contact period period 4 ± 2 % of 
unchanged dithranol was still present on the surface. There were only trace 
amounts of danthron and dimer detected thus indications are that between 42-
68 % of initial dithranol penetrated into the skin during this contact period. 
In the NaLS formulation only a small fraction, 10 ± 1.5 % of initial 
dithranol underwent surface conversion to p. after 47 minutes contact with 
the skin. As no danthron and dimer were on the surface an estimate of 
between 55.5 - 62.5% of starting dithranol penetrated into the skin. There was 
31 ± 2 % unchanged dithranol at the end of the 47 minute period. 
Using an aqueous hydrophillic ointment (oil in water) Kammerau «...al (1975) 
showed that ,after 5 hours, l.25 % of the initial dithranol dose (lOOJ.'g 
spread over 28cm2) penetrated the skin. The question of breakdown product 
chap 6.175 
formation on the skin surface was not mentioned, perhaps because the 
radiochemical approach was used for the study. In comparison to present 
results the indications are that skin permeation is greater with anyone of 
the surfactant formulations. Major differences in the analytical techniques, 
however, does not allow conclusive comparisons to be made. 
On leaving the DT-Surfactant solutions on the skin for up to 2 hours before 
removal of the holder it was seen that with the NaLS formulation the skin 
in contact with the formulation was stained brown. The staining/inflammation 
only became apparent 24 hours after removal of the solutions. With the Tw 
and CET formulations this reaction was not observed. These results suggest 
that there is a possible link between the staining/inflammation reactions 
observed and the skin surface decomposition patterns in the DT -surfactant 
solutions. In the NaLS formulation surface decomposition was minimal, thus 
.this formulation facilitates the entry of intact dithranol into the skin/stratum 
corneum. Melo ~ (1983) showed that dithranol can persist in the stratum 
corneum for up to 24 hours, while other investigators Finnen ~ (1984) 
have shown that the continued presence of dithranol in the stratum corneum 
for up to 24 hours is necessary for dithranol inflammatory reactions to be 
seen. Because of the stability of dithranol in the presence of NaLS (see ch4) 
it is able to persist, intact ,for long periods in the skin/stratum corneum 
giving rise to the staining/inflammation observed. The Tw formulation caused 
the greatest permeation of intact dithranol into the skin/stratum corneum, but 
because of a reduced stability in the presence of Tw (compared to NaLS) the 
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dithranol does not persist for long periods once in the skin, thus no 
inflammatory reaction is observed. With the CET formulation permeation of 
intact dithranol is severely hampered due to the degree of skin surface 
decomposition ,also any dithranol entering the skin/stratum corneum will not 
persist because of CET presence. 
Only one pilot study could be done using psoriatic skin due to the difficulty 
of obtaining psoriatic skin. In Fig 6.10 the decline of dithranol concentration 
and formation of metabolites in the CET formulation in contact with psoriatic 
skin is shown. After 3 hours there was 19.3% of initial dithranol present in 
the unchanged form on the skin surface, 19.5% was converted to danthron 
and 4.3% to P4' The maximum for P4 conversion was reached within 0.33 
hours with none detected after 3 hours. Using the quantities of dithranol and 
metabolites found on the skin surface, the indications were that 57% of initial 
dithranol penetrated into the skin. On extraction of the skin danthron (28 % ) 
, dimer (17%) , P4 (3%) and dithranol (1.5%) were found. The distribution of 
the applied dose of dithranol after 3 hours in contact with the psoriatic skin 
is summarised in Table 6.2. It is seen in the Table that around 90% of the 
dithranol dose is accounted for. 
When a comparison is made with the results obtained using CET formulation 
on normal human skin the immediate obvious difference is the skin surface 
decomposition pattern. With normal skin the major metabolite (70%) was P4 , 
whereas with psoriatic skin much smaller amounts (4.3%) of P4 were 
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observed. On normal skin 3 % danthron formation was observed compared to 
20% on psoriatic skin. There was also a difference in the skin permeation 
pattern. With normal skin it was estimated that between 4 - 28 % of initial 
dithranol penetrated into the skin compared to 57% with psoriatic skin. The 
results indicate that the penetration barrier presented by normal skin is 
greater than that of psoriatic skin. Wang ~ (1987) using 1 % Westragel and 
involved psoriatic skin also found that dithranol skin penetration was 
enhanced in the diseased skin compared to the normal skin. A number of 
reports in the literature concerning the penetration kinetics of dithranol using 
barrier compromised skin (stripped skin) all show that penetration is enhanced 
compared to intact skin. [Cavey ~ (1985) , Schalla ~ (1981), Scheafer ~ 
(1980)]. On comparing the concentration vs time profiles for dithranol and 
breakdown products in the CET formulation in contact with human psoriatic 
skin and normal human skin ,it is seen that on psoriatic skin the kinetics for 
dithranol penetration/decomposition were zero order, which is different from 
the first order kinetics followed on normal human skin, in the formulation when 
not in contact with skin, and also hairless mouse skin. On both skin types 
(normal and psoritic human skin) danthron and P4 were the major breakdown 
products detected - indicating that dithranol decomposition ocurred via the 
danthron pathway. The results indicate that the state of the skin barrier had 
a bearing on the kinetics for dithranol penetration/ decomposition. It can 
therefore be anticipated that there could be variation in the kinetics for skin 
surface decomposition of dithranol with the severity of the psoriasis. 
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To decide whether or not a particular formulation possesses any potential as 
an antipsoriatic preparation, it must be demonstrated that the formulation 10 
question is capable of suppressing one or more of the biological events 
present in an animal model of psoriasis. Cyclosporine A ,which is effective 
in the treatment of psoriasis was shown to block the pleiotypic responses of 
mouse skin to TPA treatment involving biochemical events, inflammatory cell 
infiltration and epidermal hyperplasia [Gupta e.Lal, 1989, Gschwendt~, 1988]. 
In the present study the anti psoriatic effect of the dithranol-surfactant 
formulations was assessed in the TPA hairless mouse skin psoriasis model. 
A visual inspection of the TPA-induced inflammatory response and 
determination of DNA content were decided as the indicators to be used. 
The results in Table 6.3 show that at a strength of 4% only the CET 
blank produced a mild inflammatory response, seen after 24 hours. With NaLS 
, 
Tw and acetone the mouse skin showed no obvious signs of inflammation 
after this period. Treatment of the skin with TPA resulted in marked 
inflammation of the treated area, this being seen after 48 hours. Treating the 
skin with TPA followed by dithranol (80JLg/mL) in acetone resulted in the 
inflammation observed after 48 hours being reduced from severe to moderate. 
TPA followed by dithranol (80 & 40JLg/mL) in 4% NaLS resulted, in both 
cases, in the TPA-induced inflammatory response being reduced from severe 
to moderate. With dithranol (40JLg/mL) in 4% Tw the TPA-induced 
inflammatory response was reduced. from severe to mild. With the CET 
formulation (dithranol 40JLg/mL in 2.5 % CET) areas of inflammation outwith the 
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confines of the cap were evident. This indicated TPA loss to surrounding 
areas. Underneath the cap , however, the TPA-induced inflammation remained 
severe. Suggesting that CET negated the effect of dithranol. 
By visual inspection alone the conclusion that could be reached regarding the 
NaLS formulations (80 and 40j.Lg/mL dithranol) was that NaLS was without 
effect on the anti-TPA effect of dithranol. With both formulations TPA-
induced inflammation was reduced from severe to moderate (cf dithranol 
80#-,g/mL in acetone). 
With the Tw formulation the result obtained suggests a very successful 
reduction in the TPA-induced inflammatory response, the response being 
reduced from severe to mild. However, since only one animal was treated 
with this formulation and given the problematic nature of the experiment this 
sample size of one reduces the reliability of the result. It could be that the 
inflammation was mild after 48 hours because of loss of TPA from the 
treated area, although no signs of inflammation were present in surrounding 
skin. 
The CET formulation had the most obvious effect. The anti-TPA effect of 
dithranol was negated. This was concluded by the fact that no evidence for 
the reduction of the inflammatory response to TPA treatment of the skin 
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under the cap was present. 
The results for the DNA content of normal hairless mouse skin determined 
using diphenylamine (Burton, 1966) are shown in Table 6.4. The Table shows 
that a DNA content of 4.9 ± 0.84 JLg/mg of skin was determined (skin from 
eight different animals). In Table 6.5 the DNA content of the skin treated 
with either TPA or a dithranol -surfactant formulation is shown. Following the 
treatment of hairless mouse skin with TPA an increase in DNA synthesis 
is expected. On comparing the DNA content determined for untreated skin 
against that determined for TPA treated skin, no significant difference (p < 
0.05) between the two types was found. The same result was obtained on 
comparing untreated skin and skin treated with TPA and the dithranol-
surfactant formulations. The results obtained can either mean that TP A 
treatment did not influence DNA synthesis or that the DNA 
'quantification method was not capable of showing changes in DNA synthesis 
at the levels that it occurred. Inadequate sensitivity of the DNA quantifiaction 
method is the more probable case. 
Using the diphenylamine method (Burton, 1966) for DNA quantification present 
results show that JLg quantities of DNA were required for the preparation of 
the DNA calibration graph. In Fig 6.11 a y-intercept value of 0.194 is 
obtained. The absorbance at 600nm of the complex formed between DPAR 
and DNA (lo",g/mL) was 0.451 thus a 1: 10 dilution (l",g/mL) would give 
an absorbance below that of a solution with no DNA present (0.194). The 
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detection limit for this diphenylamine method was determined to be in the 
region of 3J.Lg/mL. The conclusion reached is that if DNA changes occurred 
at nanogram levels the quantification procedure was incapable of detecting 
this. Gupta ~ (1989) reported the use of the Burton method in quantifying 
DNA synthesis, but the results of their findings were not indicated. 
A number of practical problems were encountered during the course of the 
experiments. These are listed below. 
(1) Because of the cost of the materials, especially TPA and hairless mice 
, sample sizes had to be small. 
(2) There was a problem with ensuring that the agents applied to the mice 
remained in contact with the skin. This was because once the caps were 
glued to the backs of the animals they tended to become extremely agitated 
some to the point of inflicting self injury in an effort to remove the cap. 
This behaviour of the animals therefore led to variation in the success with 
which contact between applied agents and the skin was obtained. 
On the whole only the visual effects on TPA-induced inflammation ,bearing 
in mind the practical problems encountered ,could serve as a guide to the 
antipsoriatic potential of the dithranol-surfactant formulations. Alternative 
approaches that could have been taken but were not, due to time and 
financial constraints, would have been to monitor the activity of enzymes such 
as ornithine decarboxylase and protein kinase C and also a measure of the 
thickness of the epidermis [Gupta ~ ,1989] these being used as indicators 
chap 6.182 
of changes in cell multiplication following various treatments. 
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a)dimer , b) danthron production for the same solution In contact, and not in contact, 
withhairless mouse skin. Results are shown as mean ± SEM (n=3) . 
• skin contact, .. no skin contact. 
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Fig 6.7 The concentration-time profile for the formation of p. in the surfactant 
solutions in Fig 6.3-6.5 in contact with hairless mouse skin at 37°C. Results are 
shown as mean ± SEM (n=3). A 4% NaLS, 9 4% Tw,. 2.5% CET. 
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(a) 
DT Dan P4 OM 
Skin surface 81:1 1.5:0.5 6:1 6.3::0.5 
Skin tissue 3:1 - - -
Recovery 92% 
(b) 
DT Dan P4 OM 
Skin surface 39:.3 21±2 1.3:2.5 1::3 
Skin tissue 4:1.5 2:0.5 3:0.5 3:1 
Recovery 86.1% 
(c) 
lOT Dan P4 OM 
Skin surface 39::5.2 3:0.6 19:2 1.5::0.8 
Skin tissue 12::3 1.5±0.2 10±2 -
Recovery 87% 
'1'able 6. l. 
'1'he amount (% ot initial dithranol applied) of dithranol and its 
metabolites on and in hairless mouse skin tor dithranol delivered 
in a)NaLS atter , hours, b)CE~ atter 3 hours and c) Tv atter 6 
hours 
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Fig 6.8 . . . 
First order plots for the decomposition of dithranol ("" 40~g/mL) In the dithranol-surfactant 
formulations in contact with normal human skin in vivo .• 2.5% CET, • 4% Tw, • 4% Nals, 
* MeOH. 
chap 6.192 
7.5 
-E 6.0 
u 
-
-.s::. 
".5 J. CI 
CD 
.s::. 
.¥ 
ft:I 3.0 
CD 
Q. 
• 1.5 c.. 
.. 
0.0 
0.0 0.6 1.2 1.8 2." 3.0 
Time (Hours) 
Fig 6.9 
The in vivo formation of P4 from dithranol (-40llg/mL) in isoascorbic acid stabilised (0.5%) 
surfactant solutions in contact with normal human skin. The results are presented as mean 
± SEM (n=3). * 2.5% CET, .4% Tw, 44% NaLS, • MeOH. 
chap 6.193 
20 
-E 
u 
15 
-.c at 
C) 
.c 10 
~ 
«I 
C) 
£l. 5 
0.0 0.6 1.2 1.8 2.4 3.0 
Time (hours) 
Fig 6.10 . 
The concentration-time profile for the decomposition and metabolite formation from dithranol 
( '" 46pg/mL) in a 2.5% CET solution with 0.5% 1M, at pH 5.5 , temperature 37 0 C In contact 
with psoriatic skin. Changes in the peak heights with time of 1:100' dilutions of the 
decomposing solution are shown. - Dithranol, • danthron , .. P 4' 
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TaDle 6.2 
~he amount (% of initial dithranol applied) of dithranol and its 
metabolites on and in psoriatic skin 3 hours attar application 
ot the CE~ tormulation. 
DT Dan P4 DM 
Skin surface 19.3 19.5." 4.3 trace 
Skin tissue 1.5 28.0 3.0 17.0 
Recovery 90.6% 
The deqree of visibly evident inflammation of hairless mouse skin 
24 and 48 hours after treatment with TPb alone,TPA and a 
dithranol solution or vehicle only. 
-Intlammation score 
Treatmenta after 24 hours after 48 hours 
A a 
4% NaLS a 
4% Tw a 
4% CET 2 
Acetone a 
TPA alone 4 
TPA + B J 
TPA + C :3 
TPA + 0 :3 
TPA + E 2 
TPA + F 4 
• ~r.atllleAt •• A - 110 tr.atsellt, B • elithr&llol aOlJfJ/raL in acetolle, C • 
cUt.hr&llol 401J9/raL in U HaLS, D - dithrallol aOlJ9/raL iA U H&LS, E • dithrUlol 
40WI/mL in n ~, F • cli.thrUlol aOlJfJ/raL ill 2.5' <:r.r • 
• Infl .... tion .cor •• 0 • no infl .... tioll , 1 • trace. of inflammation, 2 • 
~lel inflamaatioll, 3 • .aelerate iAfl .... tioll. 4 • •• y.r. iIlfl .... tioll 
In all case. do.e of ~A va. 101JmQ1 delivered in 501JL of acetolle. 
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Table ,6." 
The DNA content of hairless mouse skin, determined using the 
diphenylamine method. Skin from 8 different animals was used. 
Total DNA content 
wet weight of skin (mg) DNA extracted (JJ.g) JJ.g/mg skin 
75.3 300.6 4.0 
77.4 368.9 4.8 
84.7 476.0 5.6 
85.3 :380.0 4.5 
81.7 446.8 5.4 
75.9 276.8 3.6 
101.9 531.5 5.2 
103.6 632.0 6.1 
Average DNA content = 4.9 ... 0.84 JJ.g/mg of skin. 
'rab1e 6.S 
The DNA content of hairless mouse skin 48 hours after treat~ent 
with either TPA only or TPA and a formulation of dithranol. 
Treat':llent DNA content J.l.q/mq skin (wet weiqht) 
A 4.9 ± 0.84 
'I'PA alone 4.7 ± 0.67 
TPA + B 4.5 ± 0.38 
TPA + C 4.4 ± 0.27 
'I'PA + D 4.9 ± 0.48 
'I'PA + E 4.6 ± 0.58 
'I'PA + F 4.7 ± 0.51 
Results are presented as .ean = SEN. In all case. the ~o.e of ~A was lO~ol 
del~yere~ ~ 50~ of acetone. See ~able 6.2 for treataent code. 
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Fig 6.11 
DNA calibration graph using the diphenylamine method (y • 0.026980(X) + 0.193800). 
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A.. 
oiaqram. of t!J.e glass cap used for t!le applica.tion ot t!l.e 
d.it!1ranol-~ac""....ant solutions 
rLr----------- 0.101 c:iiameter 
I ~----- 0 .801 h.eight SIDE V!:::W 
-
1 .5.c:n diameter 
0.20 
\ 
s Dia~ of Dif!nsion cell used. 
~_;::I 
~ 
-----,..1 ( 
"'=:e == 
Sc:::l.:.. 1 C'!f 
NB not ci:'awn to sc~le 
l= Rece~tor phase! ou-clet 
2= Rece~tor phase ~e~ 
3= wate: jacket ou~let 
4= wate: jacket ~let 
9 = g"!'ounc. gla.ss 
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CHAPfER7 
CLINICAL STUDY 
7.1 Introduction 
Dithranol has been used for the treatment of psoriasis for over 100 years 
now. It is the most potent topical preparation available for this condition. The 
chemistry of dithranol is related to aspects of therapy, mechanism of action 
and side effects. Transformation to an ionised form is critical to its effect in 
psoriasis. This transformation releases free radicals and is not only closely 
linked with its therapeutic effect but also with the production of metabolites 
which stain skin and clothing. There are two possible pathways proposed for 
the oxidation/metabolism of dithranol. One pathway results in the formation 
of dimer, while the other ends . with the formation of danthron. In the 
present study both in vitro and in vivo work (see chapter 6) have shown that 
the there was a surfactant dependent alteration in the skin surface metabolism 
/ permeation of dithranol, delivered to the skin as an aqueous surfactant 
solution. In the presence of the cationic surfactant, cetrimide , (present in 
antiseptic creams and shampoos) metabolism of dithranol is such that more of 
the ionised form is produced this resulting in conversion being directed away 
from the dimer pathway and also leads to the production of a hitherto 
undescribed metabolite (P.). It was also established that there was no staining 
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and irritation when the dithranol-CET formulation was left 10 contact with 
normal human skin for two hours before removal. 
The aim of this pilot study is to assess whether the surfactant influences on 
metabolism lead to any useful enhancement of dithranol use in clinical 
practice. Because of time restrictions the clinical evaluation of only one of 
the proposed formulations was possible. CET was chosen because of its 
obvious potential to produce danthron and P4 and little dimer on human 
skin, this would allow the establishment of the relevance to the antipsoriatic 
effect of the danthron pathway. The working hypothesis was that by 
combining dithranol with CET, irritancy and staining would be reduced and 
efficacy increased. The study was based in the Dermatology Department of 
Aberdeen Royal Infirmary. 
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7.2 Methods 
7.2.1 Materials 
Dithocream 0.25% , 2% w/v CET solution pH 5.5 ,this solution was prepared 
as per 6.2.2 
7.2.2 Patients/volunteers 
Patients with psoriasis undergoing dithranol treatment as in-patients or out-
patients at Aberdeen Royal Hospitals Trust were selected .Four plaques of 
psoriasis were identified and scored seperately for thickness, scaling, erythema, 
irritancy and staining (see 7.2.3). 
7.2.3 Treatment protocol 
Patch 1 This was treated with an even coverage of dithrocream 0.25% 
rubbed in and left on for 8-12 hours. 
Patch 2 Treated with CET solution applied with a cotton bud twice to 
ensure a good soaking. 
Patch 3 Treated with the same amount of dithrocream for 8-12 hours as 
for patch 1. The dithrocream was then removed and CET applied as above. 
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Patch 4 Treated with CET solution painted on twice, the area then dabbed 
dry and dithrocream applied. 
7.2.4 Clinical assessment - This was done at the start (Day 1) and after two 
days (Day 3) of daily administration of the treatments above. The treated 
areas were clinically assessed for thickness, scaling, erythema, irritancy, and 
staining. Each modality was graded on a 0 - 4 scale of increasing severity 
(0 = absent, 1 = trace, 2 = mild, 3 = moderate, 4 = severe). 
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7.3 Results/Discussion 
Patient 1 1 2 3 4 
Treatment Dithranol Cetrimide Dithranol Cetrimide 
Cetrimide dithranol 
Dayl DayJ Day 1 DayJ Dayl DayJ Dayl DayJ 
Thickness 1 0 1 1 1 1 1 0 
Scaling 2 0 2 2 2 1 2 1 
Erythema 2 4 2 1 2 2 2 3 
Irritancy 0 3 0 0 0 1 0 2 
Staining 0 3 0 0 0 1 0 2 
Total 5 10 5 4 5 6 5 8 
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Patient 2. 
1 2 3 4 
Treatment Dithranol Cetrimide Dithranol Cetrimide 
Cetrimide Dithranol 
Day! Day3 Day! Day3 Day! Day3 DaylDay3 
Thickness 2 0 2 2 2 2 2 1 
Scaling 2 0 2 2 2 1 2 1 
Erythema 2 3 2 2 2 1 2 1 
Irritancy 0 3 0 0 0 2 0 2 
Staining 0 3 0 0 0 2 0 2 
Total 6 9 6 6 6 8 6 7 
aDle 7:1 
Tables (patient 1 & patient 2) showing the effect on side effects and 
therapeutic outcome of applying CET before and after dithranol. 
The tables of results show that in both patients, for the areas treated with 
dithrocream only, there was an increase in the total score. In patient 1 the 
increase was 100% while in patient 2 it was 60% . The main reason for the 
increase in the total score in both patients was the increase in erythema, 
irritancy and staining (EIS score). In both patients treatment with dithrocream 
alone. resulted in a thickness and scaling score (TS score) of O. The TS 
scores of 0 in both patients after the treatment period shows that clinical 
improvement of the plaques was good. Accompanying the improvement in the 
psoriasis ,however, were the side effects of erythema, irritancy ,and staining 
as indicated by the increase in the EIS score. 
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On the areas treated with CET only, it was seen that CET had no effect 
on the plaques. In patient 1 ,there was a small reduction in the overall total 
score ,this being due to a 20% reduction in the erythema score. 
On treating the skin first with dithranol then followed by CET, there was 
a 20 and 30% increase in the total scores in patient 1 and patient 2 
respectively (see Tables). In both patients the increase was due to increased 
irritancy and staining. This protocol did not have a great effect on erythema. 
In patient 1 erythema was reduced from moderate to mild while it remained 
unchanged in patient 2. When the effectiveness of dithranol is compared this 
protocol was found to be inferior to the dithrocream alone treatment. In 
patient 1 the TS score for dithrocream alone was reduced from 3 (Day I) 
to 0 (Day 3) compared to a reduction from 3 (Day I) to 2 (Day 3). The 
pattern in patient 2 was similar. The protocol however was found to be 
. superior in terms of reducing side effects. In both patients the EIS scores 
on Day 3 were lower than those for dithrocream alone. In patient I the EIS 
score on Day 3 (for dithranol followed by CET) was 4 compared to 10 for 
dithrocream only, while in patient 2 ,the EIS scores were 5 compared to 9. 
The overall observation for the dithranol-CET protocol was that while side 
effects were effectively reduced, the therapeutic effect of dithranol was also 
compromised. 
On treating the skin with CET first then followed by dithranol it was 
observed in patient I that the TS score was reduced from 3 (Day 1) to 1 
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(Day 3) ,and in patient 2 from 4 to 2 (same time period). The indication is 
that ,with regard to therapeutic outcome ,CET followed by dithranol was 
better than the other way round. The CET-dithranol protocol, however, was 
also inferior to dithrocream alone. The EIS scores on Day 3 show that in 
patient I the side effects of the CET -dithranol protocol were more severe 
than those from the dithranol-CET protocol a score of 8 compared to 6 was 
obtained respectively. In patient 2 there was no difference in the severity of 
side effects between the two protocols. For both protocols a score of five 
was obtained. 
When the three protocols involving dithranol are compared the results show 
that the presence of CET ,whether applied before or after dithranol, reduced 
side effects but also compromised the antipsoriatic effect of dithranol. This 
observation is in agreement with the in vivo results obtained for the 
dithranol-CET formulation using the TPA psoriasis model (see chapter 6). 
In chapter 6 it was shown that when a dithranol-CET solution was placed 
in contact with human psoriatic skin (in vitro) ,danthron was the predominant 
breakdown product following decomposition of dithranol. Based on the present 
in vivo results (bearing in mind limitations due to small sample sizes) it can 
be said that decomposition along the danthron pathway was not therapeutically 
benificial. Lawrence ~ (1987) showed that wiping dithranol treated areas with 
KOH (PH 14) resulted in very effective reduction of inflammatory side effects 
with no compromise of the antipsoriatic effect of dithranol. The KOH effect 
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was said to result because it caused a rapid chemical inactivation of 
dithranol. At alkaline pH dithranol decomposition, not in contact with skin, is 
along the danthron pathway (preliminary work done in this study). It can 
therefore be expected that the KOH effect on dithranol therapy would be of 
a similar pattern to that seen for CET. This was true with respect to 
reduction in side effects, but not with regard to the effect of the two agents 
on the therapeutic outcome of dithranol. Unlike Lawrence ~ (1987) ,our 
observations with CET were that effectiveness was definitely reduced. The 
decomposition pattern of dithranol on psoriatic skin at alkaline pH is not 
known thus it becomes difficult to advance reliable reasons for why there 
was a difference between the two agents. Also the present patient sample size 
(2) means the CET results have to be treated as tentative. 
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CHAPfER 8 
CONCLUSIONS 
8.1 The new knowledge gained from the present work 
There is more information available in the literature on the reactivity of 
dithranol in non aqueous systems as opposed to aqueous conditions. This , in 
the main, is because of the poor water solubility of dithranol, its poor 
stability and the lack of sensitive analytical techniques - particularly for the 
quantification of the dimer. This latter problem has been overcome in this 
study by the use of a modified hplc system. 
This is the f11'st reported quantitative study of the kinetics of dithranol 
decomposition to danthron and dimer in aqueous conditions particularly in the 
presence of surfactants. 
8.1.1 Stability of dithranol in aqueous solutions 
Decomposition of dithranol follows first order kinetics, with the resultant 
formation of danthron and dimer. At pH 5.5 decomposition half-life was 1.09 
hours. When pH was reduced to pH 0.4 the half-life was increased to 18.8 
hours. 
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8.1.2 Solubility and stability of dithranol in the presence of various surfactants 
Dithranol has been shown to be solubilised but to different extent by 
different types of surfactants. It has also been observed that the choice of 
surfactant and its concentration has relevance to the observed stability profile. 
In NaLS and Tw at pH 5.5 and in CET at pH 0.4 the enhanced solubility 
is due to micellar solubilization with the amount of dithranol in solution 
(above the surfactant c.m.c) being linearly dependent on the per cent of 
surfactant present. In CET solutions (excess CET) the acid dissociation constant 
of dithranol is drastically reduced from 9.12 to 4.68 (these values were 
established using both absorbance and fluorescence measurements). This 
increase in the acid strength of dithranol occurs due to a complexation 
interaction between dithranol and CET. Dithranol is therefore - 88% ionised 
in CET solutions of pH 5.5. Since ionised dithranol is the more soluble 
molecular species, solutions of a higher dithranol concentration compared to 
the concentrations achieved in NaLS and Tw pH 5.5 are possible (see Fig 
3.11). For the purpose of increased amounts of dithranol in aqueous solution 
formulation in CET solutions would be ideal. The major problem though is 
is that such solutions are unstable because dithranol is present in the less 
stable ionised form. Precautions such as antioxidant addition are necessary if 
shelf life is to be prolonged (see Table 4.12). 
In all three surfactants the solubilization of dithranol offered a degree of 
protection from decomposition. Plots of koold vs surfactant concentration were 
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bell shaped. Below the c.m.c values of 0.24% for NaLS pH 5.5 ,0.014% for 
Tw pH 5.5 and 0.09% for CET pH 0.4 increases in the surfactant 
concentration resulted in increases in the decomposition rate constant, whereas 
above the C.m.c values increases of surfactant concentration resulted in 
reduced rates of decomposition (see Fig 4.13 - 4.15). 
8.1.3 Pathways of degradation , the influence of pH , metal ions and 
surfactant presence 
Currently it is proposed that there are two routes by which dithranol will 
decompose. One pathway ends in the formation of dimer , normally non ionised 
dithranol will decompose by this route. The second pathway ends in the 
formation of danthron and ionised dithranol will normally decompose by this 
route. Dithranol is a weak acid with a pKa of around 9.12 (present study) 
. thus at pH 5.5 it is virtually completely non ionised. On decomposition at this 
pH - 94 % dimer and - 4 % danthron were formed. Dithranol decomposition 
in aqueous solutions of alkaline pH were studied by Upadrashta & Wurster 
(1988) who found that the main decomposition product (especially at pH 9 
and above) was danthron. 
Metal ion presence influences dithranol degradation by increasing the rate at 
which dimer is formed while danthron formation is suppressed (see Table 4.7). 
Metal ions therefore provide a means by which dithranol decomposition can 
be controlled such that dimer formation is selectively enhanced. 
chap 8.210 
In CET solutions decomposition is mainly via the danthron pathway even at 
a pH as low as pH 5.5. This is because in a CET solution (pH 5.5) dithranol 
is - 88 % ionised (see above). In both NaLS and Tw the degradation pattern 
remains as observed in plain buffer. This is because these two surfactants 
have little influence on the molecular species of dithranol present at pH 5.5. 
Surfactant presence, therefore, can also be used as a means of controlling 
the degradation pathway of dithranol allowing an assessment of the effect of 
the degradation pathway on the therapeutic outcome of dithranol. 
8.2 The stability/metabolismlpenneation profile of dithranol delivered to 
various skin types (hairless mouse, nonnal human and human psoriatic skin) 
using surfactant solutions of dithranol. 
An extraction procedure based on the use of a mixture of trichloro acetic 
acid and methanol as an extracting solvent to be used where appropriate, 
for the quantification of dithranol and its metabolites/decomposition products 
in hairless mouse skin (in vitro experiments), was developed and validated. 
By using aqueous surfactant solutions of dithranol and hplc as the analytical 
technique the concentration vs time profile for dithranol and decomposition 
products in the formulation in contact with the skin during permeation 
experiments were established. Such profiles ,unavailable till now, allowed 
various kinetic calculations to be performed. In all three surfactants the 
amount of dithranol remaining with time was observed to follow first order 
kinetics and in all cases concentration decline was faster in the presence of 
skin (see Fig 6.3). In CET the rate of decomposition was increased to 0.32 hr- I 
from 0.16 hr- I ,in NaLS to 0.04 from 0.02 hr- I and to 0.12 from 0.08 hr- I 
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in Tw. 
The profiles also revealed that an as yet unknown metabolite/decomposition 
product (P4) was formed due to decomposition of dithranol in contact with 
skin. The short retention time of this metabolite shows that it is more polar 
than either dithranol or danthron, while the UV spectrum suggests a structure 
similar to dithranol (see Fig 6.2). There are no reports in the literature of a 
similar metabolite. This is most likely due to the fact that no work has been 
reported where the skin surface surface concentration vs time profile for 
dithranol and decomposition products is monitored. 
The results obtained from the permeation experiments on normal human skin 
in vivo show that there is a significant deviation from the decomposition 
pattern of dithranol in the formulations when not in contact with skin. 
Whereas both dimer and danthron were formed in the formulations when not 
in contact with the skin - indicating decomposition via both the dimer and 
danthron pathway - on normal human skin the only decomposition products 
detected were danthron and P4, this indicating dithranol decomposition was via 
the danthron pathway only. This is significant as it gives a direct indication 
of what is expected in a "real life" situation. 
The concentration vs time profiles also show that the choice of surfactant 
will influence permeation characteristics. With hairless mouse skin between 3.2 
_ 10.8% of the dithranol applied using the NaLS formulation penetrated into 
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the skin, with the CET formulation about 10 - 27% penetrated into the skin 
compared to 57 - 65% with the Tw formulation. Using normal human skin 
dithranol penetration into the skin from the NaLS formulation was between 
55.5 - 62.5 % of dose applied, whereas with Tw penetration was between 42-
68% compared to between 4 - 28% with CET. Permeation of dithranol into 
human psoriatic skin in vitro using the CET formulation was around 57% of 
applied dose. This increased penetration (cf normal human skin) is consistent with 
permeation profiles for dithranol using diseased skin [Wang ~ , 1987]. 
8.3 The anti psoriatic potential of the surfactant solutions of dithranol 
Using the TPA/hairless mouse psoriasis model and DNA quantification as a 
marker for cell division it was difficult to judge the antipsoriatic potential 
of the surfactant formulations because no difference (p < 0.05) was found in 
the DNA content of treated and untreated skin. The indications were that 
visual inflammatory responses to TPA treatment occurred without cell division 
taking place. It is not known why this happened, it could perhaps be a 
perculiarity of the species of mice used or perhaps an inadequate TP A dose. 
The effect of the surfactant formulations on the inflammatory responses 
present in the TPA/hairless mouse psoriasis model could be judged visually. 
The indications here were that the NaLS and Tw formulations were. capable 
of blocking the inflammatory response to TPA to the same degree as an 
equivalent amount of dithranol delivered in acetone. With the CET formulation 
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the anti-inflammatory effects of dithranol in the psoriasis model were negated. 
This particular model can therefore be used to study the anti-inflammation 
effects of dithranol formulations. The CET result obtained using the 
TPA/hairless mouse psoriasis model is in agreement with the results of a brief 
clinical trial aimed at evaluating the effect of CET on the action of 
dithranol in patients with psoriasis. The trial showed that using a solution of 
CET to cleanse the skin before or after treatment with dithranol reduces side 
effects but also compromises its therapeutic action. 
During the course of the study a number of areas requiring futher reseach 
were identified. 
(1) Further investigations are required to establish the exact nature of the 
P4 • 
(2) Because of the problems encountered using conscious hairless mice in 
experiments aimed at establishing the antipsoriatic potential of surfactant 
solutions of dithranol, the possibity of using anaesthetized mice should be 
investigated. 
(3) Using patients with psoriasis and metal ions to promote dimer formation, 
the relevance of the dimer decomposition pathway of dithranol to the 
therapeutic effect of dithranol needs to be investigated. A metal ion solution 
can be painted over the area to be treated before the application of a 
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conventional formulation of dithranol e.g dithrocream. 
(4) There is also a need to establish the effect on the therapeutic outcome 
of dithranol , of cleansing the skin with NaLS and Tw before and after 
dithranol treatment. 
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'fJiE EFFEcr OF SURFAcrANTS ON THE SOLUBILITY AND STABILITY OF AQUEOUS SOLlJTIONS OF DI11IRANOL 
J,!t. PIOOdy, P. Ll.lbwika, SChool of PtlaCJlilcy, nw l!al:lert Gorden Institute of Technology, Aberdeen .\89 lFR • 
. t./Iranol is widely used and is clinically effeetivw in 
~. treal:lllent of psoriaslS (Sevi.Ue 1981 J.. . probl~ 
is. in its us. because of lts ln5tatllhty. ltS "~.uninq effects and its irritancy particularly on 
s ClIill skin (cavey et al 19851 • 'Itle pnncipal 
,,0 COIIPOsi tion products. danthrone and diMr, are less ~tective than dithranol and .. y be respo,uuble for lts 
•. de effeets. Short cootact therapy is reccmMnded to 
Sl.vent side effeets (Seville 19811. Therefore, Since 
p' ,tactants are known both to solubilise druqs and 
-t!8Ct skin penttratiClt, in this study the effect of 
• ~iua lauryl sulphate (NaLSI. cetnaide (C!:'l') and 
--en 80 ('l'JI on the soluDility and stal:lility of 
:-'thranol in water was evaluated as a prelimlnary to 
• developaent of aqueous law dose tonllllations for ~thranol. ()JantificatiClt of the dithranol in solution 
anr:s its cIe<:aIposition products '4S done uslllq a 
e'fiously deVWloped HPLC systea (Priprm 19911. 
pC c:ucat:i.CIt solubility of dithcanol in water at 2!rC 
sa 6 119 &", was increased by solubilization with the 
(l;tactants the effeet observed beinq concentration and 
SU de-ndent. For NaLS (O.OU!) the sac:uration cvr-.... -, 8-' fOluDipty .... S 3.6"9,& ; err (0.01l!), 4. uq Ill. ; 'l'J 
1.Jtl 0 - /", 3.2uq Ill. • ~ice of surfactant IIIIckedly affected the stal:lili t:y 
atile. USlnq err at O.OSlt. dithranol decomposltion 
pc. capid. complete deeomposltion takinq place Wlthln J 
·s (See Fiq.ll. wi.th both NaLS and 'l'J less than.l0\ 
Ill" oaaposi.tion was observed over the 1 h penod. 
d8C lete deqcadatlOn required 30 h foc the former and ~ for the latter. With all the surfactants both 
.. 1IJ/I' and dantheone _re formed.. In all .cases the ~ _, rapldly exceeded ,i.es satucatlonsolub1hty 1n the 
ai folctantS (- 1.,q a1. I and peeclp'tilted t)Ut. 'nIe 
sUc 
ratio of di_c to danthrCltt producwd after COIIplete 
decaaposition was 3:2 for CET and 4:1 tor both Ha'-S and 
'l'J. Surface tension _asur_nts indicated that 
sudace activity was -ase .. eked "lth cetriaJ.de -
dithranol solutions. 'nIis My acc:aunt for the IKlre 
rapld decomposition of dithranol in err, 
For all three di thranol surfactant solutions inclusion 
of 0.1\ isoaseorbic acid (1M) as antioxidant urkedly 
reduced the rate of decaaposition. particularly dillll!r 
productlon. COIIIPlete deqradation of dithranol in err 
was extended to 18 hI NaLS, 100 hI 'l'J. 150 h • 
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CAvey, D. et a1 (19851 Dcuq Res. 35:605-609. 
Prlprea, A. (19911 PhD TheslS. CNAA. 
sevilla. R.II. 11981) J. lila. Acold. DeClIIoltOl. 5:319. 
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rIlYS,("(Wm:""c.\1. rRUPERTtES OF DITHRANOL IN AQUEOUS SOLUTIONS OF SURFACTANTS 
FlFl Moody and P. Lubwika 
School of Pharmacy, The Robert Gordon University, SchoolhiB, Aberdeen, AB9 1 FR 
f'NYiouSIY we have shown tNt choice of surfactant had a marked 
.If.ct on the solubifity and the stability of dithranol (OT) in aqueous 
solutions 01 aoout pH 3.0 (Moody & Lubwlka 1992). or was least 
5table but most soluble in solutions containIng cetnmide (CE'!') 
compared to those cenlasnlng sodium lauryl sulphate (NaLS) or 
TIN"" 80 (Tw). In the present studies. AI 36"C, measurement of 
spectroscopic chang" caused by change in pH gIVe a pOSSIble 
• "planatlOn lor these observed diff....,c:es. 
eoth the absoltltion and tha nuorescence charactenstics of or chang. 
.".nth pH. The acsorption spactrUm lor the non-ionlZed and the ionised 
form are mlll'kedly differenl and only the ionIZed lorm is fluorescent 
(MeiO et at 1983). Th.s. observations w .. e used to datermlne the 
t<a ot dithranol in water using butlers 01 constant ionIC Sll'engtn f._O.5) both by absorption (Upadrashta & Wurster 1988) and 
fluorescence m.asurements (.x. 39Onm; em. 5t8nm). Fluorescence 
has the adVantage of baing more sensitive (100 tim") and it is 
SPecifiC lor the ionISed form. Both m.thods (n-3) 9ava a PK. value 
of about 5.30 when det-;,"Ined uSIng unIVersal butler. . 
01' solutions (100 ng mr) contas",ng 0.02% CET but of dlllerent pH 
vaJues, eg 3.0 and 5.0, produce a marlced pH and tim. depenaant 
fluoresc.nce reSDonse (s .. Fig.I). Incr.ase It1 the CET concentration 
at a particular pH increased ionization .g 0.()4% CET at pH 3 
a"prcnamately doubled the response. These. and other results 
Uggest that comOIU formation is oecumng between or and CET. ~h. equilibrium may be reores.nted as: 
o + CET - O'CET + H" 
For a fixed CEi eoncentration a plot of pH vs log F.JF _ • F _ where 
F is the observed ftuorr-cence resoonse at that pH and F _ the 
":.ximum resoonse lor fully ionIzed OT. gave a Straight lin. of ~t.reeot pK'wh.re K' is the aoparent stability constant e.g. lor 0.02,!,o ~c:r the pK' was 3.33. Thus CET is plomollng the IonIzation at OT at 
pH values well below its axpeded pK&. the .ffect observed baing pH 
and CET dependant. The aarne effects w .... not observed WIth NaLS 
or Tw the pK" for OT baing unatfecled by thalr presence. 
Since the ionIZed form at DT is its most soluble but I.ast stabl. lorm 
(it rll(lldly decomposes to danthron), tn. enhancement in aquaaua 
solubility whIch is associated with a decre... In liability in CET 
relllllV. to NeLS and Tw i. now axplasnabt •• 
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